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Abstract
Patterns of Lung Cancer Care and Associated Health Outcomes Among Elderly
Medicare Fee For Service Beneficiaries in West Virginia and in the United States
Pramit Amrutlal Nadpara
The elderly carry a disproportionate burden of lung cancer in the US. Although
significant improvements have been made during the past decade in cancer treatment,
substantial disparities still exist in guideline-based lung cancer care and outcomes.
Such variation in lung cancer care is a cause for major concern in rural areas like West
Virginia (WV). The purpose of this study was to do a comprehensive evaluation of
variations in lung cancer care and associated health outcomes in the elderly. This
retrospective study was conducted using SEER-Medicare and WVCR–Medicare linked
data files for the years 2002-2007. As part of the project, three studies were conducted.
In the first study, we compared geographic variations in clinical guideline-based lung
cancer care and associated health outcomes among elderly Medicare Fee-for-service
(FFS) beneficiaries. The study found disparities in receipt of minimally appropriate care
in both the WV and US populations. Receipt of minimally appropriate care was found to
be associated with longer survival times. In the second study, we compared geographic
variations in timeliness of lung cancer care and found significant variation in delays in
diagnosis and treatment in both the WV and US populations. However, non-timely care
was not associated with poorer prognosis. The third study determined the patterns of
receipt of tobacco-use cessation counseling services and found such services to be
received by more than half of all beneficiaries. Overall, the findings highlight the critical
need to address disparities in receipt of guideline-based appropriate and timely lung
cancer care among Medicare FFS beneficiaries. The findings also reveals the urgent
need for future cancer prevention efforts directed towards promoting smoking cessation
in the rural WV population. In the long run, such cancer prevention efforts can help to
reduce lung cancer incidence, which in turn can help to reduce the geographic
disparities in lung cancer mortality.

DEDICATION
This dissertation is dedicated to my mother (Chandrikaben Amrutlal Nadpara, B.A.), my
father (Amrutlal Manjibhai Nadpara, B.E. (Electrical)), and my brother (Dr. Rishit
Amrutlal Nadpara, MD, M.B.B.S.).

iii

ACKNOWLEDGEMENTS
This project was supported by grant number 1R24HS018622-01 (PI: S. Madhavan) from
the Agency of Healthcare Research and Quality. The content is solely the responsibility
of the authors and does not necessarily represent the official views of the Agency for
Healthcare Research and Quality.
There are several individuals who helped me directly or indirectly in the
completion of this dissertation, and I am truly grateful to all of them. I would like to
acknowledge the role of my mentor and chair Dr. S. Suresh Madhavan in providing me
with the financial, emotional, and intellectual support that made the completion of this
project possible. His guidance and support over the past few years has been
instrumental in shaping my career. Another individual without whom this project would
not have been possible is Dr. Cindy Tworek. Dr. Tworek was my major advisor during
my early years at West Virginia University, and she also helped me in all aspects of the
study. I am truly indebted to Dr. Madhavan and Dr. Tworek for their support.
I would also like to acknowledge the role of Dr. Usha Sambamoorthi, Dr. Michael
Hendryx, and Dr. Mohammad Almubarak in the completion of this project. The
comments and suggestions from them have markedly improved the quality of work that
was undertaken as a part of this project. I am thankful for having these wonderful
individuals as a part of my committee.
I would also like to acknowledge Myra Fernatt, Dr. Alana Hudson, and Dr. Loretta
Haddy from West Virginia Cancer Registry; Commissioner Nancy Atkins, and Nora
Antlake from West Virginia Bureau of Medical Services for their administrative and
material support.

iv

I would like to acknowledge the support provided by Dr. Ginger Scott, and my
friends and colleagues in the department. Over the course of my graduate education,
these individuals have provided me with the emotional support that was needed
especially since my family was far away. I am thankful to them for their friendship.
Finally, I would like to acknowledge my family for their support and
encouragement all my life. I feel blessed to have wonderful and amazing parents
(Chandrikaben Amrutlal Nadpara, Amrutlal Manjibhai Nadpara), brother (Dr. Rishit
Amrutlal Nadpara), and wife (Purvi Pramit Nadpara).

v

TABLE OF CONTENTS
ABSTRACT……………………………………………………………………………………

ii

DEDICATION …………..…………………………………………………………………….

iii

ACKNOWLEDGMENTS …………………………………………………………………….

iv

LIST OF TABLES …………………………………………………………………………….

x

LIST OF FIGURES …….……………………………………………………………………. xiii
CHAPTER I: INTRODUCTION …………………………………………………………….

2

Overview of Lung Cancer …………………………………………………………..
Etiology of lung cancer ………………………………………………………….
Prevention of lung cancer ………………………………………………………
Screening for lung cancer……………………………………………………….
Diagnosis and staging of lung cancer …………………………………………
Treatment of lung cancer ………………………………………………………..
Healthcare utilization and costs associated with lung cancer ………………

2
3
4
4
6
7
8

Evidence Based Lung Cancer Care ………………………………………………. 8
Appropriateness of care ………………………………………………………… 9
Timeliness of care ……………………………………………………………… 9
Preventive care ………………………………………………………………… 10
Disparities in Lung Cancer Care and Health Outcomes ………………………… 10
Geographic Variation …………………………………………………………… 12
Study Need …………………………………………………………………………... 14
Significance of the study…………………………………………………………..... 18
Bibliography…………………………………………………………………………... 20
CHAPTER 2: APPROPRIATENESS OF LUNG CANCER CARE AND ASSOCIATED
HEALTH OUTCOMES AMONG ELDERLY MEDICARE FEE-FOR-SERVICE
BENEFICIARIES IN WEST VIRGINIA AND IN THE UNITED STATES ……… 30
Introduction …...……………………………………………………………………… 30
Methods ….…………………………………………………………………………...
Data sources……………………………………………………………………...
Study populations ………………………………………………………………..
Assessing receipt of clinical guideline based lung cancer care…..…………

vi

34
34
35
36

Dependent variables…………………………………………………………..… 37
Independent variables…………………………………………………………... 38
Data analysis……………………………………………………………………... 39
Results…………………………………………………………………………………
Study population characteristics………………………………………………..
Treatment patterns……………………………………………………………….
Receipt of minimally appropriate care………………………………………….
Factors associated with receipt of minimally appropriate care………………
Survival benefits associated with receipt of minimally appropriate care……
Lung cancer mortality risk associated with non-receipt of minimally
appropriate care…………………………………………………………………..

41
41
42
43
44
45
46

Discussion ……………………………………………………………………………. 46
Bibliography ………………………………………………………………………….. 69
CHAPTER 3: TIMELINESS OF LUNG CANCER CARE AND ASSOCIATED
HEALTH OUTCOMES AMONG ELDERLY MEDICARE FEE-FOR-SERVICE
BENEFICIARIES IN WEST VIRGINIA AND IN THE UNITED STATES ………. 75
Introduction…………………………………………………………………………… 75
Methods ….……………………………………………………………………………
Data sources……………………………………………………………………...
Study populations………………………………………………………………...
Assessing delays in diagnosis and treatment…………………………………
Assessing receipt of timely lung cancer care, based on
clinical opinion-based guidelines ………………………………………………
Dependent variables……………………………………………………………..
Independent variables……………………………………………………………
Data analysis……………………………………………………………………...

80
80
81
82
84
85
86
87

Results…………………………………………………………………………………
Study population characteristics………………………………………………..
Delays in diagnosis and treatment ……………………………………………..
Receipt of timely care ……………………………………………………………
Factors associated with receipt of timely care………………………………...
Survival outcomes by receipt of timely care…………………………………...
Lung cancer mortality risk associated with non-receipt of timely care ……..

89
89
90
91
92
93
94

Discussion ……………………………………………………………………………. 95
Bibliography…………………………………………………………………………...119

vii

CHAPTER 4: PATTERNS OF RECEIPT OF TOBACCO-USE CESSATION
COUNSELING SERVICES AND ASSOCIATED HEALTH OUTCOMES AMONG
ELDERLY MEDICARE FEE-FOR-SERVICE BENEFICIARIES WITH LUNG
CANCER, AND WITH A HISTORY OF TOBACCO USE, IN WEST VIRGINIA 126
Introduction …………………………………………………………………………126
Methods ……………………………………………………………………………..129
Data sources ……………………………………………………………………129
Study population ….……………………………………………………………130
Assessing receipt of tobacco-use cessation counseling services ………..132
Dependent variables …………………………………………………………..132
Independent variables …………………………………………………………133
Data analysis …………………………………………………………………...135
Results …………………………………………………………………………….136
Receipt of tobacco-use cessation counseling services ……………………137
Factors associated with receipt of tobacco-use cessation
counseling services …………………………………………………………....137
Survival benefits associated with receipt of tobacco-use
cessation counseling services ………………………………………………..138
Lung cancer mortality risk associated with non-receipt of
tobacco-use cessation counseling services ………………………………...138
Discussion ………………………………………………………………………….139
Bibliography ………………………………………………………………………...155
CHAPTER 5: SUMMARY AND CONCLUSIONS

……………………………….160

Study summary ……………………………………………………………………..160
Significance of the study …………………………………………………………..167
Study limitations ……………………………………………………………………170
Directions for future research ……………………………………………………..174
Bibliography ………………………………………………………………………...176
APPENDIX ………………………………………………………………………………….181
Appendix 2.1. List of International Classification of Diseases (ICD-9) diagnosis
and procedure codes, Healthcare Common Procedure Coding System (HCPCS)
codes, Current Procedural Terminology (CPT) codes and revenue center codes,

viii

used to identify lung cancer specific treatments and procedures in Medicare
claim data files………………………………………………………………………182
Appendix 3.1. List of International Classification of Diseases (ICD-9) diagnosis
and procedure codes, Healthcare Common Procedure Coding System (HCPCS)
codes, Current Procedural Terminology (CPT) codes, revenue center codes, and
Health Care Financing Administration (HCFA) provider specialty codes, used to
identify symptoms associated with lung cancer, provider specialty, and lung
cancer specific treatments and procedures in Medicare claim data files …….183
Appendix 4.1. List of International Classification of Diseases (ICD-9) diagnosis
and procedure codes, Healthcare Common Procedure Coding System (HCPCS)
codes, Current Procedural Terminology (CPT) codes and revenue center codes,
used to identify lung cancer specific treatments, procedures, and other health
care services in Medicare claim data files ……………………………………….187
CURRICULUM VITAE …………………………………………………………………….188

ix

LIST OF TABLES
Table 2.1. Descriptive characteristics of continuously enrolled Medicare Fee-for-service
beneficiaries with incident diagnosis of lung cancer in West Virginia and in
the United States, July 2003 through December 2006.……………………. 56
Table 2.2. Descriptive characteristics by type of treatment among continuously enrolled
Medicare Fee-for-service beneficiaries with incident diagnosis of lung cancer
in West Virginia and in the United States, July 2003 through
December 2006.……………………………………………………………….. 58
Table 2.3. Descriptive characteristics by receipt of minimally appropriate clinical
guideline based lung cancer care among continuously enrolled Medicare
Fee-for-service beneficiaries with incident diagnosis of lung cancer
(Stages I-III) in West Virginia and in the United States, July 2003 through
December 2006.……………………………………………………………….. 60
Table 2.4. Minimally appropriate clinical guideline based lung cancer care by cancer
type and stage, among continuously enrolled Medicare Fee-for-service
beneficiaries with incident diagnosis of lung cancer (Stages I-III) in West
Virginia and in the United States, July 2003 through
December 2006.……………………………………………………………….. 62
Table 2.5. Factors associated with receipt of minimally appropriate clinical guideline
based lung cancer care among continuously enrolled Medicare Fee-forservice beneficiaries with incident diagnosis of lung cancer (Stages I-III) in
West Virginia and in the United States, July 2003 through
December 2006.……………………………………………………………….. 63
Table 2.6. Three-year median survival time and survival rate by cancer type and stage,
and by receipt of minimally appropriate clinical guideline based lung cancer
care, among continuously enrolled Medicare Fee-for-service beneficiaries
with incident diagnosis of lung cancer (Stages I-III) in West Virginia and in
the United States, July 2003 through December 2004.…………………… 65
Table 2.7. Lung cancer mortality risk associated with non-receipt of minimally
appropriate clinical guideline based lung cancer care, among continuously
enrolled Medicare Fee-for-service beneficiaries with incident diagnosis of
lung cancer (Stages I-III) in West Virginia and in the United States,
July 2003 through December 2004.…………………………………………. 67
Table 3.1. Descriptive characteristics of continuously enrolled Medicare Fee-for-service
beneficiaries with incident diagnosis of lung cancer in West Virginia and in
the United States from 2003 through 2006.………………………………… 105

x

Table 3.2. Earliest symptoms reported among continuously enrolled Medicare Fee-forservice beneficiaries with incident diagnosis of lung cancer in West Virginia
and in the United States from 2003 through 2006.………………………… 107
Table 3.3. Delays in diagnosis and treatment among continuously enrolled Medicare
Fee-for-service beneficiaries with incident diagnosis of lung cancer in West
Virginia and in the United States from 2003 through 2006………………... 108
Table 3.4. Delays (in days) in diagnosis and treatment in relation to clinical
characteristics among continuously enrolled Medicare Fee-for-service
beneficiaries with incident diagnosis of lung cancer in West Virginia and in
the United States from 2003 through 2006.………………………………… 109
Table 3.5. Descriptive characteristics by receipt of timely lung cancer care, based on
clinical opinion-based guidelines, among continuously enrolled Medicare
Fee-for-service beneficiaries with incident diagnosis of lung cancer in West
Virginia and in the United States from 2003 through 2006.………………. 111
Table 3.6. Factors associated with receipt of timely lung cancer care, based on clinical
opinion-based guidelines, among continuously enrolled Medicare Fee-forservice beneficiaries with incident diagnosis of lung cancer in West Virginia
and in the United States from 2003 through 2006.………………………… 113
Table 3.7. Three-year median survival time and survival rate by cancer type, and by
receipt of timely lung cancer care, based on clinical opinion-based
guidelines, among continuously enrolled Medicare Fee-for-service
beneficiaries with incident diagnosis of lung cancer in West Virginia and in
the United States from 2003 through 2004. ………………………………. 115
Table 3.8. Lung cancer mortality risk associated with receipt of non-timely lung cancer
care, based on clinical opinion-based guidelines, among continuously
enrolled Medicare Fee-for-service beneficiaries with incident diagnosis of
lung cancer in West Virginia and in the United States from 2003 through
2004.……………………………………………………………………………. 116
Table 3.9. Adjusted lung cancer mortality risk associated with receipt of non-timely lung
cancer care, based on clinical opinion-based guidelines, by cancer type and
stage, among continuously enrolled Medicare Fee-for-service beneficiaries
with incident diagnosis of lung cancer in West Virginia and in the United
States from 2003 through 2004.……………………………………………… 118
Table 4.1. Descriptive characteristics of continuously enrolled Medicare Fee-for-service
beneficiaries with an incident diagnosis of lung cancer and with a history of
tobacco use in West Virginia, July 2005 through October 2007.…………. 148

xi

Table 4.2. Descriptive characteristics by receipt of tobacco-use cessation counseling
services, among continuously enrolled Medicare Fee-for-service
beneficiaries with an incident diagnosis of lung cancer and with a history of
tobacco use in West Virginia, July 2005 through October 2007.…………. 149
Table 4.3. Factors associated with receipt of tobacco-use cessation counseling services
among continuously enrolled Medicare Fee-for-service beneficiaries with an
incident diagnosis of lung cancer and with a history of tobacco use in West
Virginia, July 2005 through October 2007.………………………………….. 151
Table 4.4. Lung cancer mortality risk associated with non-receipt of tobacco cessation
counseling services among continuously enrolled Medicare Fee-for-service
beneficiaries with an incident diagnosis of lung cancer (Stages I-IV) and with
a history of tobacco use in West Virginia, July 2005 through
December 2005.……………………………………………………………….. 153

xii

LIST OF FIGURES
Figure 2.1. Algorithm adapted from American College of Chest Physicians (ACCP)
evidence-based guidelines for diagnosis and management of lung cancer
published in January, 2003, and used to determine receipt of minimally
appropriate clinical guideline based lung cancer care.……………………. 54
Figure 2.2. Kaplan-Meier survival estimates with 95% confidence limits by receipt of
minimally appropriate clinical guideline based lung cancer care among
continuously enrolled Medicare Fee-for-service beneficiaries with incident
diagnosis of lung cancer (Stages I-III) in West Virginia and in the United
States, July 2003 through December 2004. Curves (unadjusted) show
cause-specific mortality.……………………………………………………… 55
Figure 3.1. Kaplan-Meier survival curves by cancer stage, and by receipt of timely lung
cancer care, based on clinical opinion-based guidelines, among
continuously enrolled Medicare Fee-for-service beneficiaries with incident
diagnosis of lung cancer in West Virginia and in the United States from 2003
through 2004. Curves (unadjusted) show cause-specific mortality.……. 104
Figure 4.1. Algorithm adapted from American College of Chest Physicians (ACCP)
evidence-based guidelines for diagnosis and management of lung cancer
published in January, 2003, and used to determine receipt of minimally
appropriate clinical guideline based lung cancer care.……………………. 146
Figure 4.2. Kaplan-Meier survival curves (with 95% confidence limits) by receipt of
tobacco-use cessation counseling services among continuously enrolled
Medicare Fee-for-service beneficiaries with an incident diagnosis of lung
cancer (Stages I-IV) and with a history of tobacco use in West Virginia, July
2005 through December 2005. Curves (unadjusted) show cause-specific
mortality.……………………………………………………………………….. 147

xiii

CHAPTER 1

1

CHAPTER 1:
INTRODUCTION

Overview of Lung Cancer
Lung cancer is the cancer that starts in the lungs. In the United States (US), lung
cancer is the second most diagnosed cancer in both men and women. During 2012, an
estimated 226,160 new cases of lung cancer were expected to be diagnosed,
representing about 14% of all cancer diagnoses.1 The elderly carry a disproportionate
burden of lung cancer, as approximately 81% of those living with lung cancer are 60
years of age or older.2 This pattern is expected to persist as the estimated number of
elderly in the US doubles to nearly 70 million by 2030. Based on cell histology, there
are two main types of lung cancer: (1) Non-small cell lung cancer, and (2) Small cell
lung cancer. Non-small cell lung cancer (NSCLC) is the most common type of lung
cancer, and it makes up about 80% of all lung cancer cases.3 It usually grows and
spreads more slowly than Small cell lung cancer (SCLC).
In the US, lung cancer is also the leading cause of cancer deaths in both men
and women.1;2 It causes more deaths than the next three most common cancers
combined (colon, breast, and prostate).1;2;4 In women, the deaths from lung cancer
surpassed those due to breast cancer in 1987.2 In men, approximately 31% of cancer
deaths are attributable to lung cancer. The number of deaths due to lung cancer has
increased approximately 4.3% between 1999 and 2008, from 152,156 to 158,656.5
While the number of deaths among men has reached a plateau, the number is still rising
among women.5 The age-adjusted death rate for lung cancer is higher for men (63.6
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per 100,000) than for women (39.0 per 100,000). It is also higher for Blacks (53.4 per
100,000) as compared to Whites (50.2 per 100,000). While Black men have a far
higher age-adjusted lung cancer death rate than White men, Black and White women
have similar rates.1;2
Substantial geographic variation in lung cancer incidence and mortality rates has
also been observed in the US. In 2009, Kentucky (KY) followed by West Virginia (WV)
had the highest age-adjusted lung cancer incidence rate (KY: 96.9 per 100,000, WV:
82.7 per 100,000), and mortality rate (KY: 69.0 per 100,000, WV: 67.0 per 100,000).6
These state-specific rates were parallel to smoking prevalence rates, and are much
higher than the average US lung cancer incidence and mortality rates (64.3 per 100,000
and 48.5 per 100,000, respectively).6 Utah had the lowest age-adjusted lung cancer
incidence and mortality rates (28.1 per 100,000 and 20.4 per 100,000, respectively).6

Etiology of lung cancer
A single etiologic agent, cigarette smoking, is by far the leading cause of lung cancer,
and it accounts for approximately 90% of lung cancer cases in the US.7 The causal
association of cigarette smoking with lung cancer is one of the most thoroughly
documented causal relationships in biomedical literature.8;9 Compared to never
smokers, smokers have an approximately 20 times increased lung cancer risk. The risk
of lung cancer among cigarette smokers increases with the duration of smoking and the
number of cigarettes smoked per day.10 While trends in lung cancer occurrence closely
reflect patterns of smoking, the rates of occurrence lag smoking rates by about 20
years.
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While the predominant cause of lung cancer is now well-known, there are other
causes as well. They include exposure to radon, arsenic, asbestos, chromates,
chloromethyl ethers, nickel, polycyclic aromatic hydrocarbons, and other carcinogenic
agents.3 Outdoor air pollution, which includes combustion generated carcinogens, is
also considered to contribute to lung cancer risk in an urban population.3 Some of
these risk factors can also act in concert with smoking to synergistically increase risk of
lung cancer.

Prevention of lung cancer
There are many interventions that might be considered as strategies for reducing lungspecific cancer risks including smoking prevention and cessation, lifestyle as well as
dietary or nutritional changes, and effective screening of identified high-risk individuals
among others. Of these strategies, only smoking prevention and cessation has been
shown to reduce lung cancer risk.11 Research has shown a close association between
national mortality rates and smoking.12 Prevention approaches that delay the age of
onset of smoking in a population could have a substantial impact on the incidence of
lung cancer by shortening the duration of smoking. Furthermore, smoking cessation
has shown to reduce the risk of lung cancer, regardless of sex, and type of tobacco
smoked.13

Screening for lung cancer
Similar to any other cancer, if lung cancer is diagnosed at an early stage, the treatment
options and survival benefits are better compared to that of late stage cancer.
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Therefore, it makes sense to have screening tests that can increase the rate of
detection at an early stage. Chest X-rays (CXR), sputum cytology and Low-Dose
computed tomography (LDCT) are the commonly used non-invasive diagnostic tests for
lung cancer screening. Prior studies assessing the utility of these non-invasive tests for
lung cancer screening purposes in asymptomatic individuals have shown mixed
results.14;15
While, conventional CXR detect tumors about 1 to 2 cm (0.4 to 0.8 inches) in
size, computed tomography (CT) is very sensitive, and is capable of routinely detecting
nodules as small as 2 to 3 mm in size. Previous screening studies have shown that,
screening increases the rate of detection of early-stage lung cancer, but it fails to
reduce the number of late-stage lung cancers or the risk for dying from lung cancer.16-18
This is because screening detects a large number of small, slowly growing, less
aggressive lung cancers that are unlikely to progress to a point that they cause clinical
disease while missing cancers that advance rapidly and cause the majority of deaths
from lung cancer. Currently, no clinical evidence-based guidelines support the use of
any test for screening purposes in the general population. However, the evidence is
changing, especially with results from the National Lung Screening Trial,14 and as new
data become available, the guidelines may be updated. The National Lung Screening
Trial was a randomized national trial involving more than 53,000 current and former
heavy smokers ages 55 to 74, which compared the effects of two screening procedures
for lung cancer: low-dose helical CT; and CXR, on lung cancer mortality. This study
was designed to have a 90% power to detect a mortality reduction of 20% by 2009. The
initial results show 20 percent fewer lung cancer deaths among trial participants
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screened with low-dose helical CT compared to those screened with CXR. In addition,
deaths from all-causes (including lung cancer) were 7% lower among those who
received the low-dose helical CT scans. In light of these findings, screening with lowdose spiral CT scans has been recommended for individuals at an increased risk of
lung cancer by the American College of Chest Physicians (ACCP) and the American
Society of Clinical Oncology (ASCO).19

Diagnosis and staging of lung cancer
A majority (90%) of patients with lung cancer are symptomatic at presentation. The
symptoms may be due to: (1) Primary tumor, example: cough, dyspnea, chest pain, and
hemoptysis; (2) Intrathoracic spread of lung cancer, example: recurrent laryngeal nerve
palsy, phenic nerve paralysis, and Horner syndrome; (3) Extrathoracic metastases,
example: bone pain, and weight loss; and/or (4) Paraneoplastic syndromes related to
malignant disease, example: hypercalcemia, and Cushing syndrome. The diagnosis is
usually suspected following an abnormality on the chest radiograph. All patients
suspected of lung cancer undergo a thorough medical history, physical examination,
and standard laboratory tests, as a screen for metastatic disease.
The basis for staging lung cancer is the American Joint Committee on Cancer
(AJCC), TNM (Tumor, Node, and Metastasis) system.20;21 Correctly staging lung cancer
is extremely important because the prognoses differ significantly by stage. Several
noninvasive imaging studies are available to aid in identifying the disease, both within
and outside of the chest. They include chest CT scanning, and whole-body positron
emission tomography (PET) scanning.22 In cases where noninvasive radiographic
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staging is not reliable, invasive staging procedures are sometimes used to confirm the
stage and diagnosis. These invasive staging tests include mediastinoscopy,
thoracoscopy (video-assisted thoracoscopic surgery), transbronchial needle aspiration
(TBNA), transthoracic needle aspiration (TTNA), and endoscopic ultrasound with fine
needle aspiration (EUS-NA).23

Treatment of lung cancer
Lung cancer treatment options primarily depend on the type of cancer and the stage at
diagnosis. The treatment options for early stage NSCLC (Stage I-III), include surgery,
chemotherapy, radiation, or its combination.24 Surgical treatment options include
lobectomy (removal of a lobe of the lung), segmentectomy (removal of an anatomic
division of a particular lobe of the lung), pnemonectomy (removal of an entire lung), and
wedge resection. Five year survival rates of approximately 40% are anticipated with
standard surgical resection.25 Unfortunately, only a few NSCLC patients are diagnosed
at an early stage, and approximately 70% of all NSCLS patients present with advanced
stage III and IV disease.25 Treatment options for advanced stage NSCLC patients
(Stage IV) are limited and include chemotherapy, radiation therapy or its combination for
palliation of symptoms.24 The median survival times are typically 6 to 10 months and
most patients die within 1 to 2 years of diagnosis.25
Small cell lung cancer without treatment has the most aggressive clinical course
with median survival from diagnosis of only 2 to 4 months.26;27 Approximately 30% of
patients with SCLC present with limited-stage disease (Stage I-III) and their treatment
options include chemotherapy and radiation therapy.26 Median survival of 16 to 24
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months and 5-year survivals of 14% with current forms of treatment have been reported
in this group.26 However, in SCLC patients with extensive-stage disease (Stage IV),
median survival of only 6 to 12 months has been reported.26

Healthcare utilization and costs associated with lung cancer
The economic burden of lung cancer in the US is significant. The National Institutes of
Health estimates that approximately $10.3 billion per year is spent in the US on lung
cancer treatment alone.28 Compared to patients without cancer, patients with lung
cancer have greater health care service utilization and costs for hospitalization,
emergency room visits, outpatient office visits, radiology procedures, laboratory
procedures and pharmacy-dispensed drugs. The main cost drivers found in one study
were hospitalization (49.0% of costs) and outpatient office visits (35.2% of costs).29 In
the same study, monthly initial treatment phase costs ($11,496 per patient) were higher
than costs during the secondary treatment phase ($3,733) or terminal care phase
($9,399).29 Over the course of the 2-year study period, patients had total costs of
$120,650, compared with $45,953 for those receiving initial treatment only.29 Strategies
for increased prevention, reduced hospitalizations, and reduced treatment failure are
much needed, which may help reduce both resource use and healthcare costs.

Evidence Based Lung Cancer Care
Significant improvements have been made during the past decade in treatment and
survival after the diagnosis of cancer.30 Substantial disparities still exist in both cancer
outcomes and the receipt of guideline-based cancer-related health care.31 Lack of
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timely and high quality cancer care is still a concern,32;33 reflecting the extensively
documented similar concern about the quality of US health care in general.34;35 In 1999,
the National Cancer Policy Board of the Institute of Medicine (IOM) released a report
entitled, “Ensuring Quality Cancer Care”, stating that many cancer patients might not be
receiving the most effective care for their conditions.32 This might be attributable to
variations in the use of appropriate standards of care and the resulting treatment
variations.32

Appropriateness of care
To ensure uniformity of care, clinical guidelines, or statements of evidence for the
management and treatment of lung cancer, have been issued by the American College
of Chest Physicians (ACCP), the American Society for Clinical Oncology (ASCO), the
National Cancer Institute (NCI), and others.36-40 Clinical practice guidelines are defined
as “systematically developed statements to assist practitioner and patient decisions
about appropriate health care for specific clinical circumstances.”41 They are thought to
be capable of improving quality, appropriateness, and cost-effectiveness of care.41

Timeliness of care
Timeliness of care is another important dimension of cancer care quality. As, lung
cancer care requires complex coordination of services by different health care
professionals, the traditional approach of referring patients for consultation with multiple
specialists in a sequential fashion often results in care that is perceived as slow and
poorly coordinated. More diagnostic and treatment options are now available in the

9

outpatient settings resulting in fewer inpatient hospital stays.42 Clinical opinion-based
guidelines have been published by the British Thoracic Society (BTS), the RAND
Corporation, and the ACCP to establish standards for timely care for lung cancer
patients.43-45

Preventive care
Clinical practice guidelines for preventive care in lung cancer have been published by
ASCO, authors Biesalski et al, Cancer Guidance Group (CGG), College des Medecins
du Quebec, National Cancer Institute (NCI), US Department of Health and Human
Services (DHHS), and US Preventive Services Task Force.46-51 Smoking cessation is
strongly encouraged among lung cancer patients in these guidelines, as it may reduce
the rate of development of metachronous tumors. Continued smoking is also known to
interfere with cancer treatment.

Disparities in Lung Cancer Care and Health Outcomes
Despite the availability of clinical practice guidelines, numerous studies of clinical
practice patterns in US have documented variations in the management of lung cancer
patients according to age, race or ethnicity, education, comorbidity, insurance and
hospital type.52-58 Most of these studies include the elderly population aged 65 years
and older.52-54;56;58 In their analysis of Surveillance, Epidemiology, and End Results
(SEER)-Medicare linked dataset, Bach and colleagues (1999)56 reported that lower
survival rates among black patients with early-stage NSCLC, as compared to white
patients is largely explained by lower rates of surgical treatment among blacks.
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Similarly, likelihood of undergoing surgical resection was also found lower among dually
(Medicare-Medicaid) eligible patients with NSCLC compared to Medicare eligible
patients.52 Wide variation in the utilization of palliative chemotherapy also exists among
SEER-Medicare patients diagnosed with stage IV NSCLC.55 While overall use of
recommended therapies for NSCLC is low in the elderly, large variations exist in the use
of therapies according to age, race and ethnicity, and marital status.53
Extensive studies in European Union member countries have found delays in
diagnosis and treatment of lung cancer than recommended in clinical opinion based
guidelines.59-73 Five studies performed in the US have show mixed results.74-78 This
included one large study from Hawaii,76 one small study from Massachusetts78 and
three small studies conducted in Veterans Affairs (VA) facilities.74;75;77 In one of these
studies, Dransfield and colleagues (2006)75 found median time to resection among
NSCLC patients (104 days) exceed the 56-day maximum recommended by BTS. In
contrast, Riedel and colleagues (2006)74 found less than expected median time to
treatment initiation (22 days), while evaluating the benefits of multidisciplinary thoracic
oncology clinics in a VA setting. In the study from Massachusetts, no differences in
time to treatment were observed between Asian immigrants compared to non-Asians.78
Multidisciplinary clinics have been recommended in the literature to improve timeliness
of care.45 However in the US, patient care coordination through a dedicated lung mass
clinic or a multidisciplinary clinic has not shown any reduction in delays with either
approach.74;75 Even with timely care, Quarterman and colleagues (2003)77 found no
benefits in survival, making it unclear whether more timely care improves health
outcomes. Delay in treatment also did not explain the observed higher mortality risk
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from NSCLC in the only large population based study from Hawaii.76 While no US study
has identified the predictors of timely care, studies in other countries have found
atypical symptoms, comorbid conditions, teaching hospital setting, receipt of curative
(versus palliative) radiotherapy, initial referral to a non-respiratory physician,
requirement for multiple diagnostic tests, and care received at more than one health
care facility, to be associated with less timely care.63;66;79-82 Household income,66;80
gender,80 hospital volume,80 rural residence80 and distance travelled to obtain care66
were not associated with timeliness in these studies. Mixed results were observed in
studies that examined effect of age on timeliness of care.63;79-81
Given the fact that smoking is common in patients with lung cancer, there is a
profound impact of preventive care services such as smoking cessation counseling.
Gritz and colleagues studied smoking behavior in 840 adults with stage I NSCLC who
had participated in clinical trials.83 They found that at the time of diagnosis, of the 60%
of the patients who were smokers only 40% had quit smoking after 2 years.83
Richardson et al found that the relative risk of developing a second lung cancer
following curative-intent therapy for SCLC was lower for those who had stopped
smoking.84 Tucker and colleagues found that continuing to smoke increased the risk of
metachronous lung cancers in SCLC survivors.85

Geographic Variation
A significant reduction in lung cancer mortality can be achieved if patients receive timely
and medically effective therapies. Unfortunately, many rural areas of the US are
economically underdeveloped and medically underserved.86;87 The patients in these
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regions carry a higher burden of lung cancer compared to their urban counterparts.88
These rural areas are also known to report a higher prevalence of lung cancer and a
higher crude all-cause mortality rate.89 One such area is the Appalachian region, a
population representing 8.1% of the total US population.90;91 Forty-two percent of the
Appalachian population live in rural areas, compared to 20% of the national
population.91 The lung cancer death rate in rural Appalachia is higher than all of
Appalachia, and it is significantly higher than the national lung cancer death rate.90 The
observed lung cancer disparities in this rural population can be attributed to limited
access to quality medical care facilities, less access to or utilization of early cancer
detection programs, increased prevalence of behavioral risk factors like tobacco use
and sedentary life style, obesity, radon exposure, and socioeconomic factors, such as
low income and education.92-98 In addition to being medically underserved, this rural
population also experiences variations in the quality, availability, and accessibility of
services when compared to their urban counterparts.99
West Virginia is the only state situated entirely within the Appalachian region and
is the third most rural state in the nation. Fifty of the 55 counties in the state are
designated as medically underserved areas, and all or part of 40 counties in the state
are classified as health professional shortage areas.100 During 2002-2006, the ageadjusted lung cancer incidence rate (WV: 481.5 per 100,000, US: 378.5 per 100,000),
and mortality rate (WV: 390.6 per 100,000, US: 310.8 per 100,000) among the elderly
were higher in the state in comparison to the rest of the country.101;102
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Study Need
I.

Need to compare the appropriateness of lung cancer care and associated health
outcomes among elderly in West Virginia and in the United States

While numerous studies have examined lung cancer treatment variations in the US,
comprehensive evaluation of variations in clinical guideline based lung cancer care and
its impact on health outcomes in the elderly, remains unknown. Furthermore, a majority
of studies completed to-date have been conducted using the SEER-Medicare data, a
dataset that represents only 17 cancer registries and states/regions, and which reflects
a population that is more likely to reside in urban settings.103 Limited information is
currently available with respect to the variation in cancer care among elderly diagnosed
with lung cancer from rural settings and from non-SEER states. Population-based
cancer research aimed at identifying such variation in cancer care and improving cancer
outcomes in the rural and medically underserved elderly population is much needed.
Such studies would also help to explain the observed geographic disparities in lung
cancer mortality among elderly.
Chapter 2 in this study assesses the appropriateness of lung cancer care and
associated health outcomes among elderly Medicare Fee-for-service (FFS)
beneficiaries in WV, and in a representative US population. Appropriateness of care
was determined using the comprehensive ACCP clinical practice guidelines for lung
cancer care.37 West Virginia is representative of Appalachia and is similar to many
other rural and medically underserved states. It therefore serves as an excellent
laboratory for studying and addressing lung cancer disparities in a rural and medically
underserved elderly population. As lung cancer is most common in the elderly,
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Medicare administrative claims data were used to determine health service utilization.
Medicare is the federally funded program that provides health insurance for more than
47 million people, including nearly all persons age 65 years and older. Cancer registry
data were also used to identify disease characteristics of lung cancer patients. This
chapter provides a thorough evaluation of appropriateness of lung cancer care and its
impact on health outcomes among the elderly in the WV and US populations.
Specifically the objectives of this study include: (1) to compare treatment patterns
among elderly with lung cancer in the WV-US populations; (2) to compare the
proportion of elderly receiving minimally appropriate clinical guideline based lung cancer
care in the WV-US populations; (3) to compare the factors associated with receipt of
minimally appropriate clinical guideline based lung cancer care in the WV-US elderly
populations; (4) to compare the survival benefits associated with receipt of minimally
appropriate clinical guideline based lung cancer care in the WV-US elderly populations;
and (5) to compare lung cancer mortality risk associated with non-receipt of minimally
appropriate clinical guideline based lung cancer care, in the WV-US elderly populations.

II.

Need to compare the timeliness of lung cancer care and associated health
outcomes among elderly in West Virginia and in the United States

Improving timeliness of lung cancer care is important, regardless of its effect on heath
outcomes. Although prior studies have provided useful information concerning the
timeliness of care in lung cancer patients, a majority of them have been conduced on
European Union member countries. This limits the conclusion that one can make about
lung cancer care in non-European Union healthcare settings. Studies performed in the
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US are also limited by small sample sizes, with the exception of the study from Hawaii
that included more that 1000 patients. As lung cancer is most often diagnosed among
the elderly, studies that describe timeliness of care in the US elderly population are
required. Furthermore, given that many rural areas of the US are economically
underdeveloped and medically underserved, studies that compare the timeliness of lung
cancer care in such states within the US are required. Such studies would also help to
explain the observed geographic disparities in lung cancer mortality among elderly.
Chapter 3 assesses the timeliness of lung cancer care and associated health
outcomes among elderly Medicare FFS beneficiaries in WV, and in a representative US
population. Timeliness of care was determined using the BTS, and the RAND
Corporation clinical opinion-based guidelines for lung cancer care.44;45 West Virginia
was again chosen as a representative of other rural and medically underserved states.
Medicare administrative claims data and cancer registry data were used to identify
timeliness of lung cancer care in elderly patients. This chapter provides a thorough
evaluation of timeliness of lung cancer care and its impact on health outcomes among
elderly in the WV and US populations. Specifically, the objectives of this study include:
(1) to compare delays in diagnosis and treatment among elderly with lung cancer in the
WV-US populations; (2) to compare the proportion of elderly receiving timely lung
cancer care based on clinical opinion-based guidelines in the WV-US populations; (3) to
compare the factors associated with receipt of timely lung cancer care based on clinical
opinion-based guidelines in the WV-US elderly populations; (4) to compare survival
outcomes by receipt of timely lung cancer care based on clinical opinion-based
guidelines in the WV-US elderly populations; and (5) to compare lung cancer mortality
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risk associated with non-receipt of timely lung cancer care based on clinical opinionbased guidelines in the WV-US elderly populations.

III.

Need to assess patterns of receipt of tobacco-use cessation counseling services
and the impact on health outcomes among elderly lung cancer patients with a
history of tobacco use in West Virginia

Continued smoking following lung cancer diagnosis can interfere with cancer therapies,
such as radiation therapy and chemotherapy; increase risk of infection due to surgery
and decrease post-operative wound healing; and, increase the rate of development of
metachronous tumors. Promoting smoking cessation following lung cancer diagnosis is
much needed. Many insurance programs including Medicare, cover tobacco-use
cessation counseling services to promote smoking cessation. Still a majority of patients
continue to use tobacco following lung cancer diagnosis. Studies that identify patterns
of receipt of tobacco-use cessation counseling service and the impact on health
outcomes among elderly lung cancer patients are needed.
Chapter 4 in this study determines the patterns of receipt of tobacco-use
cessation counseling services and the impact on health outcomes among elderly
Medicare FFS beneficiaries with lung cancer and a history of tobacco use in WV. West
Virginia was again chosen for this study, as it has the highest smoking prevalence rate
(26.8%) in the nation.104 Lung cancer incidence and mortality rates in WV are also
higher than the US, and these rates are parallel to smoking prevalence rates within the
state.101;102 Therefore, West Virginia serves as an excellent laboratory for studying the
patterns of receipt of tobacco-use cessation counseling services and the impact on
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health outcomes among elderly lung cancer patients with a history of tobacco use.
Medicare administrative claims data and cancer registry data were used to identify
receipt of tobacco-use cessation counseling services. Specifically, the objectives of this
study include: (1) to determine the proportion of elderly lung cancer patients receiving
tobacco-use cessation counseling services; (2) to determine the factors associated with
receipt of tobacco-use cessation counseling services among elderly lung cancer
patients; (3) to determine survival benefits associated with receipt of tobacco-use
cessation counseling services among elderly lung cancer patients; and (4) to determine
lung cancer mortality risk associated with non-receipt of tobacco-use cessation
counseling services among elderly lung cancer patients.

Significance of the study
This study aims to provide in-depth information concerning patterns of lung cancer care
and associated health outcomes among elderly Medicare FFS beneficiaries in the WV
and US populations. First, appropriateness of lung cancer care is determined among
elderly in the WV and US populations using ACCP evidence-based guidelines for
diagnosis and management of lung cancer. These data enable us to understand the
variation in receipt of minimal appropriate lung cancer care among the elderly. It also
helps us understand the impact of receipt of minimal appropriate care on health
outcomes. Second, the study identifies the delays in lung cancer care and the
proportion of elderly that do receive timely lung cancer care based on BTS and RAND
Corporation clinical opinion-based guidelines. It also helps us to understand the impact
of delayed care on health outcomes. Finally, the study determines the patterns of
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receipt of tobacco-use cessation counseling service among elderly lung cancer patients
with a history of tobacco use in WV. Overall, this study will help to fill critical gaps in
clinical guidelines based lung cancer care and outcomes literature. Furthermore, the
results from this study will help to explain the observed geographic disparities in lung
cancer mortality among elderly in the WV and US populations.

19

Bibliography
(1) American Cancer Society. Cancer Facts and Figures, 2012. Available
at:http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/docume
nts/document/acspc-031941.pdf. Accessed on: January 15, 2013.
(2) U.S. National Institutes of Health. National Cancer Institute: SEER Cancer
Statistics Review, 1973-2008. Available at:
http://seer.cancer.gov/csr/1975_2009_pops09/index.html. Accessed on: January
15, 2013.
(3) Alberg AJ, Ford JG, Samet JM. Epidemiology of lung cancer: ACCP evidencebased clinical practice guidelines (2nd edition). Chest 2007; 132(3 Suppl):29S55S.
(4) Greenlee RT, Hill-Harmon MB, Murray T et al. Cancer statistics, 2001. CA
Cancer J Clin 2001; 51(1):15-36.
(5) Centers for Disease Control and Prevention. National Center for Health
Statistics. National Vital Statistics Report. Deaths: Final Data for 2008. December
2011; 59(10). Available at:
http://www.cdc.gov/nchs/data/nvsr/nvsr59/nvsr59_10.pdf. Accessed on: January
15, 2013.
(6) U.S. Cancer Statistics Working Group. United States Cancer Statistics: 19992009 Incidence and Mortality Web-based Report. Atlanta: U.S. Department of
Health and Human Services, Centers for Disease Control and Prevention and
National Cancer Institute; 2013. Available at: www.cdc.gov/uscs. Accessed on:
January 15, 2013.
(7) Peto R, Lopez AD, Boreham J, et al. Mortality from smoking in developed
countries 1950-2000: indrect estimates from national vital statistics. Oxford, UK:
Oxford University Press, 1994.
(8) US Department of Health, and Human Services (US-DHHS). Reducing the health
consequences of smoking: 25 years of progress; a report of the Surgeon
General. Washington, DC: US Goverment Printing Office, 1989.
(9) Zaridze D,.Peto R Tobacco: a major international health hazard. Lyon, France:
International Agency for Research on Cancer, 1986.
(10) Doll R, Peto R. Cigarette smoking and bronchial carcinoma: dose and time
relationships among regular smokers and lifelong non-smokers. J Epidemiol
Community Health 1978; 32(4):303-313.
(11) Dragnev KH, Stover D, Dmitrovsky E. Lung cancer prevention: the guidelines.
Chest 2003; 123(1 Suppl):60S-71S.

20

(12) Samet JM. Lung cancer. In: Greenwald P, Kramer BS, Weed DL, eds. Cancer
prevention and control. New York, NY: Marcel Dekker, 995; 561-584.
(13) Kelley MJ, McCrory DC. Prevention of lung cancer: summary of published
evidence. Chest 2003; 123(1 Suppl):50S-59S.
(14) Lung cancer trial results show mortality benefit with low-dose CT: Twenty percent
fewer lung cancer deaths seen among those who were screened with low-dose
spiral CT than with chest X-ray. Available at:
http://www.cancer.gov/newscenter/pressreleases/2011/NLSTresultsRelease.
Accessed on: January 20, 2013.
(15) Swensen SJ, Jett JR, Hartman TE et al. CT screening for lung cancer: five-year
prospective experience. Radiology 2005; 235(1):259-265.
(16) Bach PB, Kelley MJ, Tate RC et al. Screening for lung cancer: a review of the
current literature. Chest 2003; 123(1 Suppl):72S-82S.
(17) Kubik AK, Parkin DM, Zatloukal P. Czech Study on Lung Cancer Screening:
post-trial follow-up of lung cancer deaths up to year 15 since enrollment. Cancer
2000; 89(11 Suppl):2363-2368.
(18) Marcus PM, Bergstralh EJ, Fagerstrom RM et al. Lung cancer mortality in the
Mayo Lung Project: impact of extended follow-up. J Natl Cancer Inst 2000;
92(16):1308-1316.
(19) Bach PB, Mirkin JN, Oliver TK et al. Benefits and harms of CT screening for lung
cancer: a systematic review. JAMA 2012; 307(22):2418-2429.
(20) Mountain CF. Revisions in the International System for Staging Lung Cancer.
Chest 1997; 111(6):1710-1717.
(21) Mountain CF. A new international staging system for lung cancer. Chest 1986;
89(4 Suppl):225S-233S.
(22) Silvestri GA, Tanoue LT, Margolis ML et al. The noninvasive staging of non-small
cell lung cancer: the guidelines. Chest 2003; 123(1 Suppl):147S-156S.
(23) Detterbeck FC, DeCamp MM, Jr., Kohman LJ et al. Lung cancer. Invasive
staging: the guidelines. Chest 2003; 123(1 Suppl):167S-175S.
(24) National Cancer Institute: PDQ® Non-Small Cell Lung Cancer Treatment.
Bethesda, MD: National Cancer Institute. Date last modified 11/05/2012.
Available at: http://www.cancer.gov/cancertopics/pdq/treatment/non-small-celllung/healthprofessional. Accessed on January 19, 2013.
(25) Ihde DC, Minna JD. Non-small cell lung cancer. Part I: Biology, diagnosis, and
staging. Curr Probl Cancer 1991; 15(2):61-104.

21

(26) National Cancer Institute: PDQ® Small Cell Lung Cancer Treatment. Bethesda,
MD: National Cancer Institute. Date last modified 1/20/2012. Available at:
http://www.cancer.gov/cancertopics/pdq/treatment/small-celllung/healthprofessional. Accessed on January 19, 2013.
(27) National Cancer Institute: What you need to know about Lung Cancer [NIH
Publication No. 07-1553]. Available at:
http://www.cancer.gov/cancertopics/wyntk/lung/page1. Accessed on: January 19,
2013.
(28) U.S. National Institutes of Health. National Cancer Institute. A Snapshot of Lung
Cancer. October, 2012. Available at:
http://www.cancer.gov/researchandfunding/snapshots/pdf/Lung-Snapshot.pdf.
Accessed on: January 15, 2013.
(29) Kutikova L, Bowman L, Chang S et al. The economic burden of lung cancer and
the associated costs of treatment failure in the United States. Lung Cancer 2005;
50(2):143-154.
(30) Eden J, Sinone JV, eds. Assessing the Quality of Cancer Care: an Approach to
Measurement in Georgia, Washington, DC: The National Academies Press;
2005.
(31) Harlan LC, Greene AL, Clegg LX et al. Insurance status and the use of guideline
therapy in the treatment of selected cancers. J Clin Oncol 2005; 23(36):90799088.
(32) Hewitt M, Simone JV, eds. Ensuring the Quality of Cancer Care. Washington,
DC: National Academy Press; 1999.
(33) Hewitt M, Simone JV, eds. Enhancing Data Systems to Improve the Quality of
Cancer Care. Washington, DC: National Acadamy Press; 2000.
(34) McGlynn EA, Asch SM, Adams J et al. The quality of health care delivered to
adults in the United States. N Engl J Med 2003; 348(26):2635-2645.
(35) Reid PP, Compton WD, Grossman JH, Fanjiang G, eds. Building a Better
Delivery System: a New Engineering/Health Care Partnership. Washington, DC:
The National Academies press; 2005.
(36) Pfister DG, Johnson DH, Azzoli CG et al. American Society of Clinical Oncology
treatment of unresectable non-small-cell lung cancer guideline: update 2003. J
Clin Oncol 2004; 22(2):330-353.
(37) Diagnosis and management of lung cancer: ACCP evidence-based guidelines.
American College of Chest Physicians. Chest 2003; 123(1 Suppl):D-337S.

22

(38) Clinical practice guidelines for the treatment of unresectable non-small-cell lung
cancer. Adopted on May 16, 1997 by the American Society of Clinical Oncology.
J Clin Oncol 1997; 15(8):2996-3018.
(39) National Comprehensive Cancer Network and American Cancer Society: Lung
Cancer: Treatment Guidelines for Patients. Version 1, December 2001. Available
at: http://www.nccn.org. Accessed on: January 15, 2013.
(40) National Cancer Institute: Physician Data Query Cancer Information Summaries.
Available at: http://www.nci.nih.gov/cancerinfo/pdf/treatment/non-small-celllung/healthprofessional/. Accessed on: January 15, 2013.
(41) Institute of Medicine Committee to Advise the Public Health Service on Clinical
Practice Guidelines. Clinial practice guidelines: directions for a new program.
Field M, Lohr Kn, eds. Washington, DC: National Academy Press, 1990.
(42) Olsson JK, Schultz EM, Gould MK. Timeliness of care in patients with lung
cancer: a systematic review. Thorax 2009; 64(9):749-756.
(43) Alberts WM, Bepler G, Hazelton T et al. Lung cancer. Practice organization.
Chest 2003; 123(1 Suppl):332S-337S.
(44) Reifel, J. L. Lung cancer. Asch, S. M.; Kerr, E. A.; Hamilton, E. G.; Reifel, J. L.,
and McGlynn, E. A. Quality of care for oncologic condition and HIV: a review of
the literature and quality indicators. RAND; 2000; pp. 133-71. Rec #: 657. 2011.
(45) BTS recommendations to respiratory physicians for organising the care of
patients with lung cancer. The Lung Cancer Working Party of the British Thoracic
Society Standards of Care Committee. Thorax 1998; 53 Suppl 1:S1-S8.
(46) Cancer Guidence Group. Guidance on commissioning ancer services; improving
outcomes in lung cancer: the manual. London, JK: National Health Service
Executive, 1998.
(47) Colllege des medecins du Quebec. Clinical practice guidelines: smoking
prevention and cessation; May 1999. Available at:
http://www.cmq.org/tabacang.pdf. Accessed on: August 16, 2012.
(48) National Cancer Institute. Lung cancer (PDQ): prevention; March 2001. Available
at: http://www.cancer.gov/cancer_information/pdq. Accessed on: December
16,2012.
(49) Fiore MC, Bailey WC, Cohen SJ, et al. Treating tobacco use and dependence:
clinical practice guideline. Rockville, MD: US Department of Health and Human
Services, Public Health Service, 2000.

23

(50) US Preventive Services Task Force. Screening for lung cancer. In: Guide to
clinical preventive services. 2nd ed. Baltimore, MD: Williams & Wilkins, 1996;
135-139.
(51) Biesalski HK, Bueno de MB, Chesson A et al. Consensus statement on lung
cancer. Lung Cancer Panel. Eur J Cancer Prev 1997; 6(4):316-322.
(52) Bradley CJ, Dahman B, Given CW. Treatment and survival differences in older
Medicare patients with lung cancer as compared with those who are dually
eligible for Medicare and Medicaid. J Clin Oncol 2008; 26(31):5067-5073.
(53) Potosky AL, Saxman S, Wallace RB et al. Population variations in the initial
treatment of non-small-cell lung cancer. J Clin Oncol 2004; 22(16):3261-3268.
(54) Earle CC, Venditti LN, Neumann PJ et al. Who gets chemotherapy for metastatic
lung cancer? Chest 2000; 117(5):1239-1246.
(55) Fry WA, Phillips JL, Menck HR. Ten-year survey of lung cancer treatment and
survival in hospitals in the United States: a national cancer data base report.
Cancer 1999; 86(9):1867-1876.
(56) Bach PB, Cramer LD, Warren JL et al. Racial differences in the treatment of
early-stage lung cancer. N Engl J Med 1999; 341(16):1198-1205.
(57) Hillner BE, McDonald MK, Desch CE et al. A comparison of patterns of care of
nonsmall cell lung carcinoma patients in a younger and Medigap commercially
insured cohort. Cancer 1998; 83(9):1930-1937.
(58) Smith TJ, Penberthy L, Desch CE et al. Differences in initial treatment patterns
and outcomes of lung cancer in the elderly. Lung Cancer 1995; 13(3):235-252.
(59) Leo F, Venissac N, Poudenx M et al. Multidisciplinary management of lung
cancer: how to test its efficacy? J Thorac Oncol 2007; 2(1):69-72.
(60) Neal RD, Allgar VL, Ali N et al. Stage, survival and delays in lung, colorectal,
prostate and ovarian cancer: comparison between diagnostic routes. Br J Gen
Pract 2007; 57(536):212-219.
(61) Devbhandari MP, Soon SY, Quennell P et al. UK waiting time targets in lung
cancer treatment: are they achievable? Results of a prospective tracking study. J
Cardiothorac Surg 2007; 2:5.
(62) Comber H, Cronin DP, Deady S et al. Delays in treatment in the cancer services:
impact on cancer stage and survival. Ir Med J 2005; 98(8):238-239.
(63) Salomaa ER, Sallinen S, Hiekkanen H et al. Delays in the diagnosis and
treatment of lung cancer. Chest 2005; 128(4):2282-2288.

24

(64) Lewis NR, Le J, I, Baldwin DR. Under utilisation of the 2-week wait initiative for
lung cancer by primary care and its effect on the urgent referral pathway. Br J
Cancer 2005; 93(8):905-908.
(65) Lee J, Marchbank A, Goldstraw P. Implementation of the British Thoracic Society
recommendations for organising the care of patients with lung cancer: the
surgeon's perspective. Ann R Coll Surg Engl 2002; 84(5):304-308.
(66) Campbell NC, Elliott AM, Sharp L et al. Impact of deprivation and rural residence
on treatment of colorectal and lung cancer. Br J Cancer 2002; 87(6):585-590.
(67) Aragoneses FG, Moreno N, Leon P et al. Influence of delays on survival in the
surgical treatment of bronchogenic carcinoma. Lung Cancer 2002; 36(1):59-63.
(68) Melling PP, Hatfield AC, Muers MF et al. Lung cancer referral patterns in the
former Yorkshire region of the UK. Br J Cancer 2002; 86(1):36-42.
(69) Koyi H, Hillerdal G, Branden E. Patient's and doctors' delays in the diagnosis of
chest tumors. Lung Cancer 2002; 35(1):53-57.
(70) Bozcuk H, Martin C. Does treatment delay affect survival in non-small cell lung
cancer? A retrospective analysis from a single UK centre. Lung Cancer 2001;
34(2):243-252.
(71) Spurgeon P, Barwell F, Kerr D. Waiting times for cancer patients in England after
general practitioners' referrals: retrospective national survey. BMJ 2000;
320(7238):838-839.
(72) Kesson E, Bucknall CE, McAlpine LG et al. Lung cancer--management and
outcome in Glasgow, 1991-92. Br J Cancer 1998; 78(10):1391-1395.
(73) Christensen ED, Harvald T, Jendresen M et al. The impact of delayed diagnosis
of lung cancer on the stage at the time of operation. Eur J Cardiothorac Surg
1997; 12(6):880-884.
(74) Riedel RF, Wang X, McCormack M et al. Impact of a multidisciplinary thoracic
oncology clinic on the timeliness of care. J Thorac Oncol 2006; 1(7):692-696.
(75) Dransfield MT, Lock BJ, Garver RI, Jr. Improving the lung cancer resection rate
in the US Department of Veterans Affairs Health System. Clin Lung Cancer 2006;
7(4):268-272.
(76) Liu DM, Kwee SA. Demographic, treatment, and survival patterns for Native
Hawaiians with lung cancer treated at a community medical center from 1995 to
2001. Pac Health Dialog 2004; 11(2):139-145.

25

(77) Quarterman RL, McMillan A, Ratcliffe MB et al. Effect of preoperative delay on
prognosis for patients with early stage non-small cell lung cancer. J Thorac
Cardiovasc Surg 2003; 125(1):108-113.
(78) Finlay GA, Joseph B, Rodrigues CR et al. Advanced presentation of lung cancer
in Asian immigrants: a case-control study. Chest 2002; 122(6):1938-1943.
(79) Bardell T, Belliveau P, Kong W et al. Waiting times for cancer surgery in Ontario:
1984-2000. Clin Oncol (R Coll Radiol ) 2006; 18(5):401-409.
(80) Simunovic M, Theriault ME, Paszat L et al. Using administrative databases to
measure waiting times for patients undergoing major cancer surgery in Ontario,
1993-2000. Can J Surg 2005; 48(2):137-142.
(81) Johnston GM, MacGarvie VL, Elliott D et al. Radiotherapy wait times for patients
with a diagnosis of invasive cancer, 1992-2000. Clin Invest Med 2004; 27(3):142156.
(82) Ringbaek T, Borgeskov S, Lange P et al. Diagnostic and therapeutic process and
prognosis in suspected lung cancer. Scand Cardiovasc J 1999; 33(6):337-343.
(83) Gritz ER, Nisenbaum R, Elashoff RE et al. Smoking behavior following diagnosis
in patients with stage I non-small cell lung cancer. Cancer Causes Control 1991;
2(2):105-112.
(84) Richardson GE, Tucker MA, Venzon DJ et al. Smoking cessation after successful
treatment of small-cell lung cancer is associated with fewer smoking-related
second primary cancers. Ann Intern Med 1993; 119(5):383-390.
(85) Tucker MA, Murray N, Shaw EG et al. Second primary cancers related to
smoking and treatment of small-cell lung cancer. Lung Cancer Working Cadre. J
Natl Cancer Inst 1997; 89(23):1782-1788.
(86) Behringer, B. (1994). Health care services in Appalachia. In: Couto, R. A.,
Simpson, N. K., and Harris, G. (eds.), Sowing Seeds in the Mountains,
Community-based Coalitions for Cancer Prevention and Control. NIH Publication
No. 94-3779:62-80. Bethesda, MD: NIH, National Cancer Institute.
(87) Newell-Withrow C. A glance at Appalachia. J Cult Divers 1997; 4(4):129-131.
(88) Monroe AC, Ricketts TC, Savitz LA. Cancer in rural versus urban populations: a
review. J Rural Health 1992; 8(3):212-220.
(89) Ricketts, T. C. (Ed.) 1999. Rural health in the United States. New York, NY:
Oxford University Press.
(90) Cancer death rates--Appalachia, 1994-1998. MMWR Morb Mortal Wkly Rep
2002; 51(24):527-529.

26

(91) ARC (Appalachian Regional Commission) (2011).The Appalachian region.
Available at: http://www.arc.gov/index.do?nodeId=2. Accessed on: August 24,
2012.
(92) State-specific prevalence and trends in adult cigarette smoking--United States,
1998-2007. MMWR Morb Mortal Wkly Rep 2009; 58(9):221-226.
(93) Casto BC, Sharma S, Fisher JL et al. Oral cancer in Appalachia. J Health Care
Poor Underserved 2009; 20(1):274-285.
(94) Wingo PA, Howe HL, Thun MJ et al. A national framework for cancer surveillance
in the United States. Cancer Causes Control 2005; 16(2):151-170.
(95) Silverstein MD, Nietert PJ, Ye X et al. Access to care and stage at diagnosis for
patients with lung cancer and esophageal cancer: analysis of the Savannah
River Region Information System cancer registry data. South Med J 2002;
95(8):900-908.
(96) Hall HI, Uhler RJ, Coughlin SS et al. Breast and cervical cancer screening
among Appalachian women. Cancer Epidemiol Biomarkers Prev 2002;
11(1):137-142.
(97) Casey MM, Thiede CK, Klingner JM. Are rural residents less likely to obtain
recommended preventive healthcare services? Am J Prev Med 2001; 21(3):182188.
(98) Wright JS, Champagne F, Dever GE et al. A comparative analysis of rural and
urban mortality in Georgia, 1979. Am J Prev Med 1985; 1(1):22-29.
(99) Amey CH, Miller MK, Albrecht SL. The role of race and residence in determining
stage at diagnosis of breast cancer. J Rural Health 1997; 13(2):99-108.
(100) West Virginia Health Care Authority (WVHCA) West Virginia State Health Plan.
2010. Available at: http://www.hcawv.org/PolicyPlan/shpBmat/shpProPiper.pdf.
Accessed on: September 17, 2011.
(101) United States Cancer Statistics: 1999-2006 Incidence, WONDER On-line
Database. United States Department of Health and Human Services, Centers for
Disease Control and Prevention and National Cancer Institute; 2010. Available at
http://wonder.cdc.gov/cancer-v2006.html. Accessed on: January 15, 2013.
(102) United States Cancer Statistics: 1999-2006 Mortality, WONDER On-line
Database. United States Department of Health and Human Services, Centers for
Disease Control and Prevention; 2010. Available at:
http://wonder.cdc.gov/CancerMort-v2006.html. Accessed on: January 15, 2013.

27

(103) Warren JL, Klabunde CN, Schrag D et al. Overview of the SEER-Medicare data:
content, research applications, and generalizability to the United States elderly
population. Med Care 2002; 40(8 Suppl):IV-18.
(104) Vital signs: current cigarette smoking among adults aged >/=18 years--United
States, 2005-2010. MMWR Morb Mortal Wkly Rep 2011; 60(35):1207-1212.

28

CHAPTER 2

29

CHAPTER 2:
APPROPRIATENESS OF LUNG CANCER CARE AND ASSOCIATED HEALTH
OUTCOMES AMONG ELDERLY MEDICARE FEE-FOR-SERVICE BENEFICIARIES IN
WEST VIRGINIA AND IN THE UNITED STATES

Introduction
In the United States (US), lung cancer is the leading cause of cancer deaths in both
men and women.1;2 It causes more deaths than the next three most common cancers
combined (colon, breast, and prostate).1-3 The elderly carry a disproportionate burden
of lung cancer, since approximately 81% of those living with lung cancer are 60 years of
age or older.2 This pattern is expected to persist as the estimated number of elderly in
the U.S. doubles to nearly 70 million by 2030.
Although lung cancer in the elderly is associated with a poor prognosis, several
treatment strategies can cure, or at least prolong survival. These treatment options
primarily depend on the type of lung cancer and the stage at diagnosis. Non-small cell
lung cancer (NSCLC) is the most common type of lung cancer, and it makes up about
80% of all lung cancer cases.4 The treatment options for early stage NSCLC (Stages IIII), include surgery, chemotherapy, radiation, or its combination.5 Five year survival
rates of approximately 40% are anticipated with standard surgical resection.6
Treatment options for individuals with advanced stage NSCLC (Stage IV) are limited
and include chemotherapy, radiation therapy, or its combination for palliation of
symptoms.5 The median survival times are typically 6 to 10 months and most
individuals die within 1 to 2 years of diagnosis.6 Compared to NSCLC, small cell lung
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cancer (SCLC) grows and spreads more quickly, and without treatment has the most
aggressive clinical course with median survival time from diagnosis of only 2 to 4
months.7;8 Approximately 30% of individuals with SCLC present with limited-stage
disease (Stages I-III) and their treatment options include chemotherapy and radiation
therapy.8 Median survival time of 16 to 24 months and 5-year survivals of 14% with
current forms of treatment have been reported in this group.8 However, in individuals
with extensive-stage SCLC (Stage IV), median survival time of only 6 to 12 months has
been reported.8
A significant reduction in lung cancer mortality can be achieved if the elderly
receive timely and medically effective therapies. To that end, specific strategies for the
management and treatment of lung cancer have been recommended in clinical
guidelines by the American College of Chest Physicians (ACCP), the American Society
for Clinical Oncology (ASCO), the National Cancer Institute (NCI), and others.9-13
These clinical guidelines ensure uniformity of care, and are thought to be capable of
improving quality, appropriateness, and cost-effectiveness of care.14 However,
numerous studies of clinical practice patterns in the US have documented variations in
the management of individuals with lung cancer according to age, race or ethnicity,
education, comorbidity, insurance and hospital type.15-21 In one study, lower rates of
surgical treatment among elderly black individuals with early-stage NSCLC, as
compared to white individuals, largely explained the survival difference by race.19 In
another study, the likelihood of undergoing surgical resection among elderly with
NSCLC was found to be lower among dually (Medicare-Medicaid) eligible individuals
compared to Medicare eligible individuals.15 Besides treatment with curative intent,
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wide variation in the utilization of palliative chemotherapy also exists among individuals
diagnosed with stage IV NSCLC.18 Lack of high quality cancer care remains a concern,
and it is attributable to variations in the use of appropriate standards of care.22-24
While variations in lung cancer management and outcomes exist across the
nation, it is a cause for major concern in the rural areas. Many rural areas of the US are
economically underdeveloped and medically underserved.25;26 The elderly in these
regions carry a higher burden of lung cancer compared to their urban counterparts.27
These rural areas are also known to report a higher prevalence of lung cancer and a
higher crude all-cause mortality rate among the elderly.28;29 One such area is the
Appalachian region, a population representing 8.1% of the total US population.29 West
Virginia (WV) is the only state situated entirely within the Appalachian region and is the
third most rural state in the nation.29 Fifty of the 55 counties in the state are designated
as medically underserved areas, and all or part of 40 counties in the state are classified
as health professional shortage areas.30 During 2002-2006, the age-adjusted lung
cancer incidence rate (WV: 481.5 per 100,000, US: 378.5 per 100,000), and mortality
rate (WV: 390.6 per 100,000, US: 310.8 per 100,000) among the elderly were higher in
the state in comparison to rest of the country.31;32 Interestingly, the proportional
difference in age-adjusted lung cancer mortality rates among the elderly from WV and
the US was lower than the difference in age-adjusted lung cancer incidence rates. This
might suggest better survival outcomes among elderly lung cancer patients in WV as
compared to the US; however, such a hypothesis remains unexplored. The observed
lung cancer disparities in the rural population can be attributed to limited access to
quality medical care facilities; less access to, or utilization, of early cancer detection
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programs; increased prevalence of behavioral risk factors, such as tobacco use and
sedentary life style, and socioeconomic factors, such as low income and education.33-39
In addition to being medically underserved, the rural population may also experience
variations in the quality, availability, and accessibility of services when compared to
urban counterparts.40
While numerous studies have examined lung cancer treatment variations in the
US, comprehensive evaluation of variations in clinical guideline based lung cancer care,
and its impact on health outcomes in the elderly remains unknown. Furthermore,
comparison of geographical variations in clinical guideline based lung cancer care and
associated health outcomes among the elderly from a diverse region like WV with those
in the US is much needed. Such studies would help to explain the observed regional
disparities in lung cancer mortality among the elderly. To this end, the main focus of
this study is to investigate and compare the appropriateness of lung cancer care based
on clinical guidelines among the elderly in WV, and in a representative US population.
Specifically the objectives of this study include: (1) to compare treatment patterns
among elderly with lung cancer in the WV-US populations; (2) to compare the
proportion of elderly receiving minimally appropriate clinical guideline based lung cancer
care in the WV-US populations; (3) to compare the factors associated with receipt of
minimally appropriate clinical guideline based lung cancer care in the WV-US elderly
populations; (4) to compare the survival benefits associated with receipt of minimally
appropriate clinical guideline based lung cancer care in the WV-US elderly populations;
and (5) to compare lung cancer mortality risk associated with non-receipt of minimally
appropriate clinical guideline based lung cancer care, in the WV-US elderly populations.
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Methods

Data sources
This retrospective study was conducted using cancer registry linked Medicare data files
for the years 2002 through 2007. Cancer registry data files provided clinical,
demographic, cause of death, and initial treatment information for elderly individuals
with lung cancer in selected geographic regions. The Medicare administrative data files
provided the health service claims information for care provided by physicians, inpatient
hospital stays, hospital outpatient clinics, home health care agencies, skilled nursing
facilities, and hospice programs.
Specifically, the Surveillance, Epidemiology, and End Results (SEER) - Medicare
linked data files were purchased from the National Cancer Institute, and were used to
estimate the appropriateness of lung cancer care based on clinical guidelines in the
elderly US population. Data from the SEER program are representative of US cancer
incidence and mortality, as they contain information from 20 population-based cancer
registries covering approximately 28 percent of the US population.41
To estimate the appropriateness of lung cancer care based on clinical guidelines
in the elderly WV population, we used West Virginia Cancer Registry (WVCR) Medicare linked data files. The WVCR-Medicare linked data files are similar in structure
to the SEER-Medicare linked data files, and represent data from the West Virginia
Cancer Registry, which does not participate in the SEER program. Details on the
creation of WVCR-Medicare linked data files can be found elsewhere.42
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Study populations
We initially identified all Medicare Fee-for-service (FFS) beneficiaries aged 66 years
and older, with incident lung cancer (Stages I-IV) diagnosis, between July 1, 2003 and
December 31, 2006, from the SEER-Medicare linked data files (hereafter referred to as
‘US population’), and the WVCR-Medicare linked data files (hereafter referred to as ‘WV
population’), separately. Lung cancer diagnosis was identified among individuals in the
cancer registry files using the International Classification of Diseases for Oncology
(ICD-O) codes (C34.0, C34.1, C34.2, C34.3, C34.8, C34.9, and C33.9). Lung cancer
stage was identified using American Joint Committee on Cancer (AJCC), Tumor Node
Metastasis (TNM), 3rd edition stage (for 2003 diagnosis) and 6th edition stage (for 20042006 diagnosis).43;44 While Medicare eligibility starts at age 65, we only included
beneficiaries aged 66 years and older at the time of diagnosis, so that we would have a
full year of Medicare claims before lung cancer diagnosis for assessing comorbidity.
We then excluded individuals with multiple primary cancer diagnosis or whose diagnosis
was made only at the time of death (death certificate review/autopsy diagnosis). We
also excluded beneficiaries who were enrolled in a Medicare managed care plan or who
had non-continuous Medicare Part A and Part B enrollment, in the year prior to
diagnosis, and during the year following diagnosis. This is because their Medicare files
would not have complete treatment information. The remaining cohorts of continuously
enrolled elderly Medicare FFS beneficiaries in WV and the US population (study
cohorts) were then used to compare treatment patterns, to compare the proportion of
beneficiaries receiving minimally appropriate clinical guideline based lung cancer care,
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and to compare the factors associated with receipt of minimally appropriate clinical
guideline based lung cancer care.
Given the limited years of data available for follow up in our data sources, we
further subset the above study cohorts for survival analysis. Specifically, from the study
cohorts we selected beneficiaries with lung cancer diagnosis between July 1, 2003 and
December 31, 2004, and then followed them for three years following the incident lung
cancer diagnosis to determine lung cancer specific mortality. These subsets of study
cohorts in WV and the US population were then used to compare survival benefits
associated with receipt of minimally appropriate clinical guideline based lung cancer
care, and to compare lung cancer mortality risk associated with non-receipt of minimally
appropriate clinical guideline based lung cancer care.

Assessing receipt of clinical guideline based lung cancer care
Continuously enrolled elderly Medicare FFS beneficiaries in WV and in the US
population were followed for one year after an incident lung cancer diagnosis to
determine receipt of minimally appropriate clinical guideline based lung cancer care
(hereafter referred to as ‘minimally appropriate care’). Minimally appropriate care was
defined using the ACCP evidence-based guidelines for diagnosis and management of
lung cancer, published in January, 2003.10 We choose ACCP evidence-based
guidelines, as they are the most comprehensive of all published clinical guidelines.9-13
Figure 2.1 shows the algorithm adapted from the ACCP guidelines, and used to
determine receipt of minimally appropriate care. Lung cancer specific treatments and
procedures were identified from the Medicare claim data files using appropriate
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International Classification of Diseases (ICD-9) diagnosis and procedure codes,
Healthcare Common Procedure Coding System (HCPCS) codes, Current Procedural
Terminology (CPT) codes and revenue center codes (Appendix 1). Considering the
poor quality of life following curative treatment among some individuals with stage IV
lung cancer, clinical guidelines recommend ‘no curative treatment’ for such individuals,
except for palliation of symptoms. We therefore excluded beneficiaries with stage IV
lung cancer from our analysis, except for separately reporting the proportion of
beneficiaries receiving minimally appropriate care with curative intent.

Dependent variables
The primary outcome of interest was receipt of minimally appropriate clinical guideline
based lung cancer care, which was categorized as (a) minimally appropriate care or (b)
inappropriate care. Treatment patterns were categorized as ‘surgery only’, ‘radiation
only’, ‘chemotherapy only’, ‘combination treatment’, or ‘no treatment’. Combination
treatment included any combination of surgery, radiation, and chemotherapy. Survival
time in days was calculated for each beneficiary from the time of incident lung cancer
diagnosis to date of death or the three year follow-up cutoff date, which ever came first.
To estimate lung cancer specific survival, beneficiaries who were not found to be
deceased by the cutoff date, or who died due to causes other than lung cancer were
censored at that time and considered to be alive. We measured lung cancer specific
survival instead of overall survival, as we wanted to determine the association between
minimally appropriate clinical guideline based lung cancer care and survival.
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While exact date of lung cancer diagnosis was available in the WVCR-Medicare
linked data files to calculate survival time, the SEER-Medicare linked data files only
contained the month and year of diagnosis. Hence to approximate the date of lung
cancer diagnosis in the US population, we used the earliest Medicare claim date, which
had a lung cancer diagnosis code, and which was in the month of lung cancer
diagnosis. This approximation is appropriate given the high level of agreement (nearly
90%) within one month of diagnosis between the SEER diagnosis date and the first
Medicare claim date with a cancer diagnosis.45 In cases where beneficiaries had no
Medicare claims with a lung cancer diagnosis code, earliest date from any claim in the
month of cancer diagnosis was used as the date of diagnosis. Finally, among
beneficiaries with no Medicare claim in the month of diagnosis, the date of diagnosis
was approximated as the 15th day of the diagnosis month. Date of death was identified
from Medicare enrollment records.

Independent variables
The main independent variables were lung cancer type and stage, age at diagnosis,
gender, race, urban-rural residence, Charlson comorbidity index score, and census tract
level measures of education and income. These variables were considered in our
analysis because of their prognostic significance. Lung cancer type was categorized
based on cell histology. Beneficiaries with ICD-O histology codes 8000-8040 or 80469989 were categorized as NSCLC, and those with codes 8041-8045 were categorized
as SCLC. Lung cancer stage was categorized based on AJCC TNM staging
system.43;44 Age at diagnosis was categorized as 66-69 years, 70-74 years, 75-79
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years, and 80 years and older. Given that WV population is predominantly White, race
was classified as White and others. Based on Rural-Urban Continuum codes
developed by the US Department of Agriculture (USDA), urban-rural residence was
categorized as Metro, Urban, or Rural. Charlson comorbidity index score was
calculated using diagnosis and procedure codes reported in Medicare inpatient claims
from the year prior to incident lung cancer diagnosis.46-48 Comorbidities related to
cancer were excluded from the index score. The Charlson comorbidity index score was
used to categorize comorbidity into three groups: 0, 1 and 2 or more, with a higher
score indicating a greater burden of comorbid illness.
Given the lack of individual socioeconomic status measures in our data sources,
we used as proxy, the year 2000 US Census tract level measures of college education
and income.49 Specifically, we used the percentage of individuals in the census tract
with some college education as a proxy measure for education, and categorized it
based on tercile distribution (using WV population) as 0%-0.10%, 0.11%-0.20%, and
0.21% or greater. Similarly, we used median household income at the census tract
level as a proxy measure of income, and categorized it based on tertile distribution
(using WV population) as $0-25,000, $25,000-50,000, and $50,001 or more.

Data Analysis
The Pearson chi-square test was used to determine unadjusted associations between
categorical variables of interest. Three hierarchical generalized logistic models were
constructed with PROC GLIMMIX procedure in SAS 9.2 50 to assess the association
between independent variables and the receipt of minimally appropriate care. In each
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model, the estimated probability of a beneficiary receiving minimally appropriate care
conditioned on a set of predictor variables was modeled. First and second models
included beneficiaries from the WV and US populations, respectively. The third model
was constructed to determine population variation in likelihood of beneficiaries receiving
minimally appropriate care, and therefore included beneficiaries from both populations
combined. The hierarchical model was chosen, as individual measures of
socioeconomic status were not available in our data sources, and we relied on census
tract level measures of education and income. This was done by treating census tract
as a random effect to account for potential correlation among beneficiaries within the
same county. Odds ratios, 95% confidence intervals, and two-sided p-values were
calculated for each predictor.
Non-parametric estimates of the survivor function, by receipt of minimally
appropriate care, were calculated for each population using the Kaplan-Meier method.
The log-rank test was used to assess the statistical significance of the differences
between the survival curves. Three-year survival estimates were also computed by
receipt of minimally appropriate care within each population. Stratified analysis was
performed by lung cancer type and stage within each population.
Three multivariate Cox proportional hazards models were constructed to
estimate lung cancer mortality risk associated with non-receipt of minimally appropriate
care. First and second model included beneficiaries from the WV and US populations,
respectively. The third model was constructed to determine population variation in lung
cancer mortality risk, and therefore included beneficiaries from both populations
combined. To evaluate the proportional hazards assumption, we plotted smoothed
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Schoenfeld residuals against time and found no evidence of a systematic deviation from
proportional hazards in any model. Variance in all Cox models were adjusted to
account for patient clustering at the census tract level by use of the robust inference of
Lin and Wei.51 Adjusted hazard ratios, 95% confidence intervals and their two-sided pvalues were calculated for each predictor.
All data were analyzed using the SAS Version 9.2 (SAS Institute, Cary, NC)
statistical software package.50 Results were considered to be statistically significant
when p ≤ 0.05. The study was approved by the West Virginia Institutional Review
Board, and is in full compliance with federal, state, and institutional regulations and
guidelines.

Results

Study population characteristics
Based on study inclusion and exclusion criteria, we identified 1,689 beneficiaries in WV
population, and 42,323 beneficiaries in the US population. Table 2.1 shows the
distribution of clinical and sociodemographic characteristics of these beneficiaries by
type of lung cancer. Compared to beneficiaries with NSCLC in the US population,
beneficiaries with NSCLC in WV population were younger, male, white, resided in nonmetro areas, had higher comorbidity score, and were diagnosed at earlier stages (p ≤
0.05). Similarly, compared to beneficiaries with SCLC in the US population,
beneficiaries with SCLC in WV population were of white race, resided in non-metro
areas, and were diagnosed at earlier stages (p ≤ 0.05). In both populations,
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beneficiaries with SCLC were diagnosed at late stages, compared to beneficiaries with
NSCLC (p ≤ 0.05). In the US population, compared to beneficiaries with SCLC,
beneficiaries with NSCLC were older, male, resided in metro areas, and had lower
comorbidity scores (p ≤ 0.05).

Treatment patterns
Table 2.2 shows the descriptive characteristics by type of treatment among
beneficiaries in the WV and US populations. Overall, proportion of beneficiaries
receiving no treatment was lower in the WV population, as compared to the US
population (26.8% vs. 33.4%) (p ≤ 0.05). Significant population variation in treatment
patterns were observed by lung cancer type, stage, age, gender, race, urban-rural
residence, comorbidity score, and by year of diagnosis (p ≤ 0.05). The proportion of
beneficiaries receiving treatment as ‘surgery alone’, ‘radiation alone’, or ‘combination
treatment’ was higher in WV population, compared to the US population (p ≤ 0.05).
However, proportion of beneficiaries receiving treatment as ‘chemotherapy alone’ was
lower in the WV population, compared to the US population (p ≤ 0.05). In both
populations, the proportion of beneficiaries receiving treatment as ‘surgery alone’ or
‘radiation alone’ was higher among beneficiaries with NSCLC, compared to
beneficiaries with SCLC (p ≤ 0.05). Similarly, the proportion of beneficiaries receiving
treatment as ‘surgery alone’ was also higher among those with early stage disease,
compared to those with late stage disease in both populations (p ≤ 0.05). Within the
two populations, variations in treatment patterns were also observed by age, gender,
urban-rural residence, and comorbidity score (p ≤ 0.05). Significant variation in
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treatment patterns by race and by year of diagnosis were only observed among
beneficiaries in the US population (p ≤ 0.05).

Receipt of minimally appropriate care
Table 2.3 shows the descriptive characteristics of beneficiaries by receipt of minimally
appropriate care in the WV and US populations. Overall, the proportion of beneficiaries
receiving minimally appropriate care was 46.5% in WV population, and 44.7% in the US
population. However, this population variation in overall receipt of minimally appropriate
care was not significant. Significant population variations in receipt of minimally
appropriate care were observed only among female beneficiaries. Specifically, the
proportion of female beneficiaries receiving minimally appropriate care was higher in
WV population as compared to the US population (51.2% vs. 44.8%) (p ≤ 0.05). Within
the WV population, receipt of minimally appropriate care was also higher among female
beneficiaries as compared to male beneficiaries (p ≤ 0.05). In both populations,
compared to beneficiaries receiving inappropriate care, beneficiaries receiving minimally
appropriate care were of young age (p ≤ 0.05). Variations in receipt of minimally
appropriate care by race, urban-rural residence, comorbidity score, and year of
diagnosis were only observed among beneficiaries in the US population (p ≤ 0.05).
Table 2.4 shows the proportion of beneficiaries receiving minimally appropriate
care by lung cancer type and stage in the WV and US populations. The proportion of
beneficiaries with NSCLC receiving minimally appropriate care was slightly higher in
WV population, than in the US population (47.2% vs. 44.3%). However, the proportion
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of beneficiaries with SCLC, receiving minimally appropriate care was lower in the WV
population, than in the US population (40.0% vs. 48.0%).
Among beneficiaries with stage IV lung cancer, the overall proportion of
beneficiaries receiving minimally appropriate care with curative intent was 24.2% in the
WV population, and 21.6% in the US population. Among beneficiaries with NSCLC
(Stage IV), this proportion was 17.8% in WV population and 16.3% in the US
population. Similarly, among beneficiaries with SCLC (Stage IV) this proportion was
47.7% in the WV population and 45.7% in the US population.

Factors associated with receipt of minimally appropriate care
Controlling for all sociodemographic variables, age remained a strong predictor of
receipt of minimally appropriate care in all models (Table 2.5). Compared to
beneficiaries aged 80 years and older, beneficiaries aged 66 to 69 years were more
than twice likely to receive minimally appropriate care, and these odds gradually
decreased with increase in age. Gender was only significant in model 1 (WV
population), with males 27% less likely to receive minimally appropriate care as
compared to females. Race, comorbidity score, and census tract level measure of
income, were the other significant predictors of receipt of minimally appropriate care in
model 2 (US population) and model 3 (Combined population). Specifically, beneficiaries
of non-white race were 21% less likely to receive minimally appropriate care as
compared to whites. The likelihood of receipt of minimally appropriate care was also
higher among beneficiaries with low comorbidity score as compared to those with high
comorbidity score. Finally, the likelihood of receipt of minimally appropriate care
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decreased with decrease in median household income. Census tract level measure of
education and urban-rural residence were not statistically significant in any model. After
controlling for all sociodemographic variables, population variation in likelihood of
beneficiaries receiving minimally appropriate care was not significant.

Survival benefits associated with receipt of minimally appropriate care
Figure 2.2 compares the three year Kaplan-Meier survival curves by receipt of minimally
appropriate care in the WV and US populations. In both populations, the three year
survival rates and median survival times were significantly greater for beneficiaries
receiving minimally appropriate care as compared to beneficiaries receiving
inappropriate care (p ≤ 0.05). Specifically, with receipt of minimally appropriate care the
three year median survival time exceeded by 433 days in WV population, and by 487
days in the US population (p ≤ 0.05). Compared to the US population, the median
survival times by receipt of minimally appropriate care were significantly greater among
beneficiaries in WV population (p ≤ 0.05). However, the three year survival rates
among beneficiaries receiving minimally appropriate care were lower in WV population
as compared to the US population (p ≤ 0.05).
Table 2.6 shows the three year survival rates and median survival times among
beneficiaries receiving minimally appropriate care by lung cancer type and stage, in the
WV and US populations. In WV population, survival benefits associated with receipt of
minimally appropriate care were significant only among beneficiaries with SCLC (Stages
I-III) (p ≤ 0.05). However, in the US population, survival benefits associated with receipt
of minimally appropriate care were significant for all beneficiaries except for

45

beneficiaries with SCLC (stage I or stage II) (p ≤ 0.05). Significant population variations
in survival among beneficiaries receiving either minimally appropriate care or
inappropriate care were also observed by lung cancer type and stage (p ≤ 0.05).

Lung cancer mortality risk associated with non-receipt of minimally appropriate care
In all Cox proportional hazards models, the adjusted lung cancer mortality risk was
significantly higher among beneficiaries not receiving minimally appropriate care,
relative to those who did receive minimally appropriate care (Table 2.7). Specifically,
lung cancer mortality risk among beneficiaries not receiving minimally appropriate care
increased by 60% in WV population, by 91% in the US population, and by 90% in the
combined population (p ≤ 0.05). In all models, NSCLC diagnosis and early stage
disease were the only other factors independently associated with lower lung cancer
specific mortality (p ≤ 0.05). In model 1 (WV population), less education was the only
other factor significantly associated with higher lung cancer specific mortality (p ≤ 0.05).
Older age, male sex, White race, higher comorbidity score, and lower income were the
only other factors significantly associated with higher lung cancer specific mortality in
model 2 (US population) and model 3 (Combined population). After controlling for all
clinical and sociodemographic variables and for appropriateness of care, population
variation in lung cancer mortality risk was not significant.

Discussion
Compared to other types of cancer, lung cancer diagnosis in the elderly is usually
associated with poor prognosis. This burden is especially higher among elderly residing
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in rural and medically underserved regions of the US.25-27 Appropriate use of treatment
options, as recommended in evidence-based clinical guidelines, has the potential to
cure the disease, or prolong survival in this population. Prior studies have found
variation in receipt of recommended lung cancer care according to age, race,
comorbidity, and hospital type.15-21 However, these studies mainly represented NSCLC
individuals from non-rural populations. In this study, using cancer registry linked
Medicare administrative data files, we compare geographic variations in clinical
guideline based lung cancer care and associated health outcomes among elderly in a
representative rural and medically underserved state population, with a representative
US population.
Overall, treatment patterns varied significantly among beneficiaries with lung
cancer in the WV and US populations. Despite availability of various treatment options
to treat the disease, many beneficiaries did not receive any treatment in either
population. Among those beneficiaries who did receive treatment, other than
chemotherapy alone, the proportions were higher among beneficiaries in the WV
population, as compared to the US population. Similar population variation in treatment
patterns was also seen by lung cancer type and stage. These observed population
variations in treatment patterns may be related to differences in disease severity,
comorbid illness burden, physician judgment, and/or individual preferences.
Minimally appropriate care was only received by less than half of all beneficiaries
in each population. More female beneficiaries in the WV population received minimally
appropriate care, as compared to that in the US population. Controlling for other
factors, increasing age at diagnosis was associated with a decline in receipt of
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minimally appropriate care in both populations. This finding is similar to that reported in
prior studies, and may be due to physician treatment choice, and/or individual treatment
preferences.16;17;20;21 Compared to younger individuals, some physicians may be
conservative in their choice of curative treatment for the elderly given its impact on
patient morbidity and quality of life. Gender disparities in receipt of minimally
appropriate care were observed only in WV population, with males less likely to receive
minimally appropriate care. Racial differences in receipt of minimally appropriate care
were observed only in the US population, with non-white beneficiaries having less
likelihood of receipt of minimally appropriate care than white beneficiaries. These racial
differences are similar to that reported in prior studies.16;19 Similar to results found in
prior studies, comorbidity was inversely associated with receipt of minimally appropriate
care in the US population.16 This may be due to less aggressive treatment approach by
physicians in elderly with higher comorbidities, or due to individual preference to avoid
aggressive treatments in favor of better quality of life. Increasing poverty was
associated with decrease in likelihood of receipt of minimally appropriate care only in
the US population. Compared to the US population, the WV population is much poorer,
and that may explain the non-significance of income on receipt of minimally appropriate
care among beneficiaries in the WV population. Urban-rural residence and education
had no impact on receipt of minimally appropriate care in either population. After
controlling for all sociodemographic variables, likelihood of receipt of minimally
appropriate care among beneficiaries in the WV and US populations were not
significantly different.
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Receipt of minimally appropriate care by beneficiaries was associated with longer
survival times in both populations. Although beneficiaries receiving minimally
appropriate care in the WV population had greater median survival times, compared to
the US population, their three year survival rates were significantly lower. Survival
benefits associated with receipt of minimally appropriate care also varied by lung cancer
type and stage among beneficiaries in both the populations. In both populations, we
found the adjusted lung cancer mortality risk significantly higher among beneficiaries not
receiving minimally appropriate care than those who did receive such care. However,
the magnitude of risk associated with non-receipt of minimally appropriate care was
lower in the WV population, than in the US population. These findings highlight the fact
that significant survival benefits can be achieved in beneficiaries, if they receive
minimally appropriate care. Early stage disease and NSCLC diagnosis were the only
other factors independently associated with lower lung cancer mortality risk in both
populations. This is true given that the treatment management for beneficiaries is
easier among those with early stage disease compared to late stage disease, and is
also easier among those with NSCLC diagnosis compared to SCLC diagnoses. Lung
cancer mortality risk varied significantly by census tract measure of education, only in
the WV population, as risk increased with less education. Variation in lung cancer
mortality risk by age, sex, race, comorbidity score, and income were only observed in
the US population. After controlling for the variability associated with receipt of
minimally appropriate care and all sociodemographic variables, lung cancer mortality
risk was no different among beneficiaries in the WV and US populations.
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Although treatment patterns varied between the two populations, significant
population variation in receipt of minimally appropriate care and associated lung cancer
mortality risk were not observed in this study. These findings are contrary to what
would be expected given that the WV population is more rural and medically
underserved, and has higher lung cancer mortality rates as compared to the US
population. The finding suggests that observed geographic differences in lung cancer
mortality may not be associated with variation in receipt of minimally appropriate care
among elderly beneficiaries with an incident diagnosis of lung cancer. Furthermore,
higher lung cancer incidence in the WV population, as compared to the US population,
may partly explain the disparities seen in lung cancer mortality among these
populations. Future cancer prevention efforts directed towards promoting smoking
cessation are much needed in the rural WV population, where the smoking prevalence
rates are the highest in the nation. In the long run, these cancer prevention efforts can
help to reduce the incidence of lung cancer in this rural population, which in turn can
help to reduce the geographic disparities in lung cancer mortality.
The findings from this study are subject to several limitations. Although we used
cancer registry linked claims data, an inherent limitation of using administrative claims
data for epidemiologic studies is the possibility of misclassification as a result of coding
errors.52;53 However, claims data have been evaluated for their utility as a source of
epidemiologic or health services information in cancer patients.52-56 Increasing the use
of these types of data to assess the quality of cancer care has also been identified as a
priority by the Institute of Medicine.57 Studies using claims data are usually population
based and have the potential to address a number of priority questions regarding the
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quality of cancer care and health care disparities. These population based studies
provide valuable information for future planning and prioritization of health programs
that improve cancer outcomes. Therefore, there is increasing interest in analyzing large
health claims databases to assess treatment and outcomes for cancer.52;53;57
The results of this study are generalizable only to the elderly Medicare FFS
population aged 66 years and older, as encounter data for Medicare recipients enrolled
in the managed care plan were not available for this study. There was a small increase
in percentage of Medicare recipients enrolled in managed care during the study years in
both populations; in 2007 it was ~16% in WV population and ~19% in the US
population.58 Information on care received by the Medicare recipients outside of the
Medicare system, or through non-Medicare providers, was also not available in the
claims data for our study. However, Medicare is the largest and most comprehensive
insurance provider for the elderly in the United States. Racial disparities in cancer
outcomes could not be ascertained in this study, as the populations were predominantly
White.
One of the inclusion criteria for cohort selection in this study was continuous
enrollment in Medicare Part A and B during the study period. This resulted in the noninclusion of individuals with non-continuous enrollment and the loss of individuals who
were enrolled intermittently. We acknowledge that various clinical guidelines have been
published for lung cancer diagnosis and management, each with recommendations that
are more or less the same.9-13 For the purpose of this study, we chose ACCP
guidelines for lung cancer management and outcomes, as it is the most comprehensive
of all available guidelines.10 The algorithm we adapted from these guidelines to identify
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minimally appropriate care takes into account the limitations in our data sources.
Specifically, information on various lung function test results and lung performance
scores were not available in our data source, and were not considered in our analysis.
However, these indicators of lung performance are most crucial only in planning for
chemotherapy in NSCLC stage IV individuals who we excluded from our analysis. Our
estimates of proportion of beneficiaries receiving minimally appropriate care may be
biased slightly upward as we included patients who received minimally appropriate care
and additional unproven therapies. We also acknowledge that our definition of receipt
of minimally appropriate care may be too narrow, and that given the heterogeneity of
patients seen by physicians, receipt of no therapy may still be considered as
appropriate care. None the less, our definition of receipt of minimally appropriate care
provides a conceptual framework to assess and compare patterns of care that were
prevalent during the years 2002 through 2007. Because of limited data availability at
the time of study, we were unable to conduct a long-term (5-10 year) follow-up to
assess the health outcomes associated with receipt of minimally appropriate care.
Individual-level socioeconomic measures of educational attainment, marital status, and
family income were also unavailable for this study. However, aggregate measures of
socioeconomic status at the census tract level from 2000 decennial census data were
used as a proxy. Finally, our definition of minimally appropriate versus inappropriate
care is limited to the data recorded in the claims such as the presence or absence of
ICD-9 diagnosis and procedure codes, HCPCS procedure codes, CPT procedure codes
and revenue center codes. Future studies can overcome the barriers seen in this study
by collecting data on physician behaviors and patient preferences on treatment choices.
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This study is the first of its kind to compare geographic variations in clinical
guideline based lung cancer care and associated health outcomes among elderly
Medicare FFS beneficiaries. Although lung cancer diagnostic and management
services are covered under the Medicare program, underutilization of these services
among recipients in the Medicare FFS population is a concern. Results of this study
also emphasize the need to address disparities in receipt of minimally appropriate care
among recipients in the Medicare FFS population. Reducing observed treatment
variations according to individual characteristics can help to improve the use of clinical
guideline based treatments in the elderly and that in turn would improve health
outcomes. Furthermore, increased lung cancer risk and incidence among the elderly
from economically underdeveloped and medically underserved regions, such as WV,
may be the reason behind observed geographical disparities in lung cancer mortality.
Promoting smoking cessation among individuals residing in such rural areas has the
potential to reduce observed geographic disparities in lung cancer mortality.
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Figure 2.1. Algorithm adapted from American College of Chest Physicians (ACCP)
evidence-based guidelines for diagnosis and management of lung cancer published in
January, 2003, and used to determine receipt of minimally appropriate clinical guideline
based lung cancer care.
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Figure 2.2. Kaplan-Meier survival estimates with 95% confidence limits by receipt of
minimally appropriate clinical guideline based lung cancer care among continuously
enrolled Medicare Fee-for-service beneficiaries with incident diagnosis of lung cancer
(Stages I-III) in West Virginia and in the United States, July 2003 through December
2004. Curves (unadjusted) show cause-specific mortality.

WV = West Virginia population, US = United States population represented by the Surveillance, Epidemiology and End Results
(SEER) population, CI = confidence interval.
*
Survival times and rates were obtained from Kaplan-Meier survival estimates.
Minimally appropriate care determined using American College of Chest Physicians (ACCP) evidence-based guidelines for
diagnosis and management of lung cancer published in January, 2003.
Log-rank test (p ≤ 0.05) comparing differences in survival by receipt of minimally appropriate care, among beneficiaries within US
population.
Log-rank test (p ≤ 0.05) comparing differences in survival by receipt of minimally appropriate care, among beneficiaries within WV
population.
Log-rank test (p ≤ 0.05) comparing population differences in survival among beneficiaries receiving minimally appropriate care.
Log-rank test (p ≤ 0.05) comparing population differences in survival among beneficiaries receiving inappropriate care.
Source: West Virginia Cancer Registry - Medicare linked data files, 2002-2007, Surveillance, Epidemiology and End Results Medicare linked data files, 2002-2007.
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Table 2.1. Descriptive characteristics of continuously enrolled Medicare Fee-for-service
beneficiaries with incident diagnosis of lung cancer in West Virginia and in the United
States, July 2003 through December 2006.
Proportion (%)
Characteristics

NSCLC

SCLC

WV

US

WV

US

1,444
(85.5)

36,417
(86.0)

245
(14.5)

5,906
(14.0)

AJCC TNM stage * # + ^
I
II
III
IV

26.9
9.8
23.3
40.0

20.6
4.7
28.4
46.2

6.9
4.5
25.3
63.3

5.1
2.2
29.8
62.9

Age (years) * ^
66-69
70-74
75-79
80 or more

23.0
29.4
26.0
21.5

19.2
25.8
25.9
29.1

24.9
30.6
23.7
20.8

24.0
28.8
26.2
21.0

Gender * ^
Male
Female

58.2
41.8

51.9
48.1

51.8
48.2

47.4
52.6

Race * # ^
Other
White

2.2
97.8

13.3
86.7

0.8
99.2

9.2
90.8

Urban-rural residence * # ^
Metro
Urban
Rural

54.8
39.5
5.6

83.1
14.9
2.0

60.0
32.2
7.8

80.2
17.2
2.6

Comorbidity, Charlson score * ^
0
1
2 or more

26.5
29.9
43.6

31.7
28.5
39.8

30.2
29.4
40.4

29.7
28.8
41.5

Year of diagnosis * ^
2003 (July-Dec)
2004
2005
2006

11.4
28.9
29.4
30.2

15.3
28.3
28.4
28.0

13.5
29.4
29.4
27.8

15.3
30.0
28.1
26.7

Overall, n (%)

WV = West Virginia population, US = United States population represented by the Surveillance, Epidemiology and End Results
(SEER) population, NSCLC = Non-Small Cell Lung Cancer, SCLC = Small Cell Lung Cancer, AJCC = American Joint Committee
on Cancer, TNM = Tumor Node Metastasis.
* Chi-square test (p ≤ 0.05) measuring association between beneficiary characteristics and population type, among beneficiaries
with non-small cell lung cancer.
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#

Chi-square test (p ≤ 0.05) measuring association between beneficiary characteristics and population type, among beneficiaries
with small cell lung cancer.
+
Chi-square test (p ≤ 0.05) measuring association between beneficiary characteristics and cancer type, among beneficiaries in
West Virginia population.
^
Chi-square test (p ≤ 0.05) measuring association between beneficiary characteristics and cancer type, among beneficiaries in
United States population.
Source: West Virginia Cancer Registry - Medicare linked data files, 2002-2007, Surveillance, Epidemiology and End Results Medicare linked data files, 2002-2007.
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Table 2.2. Descriptive characteristics by type of treatment among continuously enrolled Medicare Fee-for-service
beneficiaries with incident diagnosis of lung cancer in West Virginia and in the United States, July 2003 through
December 2006.
Proportion (%) #
Characteristics

No Treatment

Surgery Only

Radiation Only

Chemotherapy
Only

Combination
Treatment

WV

US

WV

US

WV

US

WV

US

WV

US

453
(26.8)

14,137
(33.4)

228
(13.5)

4,172
(9.9)

321
(19.0)

6,730
(15.9)

176
(10.4)

5,461
(12.9)

511
(30.3)

11,832
(27.9)

Cancer type + ^
NSCLC *
SCLC

26.7
27.8

34.1
28.9

15.7
0.4

11.4
0.5

20.6
9.4

17.1
8.4

8.4
22.5

11.2
23.6

28.6
40.0

26.2
38.7

AJCC TNM stage + ^
I
II
III
IV

17.5
19.6
25.9
34.0

23.7
17.0
32.5
39.1

43.2
22.2
3.5
0.7

41.0
19.7
3.5
0.8

11.4
12.4
18.3
25.0

12.7
10.7
14.5
18.4

3.0
2.6
11.8
15.4

3.6
4.9
13.1
17.1

24.9
43.1
40.5
25.0

19.0
47.8
36.5
24.5

Age (years) + ^
66-69 *
70-74
75-79
80 or more *

20.6
21.8
27.9
39.2

23.0
26.1
32.5
48.5

14.0
14.6
14.1
10.8

9.8
10.4
11.3
8.1

13.0
18.4
21.2
23.8

12.9
14.7
15.9
19.2

10.4
11.0
10.4
9.7

13.8
13.7
13.9
10.6

42.0
34.2
26.5
16.6

40.5
35.0
26.5
13.7

Gender + ^
Male *
Female *

29.6
23.1

33.4
33.4

12.4
15.0

8.8
11.0

18.3
19.9

15.9
15.9

9.8
11.2

13.0
12.8

29.9
30.7

28.8
27.0

Overall, n (%) *

Race ^

58

Other
White *

44.1
26.5

37.9
32.7

11.8
13.5

7.0
10.3

11.8
19.2

17.6
15.7

14.7
10.3

12.4
13.0

17.7
30.5

25.1
28.3

27.6
26.8
20.0

32.9
36.2
34.2

13.4
14.2
10.0

10.1
8.7
8.2

20.7
17.1
16.0

16.1
15.1
14.8

8.4
12.2
18.0

13.1
11.6
13.6

29.9
29.8
36.0

27.8
28.5
29.2

31.3
21.6
27.6

33.1
29.4
36.6

10.3
15.7
14.0

7.9
11.2
10.4

17.9
18.8
19.8

14.9
15.6
16.9

10.9
10.1
10.3

13.2
13.2
12.5

29.5
33.7
28.3

31.0
30.6
23.6

25.8
24.9
27.4
28.6

33.6
32.2
33.2
34.8

15.7
14.5
12.9
12.3

9.4
9.5
9.7
10.6

19.7
17.8
16.9
22.0

15.2
14.5
15.0
18.7

11.1
10.0
11.1
9.9

13.3
13.4
13.5
11.6

27.8
32.9
31.8
27.2

28.5
30.5
28.6
24.4

Urban-rural
residence + ^
Metro *
Urban
Rural
Comorbidity,
Charlson score +

^

0
1*
2 or more *
Year of diagnosis ^
2003 (JulyDec)
2004 *
2005 *
2006 *

WV = West Virginia population, US = United States population represented by the Surveillance, Epidemiology and End Results (SEER) population, NSCLC = Non-Small Cell Lung
Cancer, SCLC = Small Cell Lung Cancer, AJCC = American Joint Committee on Cancer, TNM = Tumor Node Metastasis.
#
Proportions reported are row percentages of beneficiaries receiving particular treatment within WV or the US population.
* Chi-square test (p ≤ 0.05), measuring association between type of treatment and population type, among beneficiaries within each row category.
+
Chi-square test (p ≤ 0.05) measuring association between beneficiary characteristics and type of treatment, among beneficiaries in West Virginia population.
^
Chi-square test (p ≤ 0.05) measuring association between beneficiary characteristics and type of treatment, among beneficiaries in United States population.
Source: West Virginia Cancer Registry - Medicare linked data files, 2002-2007, Surveillance, Epidemiology and End Results - Medicare linked data files, 2002-2007.
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Table 2.3. Descriptive characteristics by receipt of minimally appropriate clinical
guideline based lung cancer care among continuously enrolled Medicare Fee-forservice beneficiaries with incident diagnosis of lung cancer (Stages I-III) in West Virginia
and in the United States, July 2003 through December 2006.
Characteristics

Minimally Appropriate Care ~
WV
US

WV

Inappropriate Care
US

No.

%#

No.

%#

No.

%#

No.

%#

Overall

445

46.5

9,736

44.7

511

53.5

12,048

55.3

Age (years) + ^
66-69
70-74
75-79
80 or more

118
159
112
56

51.8
53.9
45.0
30.4

2,325
2,899
2,576
1,936

55.7
50.4
45.0
31.6

110
136
137
128

48.2
46.1
55.0
69.6

1,849
2,851
3,152
4,196

44.3
49.6
55.0
68.4

Gender +
Male
Female *

231
214

42.9
51.2

4,930
4,806

44.6
44.8

307
204

57.1
48.8

6,130
5,918

55.4
55.2

Race ^
Other
White

7
438

38.9
46.7

1,090
8,646

39.7
45.4

11
500

61.1
53.3

1,654
10,394

60.3
54.6

254
170
21

46.8
47.2
39.6

8,101
1,446
189

45.3
42.0
42.1

289
190
32

53.2
52.8
60.4

9,793
1,995
260

54.7
58.0
57.9

103
139
203

45.0
49.3
45.6

2,820
3,040
3,876

46.0
48.2
41.5

126
143
242

55.0
50.7
54.4

3,314
3,265
5,469

54.0
51.8
58.5

43
135
136
131

43.9
45.8
48.2
46.6

1,511
2,846
2,788
2,591

42.5
46.5
45.5
43.4

55
160
146
150

56.1
54.2
51.8
53.4

2,046
3,274
3,344
3,384

57.5
53.5
54.5
56.6

Urban-rural
residence ^
Metro
Urban
Rural
Comorbidity,
Charlson score

^

0
1
2 or more
Year of diagnosis

^

2003 (July-Dec)
2004
2005
2006

WV = West Virginia population, US = United States population represented by the Surveillance, Epidemiology and End Results
(SEER) population.
~
Minimally appropriate care determined using American College of Chest Physicians (ACCP) evidence-based guidelines for
diagnosis and management of lung cancer published in January, 2003.
#
Proportions reported are row percentages of beneficiaries receiving minimally appropriate care, or inappropriate care, within WV
or the US population.
*
Chi-square test (p ≤ 0.05), measuring association between receipt of minimally appropriate care and population type, among
beneficiaries within each row category.
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+

Chi-square test (p ≤ 0.05) measuring association between beneficiary characteristics and receipt of minimally appropriate care,
among beneficiaries in West Virginia population.
^
Chi-square test (p ≤ 0.05) measuring association between beneficiary characteristics and receipt of minimally appropriate care,
among beneficiaries in United States population.
Source: West Virginia Cancer Registry - Medicare linked data files, 2002-2007, Surveillance, Epidemiology and End Results Medicare linked data files, 2002-2007.
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Table 2.4. Minimally appropriate clinical guideline based lung cancer care by cancer
type and stage, among continuously enrolled Medicare Fee-for-service beneficiaries
with incident diagnosis of lung cancer (Stages I-III) in West Virginia and in the United
States, July 2003 through December 2006.
Minimally Appropriate Care ~
WV
US

Characteristics
*

WV

Inappropriate Care
US

No.

%#

No.

%#

No.

%#

No.

%#

NSCLC
Stage I
Stage II
Stage III
Stages I-III

209
67
133
409

53.9
47.2
39.6
47.2

4,188
844
3,653
8,685

55.7
49.1
35.3
44.3

179
75
203
457

46.1
52.8
60.4
52.8

3,332
876
6,701
10,909

44.3
50.9
64.7
55.7

SCLC
Stage I
Stage II
Stage III
Stages I-III

6
2
28
36

35.3
18.2
45.2
40.0

130
59
862
1,051

43.2
45.7
49.0
48.0

11
9
34
54

64.7
81.8
54.8
60.0

171
70
898
1,139

56.8
54.3
51.0
52.0

WV = West Virginia population, US = United States population represented by the Surveillance, Epidemiology and End Results
(SEER) population.
~
Minimally appropriate care determined using American College of Chest Physicians (ACCP) evidence-based guidelines for
diagnosis and management of lung cancer published in January, 2003.
#
Proportions reported are row percentages of beneficiaries receiving minimally appropriate care, or inappropriate care, within WV
or the US population.
*
Stages based on American Joint Committee on Cancer (AJCC), Tumor Node Metastasis (TNM) staging system.
Source: West Virginia Cancer Registry - Medicare linked data files, 2002-2007, Surveillance, Epidemiology and End Results Medicare linked data files, 2002-2007.
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Table 2.5. Factors associated with receipt of minimally appropriate clinical guideline
based lung cancer care among continuously enrolled Medicare Fee-for-service
beneficiaries with incident diagnosis of lung cancer (Stages I-III) in West Virginia and in
the United States, July 2003 through December 2006.
Model 1: WV

Odds Ratio (95% Confidence Interval)
Model 2: US
Model 3: WV + US

Intercept (p-value)

0.09

0.15

0.11

Population
WV
US

NA
NA

NA
NA

0.94 (0.78 to 1.13)
1 (Ref)

2.50*** (1.65 to 3.79)
2.68*** (1.81 to 3.98)
1.84** (1.22 to 2.77)
1 (Ref)

2.66*** (2.44 to 2.89)
2.13*** (1.97 to 2.31)
1.79*** (1.66 to 1.93)
1 (Ref)

2.65*** (2.44 to 2.87)
2.16*** (2.00 to 2.33)
1.79*** (1.66 to 1.93)
1 (Ref)

Gender
Male
Female

0.73* (0.56 to 0.95)
1 (Ref)

0.97 (0.92 to 1.03)
1 (Ref)

0.96 (0.91 to 1.01)
1 (Ref)

Race
Other
White

0.77 (0.25 to 2.34)
1 (Ref)

0.79*** (0.72 to 0.86)
1 (Ref)

0.79*** (0.72 to 0.86)
1 (Ref)

Metro
Urban
Rural

1.50 (0.82 to 2.77)
1.44 (0.78 to 2.66)
1 (Ref)

1.11 (0.90 to 1.38)
0.99 (0.79 to 1.22)
1 (Ref)

1.15 (0.94 to 1.40)
1.03 (0.84 to 1.26)
1 (Ref)

Comorbidity,
Charlson
score
0
1
2 or more

0.95 (0.68 to 1.32)
1.14 (0.83 to 1.55)
1 (Ref)

1.14*** (1.06 to 1.21)
1.27*** (1.18 to 1.35)
1 (Ref)

1.13*** (1.06 to 1.20)
1.26*** (1.18 to 1.34)
1 (Ref)

0.34 (0.09 to 1.31)
1.20 (0.90 to 1.59)

1.00 (0.02 to 45.32)
1.09 (0.05 to 8.79)

0.52 (0.01 to 0.60)
1.25 (0.22 to 7.16)

1 (Ref)

1 (Ref)

1 (Ref)

Age (years)
66-69
70-74
75-79
80 or more

Urban-rural
residence

Percentage
with some
college
education (%) ^
0.0-0.10
0.11-0.20
0.21 or
more
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Median
household
income ($) ^
0-25,000
25,001-50,000
50,001 or
more

1.53 (0.64 to 3.66)
1.58 (0.70 to 3.59)

0.75*** (0.67 to 0.84)
0.85** (0.77 to 0.94)

0.76*** (0.68 to 0.85)
0.86** (0.78 to 0.95)

1 (Ref)

1 (Ref)

1 (Ref)

WV = West Virginia population, US = United States population represented by the Surveillance, Epidemiology and End Results
(SEER) population, Ref = reference category, NA = Not Applicable.
*
Estimates are statistically significant (p ≤ 0.05).
**
Estimates are statistically significant (p ≤ 0.01).
***
Estimates are statistically significant (p ≤ 0.001).
^
Census tract level measures of beneficiaries socioeconomic status.
Minimally appropriate care determined using American College of Chest Physicians (ACCP) evidence-based guidelines for
diagnosis and management of lung cancer published in January, 2003.
Model 1: WV population (N = 956), Fit Statistics: -2 restricted log pseudo-likelihood = 4110.26, Covariance parameter estimates:
Intercept = county, estimate = 0.33, standard error = 0.001.
Model 2: US population (N = 21,784), Fit Statistics: -2 restricted log pseudo-likelihood = 93427.13, Covariance parameter estimates:
Intercept = county, estimate = 0.56, standard error = 0.011.
Model 3: Combined WV + US population (N = 22,740), Fit Statistics: -2 restricted log pseudo-likelihood = 97505.27, Covariance
parameter estimates: Intercept = county, estimate = 0.05, standard error = 0.011.
Source: West Virginia Cancer Registry - Medicare linked data files, 2002-2007, Surveillance, Epidemiology and End Results Medicare linked data files, 2002-2007.
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Table 2.6. Three-year median survival time and survival rate by cancer type and stage, and by receipt of minimally
appropriate clinical guideline based lung cancer care, among continuously enrolled Medicare Fee-for-service beneficiaries
with incident diagnosis of lung cancer (Stages I-III) in West Virginia and in the United States, July 2003 through December
2004.
Minimally Appropriate Care ~
Median survival time, days
(95% CI) *

Inappropriate Care

3-year survival rate
(95% CI) *

Median survival time, days
(95% CI) *

3-year survival rate
(95% CI) *

WV

US

WV

US

WV

US

WV

US

983
(797 to NA^)

-

0.46
(0.34 to 0.57)

0.62
(0.60 to 0.65)

-

-

0.60
(0.49 to 0.70)

0.55
(0.53 to 0.58)

-

-

0.51
(0.30 to 0.68)

0.54
(0.48 to 0.59)

493
(299 to 643)

384
(328 to 459)

0.17
(0.05 to 0.34)

0.20
(0.16 to 0.25)

493
(293 to 705)

439
(412 to 475)

0.28
(0.16 to 0.41)

0.25
(0.23 to 0.27)

188
(119 to 256)

146
(135 to 164)

0.12
(0.05 to 0.21)

0.09
(0.08 to 0.11)

851
(677 to 992)

835
(781 to 912)

0.41
(0.33 to 0.48)

0.44
(0.43 to 0.46)

493
(341 to 643)

283
(265 to 301)

0.35
(0.28 to 0.42)

0.25
(0.24 to 0.26)

I

449
(300 to NA^)

585
(464 to 701)

0

0.28
(0.18 to 0.39)

211
(71 to 366)

324
(204 to 474)

0

0.16
(0.09 to 0.26)

II

490
(21 to 958)

423
(276 to 618)

0

0.14
(0.04 to 0.31)

150
(3 to 552)

276
(99 to 498)

0

0.06
(0.00 to 0.25)

281
^
(171 to NA )

448
(405 to 491)

0.32
(0.09 to 0.59)

0.18
(0.14 to 0.22)

85
(6 to 219)

109
(92 to 133)

0

0.02
(0.01 to 0.05)

345
^
(263 to NA )

457
(428 to 509)

0.27
(0.07 to 0.51)

0.19
(0.16 to 0.23)

150
(16 to 219)

135
(109 to 160)

0

0.05
(0.03 to 0.07)

NSCLC
I

#

II

#

III

@

#

I-III

$@#

SCLC

III

@

#

I-III
+

@#

WV = West Virginia population, US = United States population represented by the Surveillance, Epidemiology and End Results (SEER) population, NSCLC = Non-small cell lung cancer, SCLC = Small cell lung
cancer, CI = confidence interval, - = median survival time not yet reached.
*
Survival times and rates were obtained from Kaplan-Meier survival estimates.
^
Upper limit of confidence interval is not available because of censoring.
~
Minimally appropriate care determined using American College of Chest Physicians (ACCP) evidence-based guidelines for diagnosis and management of lung cancer published in January, 2003. Stages
based on American Joint Committee on Cancer (AJCC), Tumor Node Metastasis (TNM) staging system.
$
Log-rank test (p ≤ 0.05) comparing population differences in survival among beneficiaries receiving minimally appropriate care.
@
Log-rank test (p ≤ 0.05) comparing population differences in survival among beneficiaries receiving inappropriate care.
#
Log-rank test (p ≤ 0.05) comparing differences in survival by receipt of minimally appropriate care, among beneficiaries within US population.
+
Log-rank test (p ≤ 0.05) comparing differences in survival by receipt of minimally appropriate care, among beneficiaries within WV population. NSCLC, Minimally appropriate care: Stage I (WV: N = 84,
Censored = 51.2%; US: N = 1,759, Censored = 65.2%), Stage II (WV: N = 25, Censored = 52.0%; US: N = 338, Censored = 56.5%), Stage III (WV: N = 51, Censored = 29.4%; US: N = 1,765, Censored =
29.8%), Stages I-III (WV: N = 160, Censored = 44.4%; US: N = 3,862, Censored = 48.3%). NSCLC, Inappropriate care: Stage I (WV: N = 84, Censored = 61.9%; US: N = 1,464, Censored = 59.8%), Stage II
(WV: N = 31, Censored = 25.8%; US: N = 343, Censored = 25.7%), Stage III (WV: N = 77, Censored = 20.8%; US: N = 2,921, Censored = 19.2%), Stages I-III (WV: N = 192, Censored = 39.6%; US: N =
4,728, Censored = 32.3%). SCLC, Minimally appropriate care: Stage I (WV: N = 3, Censored = 66.7%; US: N = 74, Censored = 32.4%), Stage II (WV: N = 2, Censored = 0%; US: N = 26, Censored = 23.1%),
Stage III (WV: N = 13, Censored = 38.5%; US: N = 395, Censored = 22.8%), Stages I-III (WV: N = 18, Censored = 38.9%; US: N = 495, Censored = 24.2%). SCLC, Inappropriate care: Stage I (WV: N = 5,
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Censored = 0%; US: N = 80, Censored = 25.0%), Stage II (WV: N = 4, Censored = 25.0%; US: N = 26, Censored = 23.1%), Stage III (WV: N = 14, Censored = 0%; US: N = 409, Censored = 12.0%), Stages
I-III (WV: N = 23, Censored = 4.3%; US: N = 515, % censored = 14.6%).
Source: West Virginia Cancer Registry - Medicare linked data files, 2002-2007, Surveillance, Epidemiology and End Results - Medicare linked data files, 2002-2007.
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Table 2.7. Lung cancer mortality risk associated with non-receipt of minimally
appropriate clinical guideline based lung cancer care, among continuously enrolled
Medicare Fee-for-service beneficiaries with incident diagnosis of lung cancer (Stages IIII) in West Virginia and in the United States, July 2003 through December 2004.
Model 1: WV
Population
WV
US

Hazard Ratio (95% Confidence Interval)
Model 2: US
Model 3: WV + US

NA
NA

NA
NA

0.99 (0.82 to 1.20)
1 (Ref)

1.60*** (1.23 to 2.10)

1.91*** (1.82 to 2.00)

1.90*** (1.81 to 1.99)

1 (Ref)

1 (Ref)

1 (Ref)

Lung cancer type
NSCLC
SCLC

0.46*** (0.30 to 0.71)
1 (Ref)

0.72*** (0.66 to 0.77)
1 (Ref)

0.70*** (0.65 to 0.76)
1 (Ref)

AJCC TNM stage
I
II
III

0.38*** (0.27 to 0.53)
0.65* (0.46 to 0.91)
1 (Ref)

0.29*** (0.27 to 0.31)
0.55*** (0.50 to 0.60)
1 (Ref)

0.29*** (0.27 to 0.31)
0.55*** (0.50 to 0.60)
1 (Ref)

Age (years)
66-69
70-74
75-79
80 or more

0.70 (0.46 to 1.08)
0.69 (0.46 to 1.05)
0.76 (0.51 to 1.14)
1 (Ref)

0.62*** (0.57 to 0.67)
0.71*** (0.65 to 0.77)
0.78*** (0.72 to 0.84)
1 (Ref)

0.62*** (0.58 to 0.67)
0.71*** (0.66 to 0.77)
0.78*** (0.72 to 0.84)
1 (Ref)

Gender
Male
Female

1.20 (0.91 to 1.58)
1 (Ref)

1.19*** (1.13 to 1.26)
1 (Ref)

1.19*** (1.13 to 1.25)
1 (Ref)

Race
Other
White

1.23 (0.50 to 2.98)
1 (Ref)

0.93* (0.86 to 0.99)
1 (Ref)

0.93* (0.86 to 0.99)
1 (Ref)

Urban-rural residence
Metro
Urban
Rural

0.93 (0.52 to 1.66)
0.81 (0.44 to 1.50)
1 (Ref)

1.08 (0.92 to 1.27)
1.18 (0.99 to 1.40)
1 (Ref)

1.06 (0.91 to 1.24)
1.14 (0.96 to 1.34)
1 (Ref)

Comorbidity, Charlson
score
0
1
2 or more

0.74 (0.54 to 1.03)
1.09 (0.81 to 1.46)
1 (Ref)

0.83*** (0.78 to 0.90)
0.88*** (0.82 to 0.94)
1 (Ref)

0.83*** (0.78 to 0.89)
0.89*** (0.83 to 0.95)
1 (Ref)

2.77*** (1.72 to 4.45)
0.99 (0.73 to 1.34)
1 (Ref)

1.49 (0.56 to 3.98)
1.30 (0.66 to 3.78)
1 (Ref)

2.09 (0.91 to 4.77)
1.13 (0.86 to 1.49)
1 (Ref)

2.50 (0.98 to 6.38)
1.76 (0.72 to 4.30)

1.28*** (1.16 to 1.42)
1.10 (0.99 to 1.22)

1.29*** (1.17 to 1.43)
1.11 (1.00 to 1.22)

Appropriateness of care
Inappropriate care
Minimally appropriate
care

~

Percentage with some
^
college education (%)
0.0-0.10
0.11-0.20
0.21 or more
Median household income
^
($)
0-25,000
25,001-50,000
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50,001 or more

1 (Ref)

1 (Ref)

1 (Ref)

WV = West Virginia population, US = United States population represented by the Surveillance, Epidemiology and End Results
(SEER) population, NSCLC = Non-Small Cell Lung Cancer, SCLC = Small Cell Lung Cancer, AJCC = American Joint Committee
on Cancer, TNM = Tumor Node Metastasis, Ref = reference category, NA = Not Applicable.
^
Census tract level measures of beneficiaries socioeconomic status.
*
Estimates are statistically significant (p ≤ 0.05).
**
Estimates are statistically significant (p ≤ 0.01).
***
Estimates are statistically significant (p ≤ 0.001).
~
Minimally appropriate care determined using American College of Chest Physicians (ACCP) evidence-based guidelines for
diagnosis and management of lung cancer published in January, 2003.
Model 1: WV population (N = 393), Fit Statistics: -2 log likelihood = 2613.12 (without covariates) and 2521.42 (with covariates),
Global null hypothesis: Likelihood ratio chi-square test = 91.70 (p ≤ 0.05).
Model 2: US population (N = 9,677), Fit Statistics: -2 log likelihood = 103906.66 (without covariates) and 100941.84 (with
covariates), Global null hypothesis: Likelihood ratio chi-square test = 2964.82 (p ≤ 0.05).
Model 3: Combined WV + US population (N = 10,070), Fit Statistics: -2 log likelihood = 108543.65 (without covariates) and
105501.06 (with covariates), Global null hypothesis: Likelihood ratio chi-square test = 3042.59 (p ≤ 0.05).
Source: West Virginia Cancer Registry - Medicare linked data files, 2002-2007, Surveillance, Epidemiology and End Results Medicare linked data files, 2002-2007.
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CHAPTER 3:
TIMELINESS OF LUNG CANCER CARE AND ASSOCIATED HEALTH OUTCOMES
AMONG ELDERLY MEDICARE FEE-FOR-SERVICE BENEFICIARIES IN WEST
VIRGINIA AND IN THE UNITED STATES

Introduction
Lung cancer is the most common cause of cancer death among elderly in the United
States (US).1 Despite significant advances in treatment options, prognosis associated
with lung cancer diagnosis remains poor, with five year survival of approximately 10%.
Cancer stage at diagnosis is the most important factor for survival among patients with
lung cancer. If diagnosed at an early stage, standard surgical resection can result in
five year survival rates of approximately 40% among patients with non-small cell lung
cancer (NSCLC).2 Among patients diagnosed with early stage small cell lung cancer
(SCLC), five-year survival rates of approximately 14% can be achieved with
chemotherapy and radiation therapy.3 Unfortunately, most lung cancers are found too
late to cure, and the median survival times among those patients is typically 6 to 12
months.2;3
Delays in lung cancer diagnosis can be attributed to patient’s delay in seeking
medical services, and/or physician delay in diagnosis. These delays may primarily
result from lack of routine lung cancer screening tests for the general public.
Furthermore, delayed diagnosis may also occur as lung cancer patients present with
symptoms such as cough and dyspnoea, which are very common in general practice.
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Reducing diagnostic delays may increase the proportion of early stage cancers, and
improve survival.
Elderly carry a disproportionate burden of lung cancer, since approximately 81%
of those living with lung cancer are 60 years of age or older.1 Therefore, significant
reduction in lung cancer mortality can also be achieved if the elderly receive timely and
medically effective therapies following diagnosis. As lung cancer care requires complex
coordination of services by a medical or surgical specialist, the traditional approach of
referring patients for consultation with multiple specialists in a sequential fashion often
results in care that is perceived slow. To establish standards for timely lung cancer
care, clinical opinion-based guidelines have been published by the British Thoracic
Society (BTS), the RAND Corporation, and by the American College of Chest
Physicians (ACCP).4-6 However, extensive studies in European Union member
countries have found delays in time to diagnosis and treatment of lung cancer than
recommended in clinical opinion-based guidelines.7-21 A few studies performed in the
US have shown mixed results.22-28 Dransfield and colleagues (2006) found median time
to resection among NSCLC patients (104 days) exceed the 56-day maximum
recommended by BTS.23 Similarly, Gould and colleagues (2008) found time to
treatment among NSCLC patients often longer than recommended.28 On the contrary,
Riedel and colleagues (2006) found less than expected median time to treatment
initiation (22 days), while evaluating the benefits of multidisciplinary thoracic oncology
clinics in a Veterans Affairs setting.22 In another study from Massachusetts, no
differences in time to treatment were observed between Asian immigrants compared to
non-Asians.26 While multidisciplinary clinics have been recommended in the literature
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to improve timeliness of care, patient care coordination through a dedicated lung mass
clinic or a multidisciplinary clinic have not shown any reduction in delays in the US.4;22;23
Various factors have been associated with less timely care, and they include
atypical symptoms, comorbid conditions, teaching hospital setting, receipt of curative
(versus palliative) radiotherapy, initial referral to a non-respiratory physician,
requirement for multiple diagnostic tests, and care received at more than one health
care facility.11;14;29-32 However, gender,30 household income,14;30 hospital volume,30 rural
residence,30 and distance travelled to obtain care14 have not been associated with
timeliness of lung cancer care. Mixed results were observed in studies that examined
effect of age on timeliness of lung cancer care.11;29-31
While timely lung cancer care is important, its impact on health outcomes
remains unclear. Three studies from non-US countries reported poorer survival among
patients with delayed diagnosis and treatment.33-35 However, four other studies from
non-US countries found better median survival among patients that received less timely
care.8;10;36;37 Similarly in the US, while two studies found no benefits in survival
following timely care, only one study found survival benefits among patients with a
solitary pulmonary nodule, making it unclear whether or not more timely care improves
health outcomes.25;27;28 Delay in treatment also failed to explain the observed higher
mortality risk from NSCLC in the only large population based study from Hawaii.24
Improving timeliness of lung cancer care is important regardless of its effect on
health outcomes. It is particularly important for patients residing in rural areas of the
US. Many rural areas of the US are economically underdeveloped and medically
underserved,38;39 and the elderly in these regions carry a higher burden of lung cancer

77

compared to their urban counterparts.40 These rural areas are also known to report a
higher prevalence of lung cancer and a higher crude all-cause mortality rate among the
elderly.41;42 One such area is the Appalachian region, a population representing 8.1%
of the total US population.42 West Virginia (WV) is the only state situated entirely within
the Appalachian region and is the third most rural state in the nation.42 Fifty of the 55
counties in the state are designated as medically underserved areas, and all or part of
40 counties in the state are classified as health professional shortage areas.43 During
2002-2006, the age-adjusted lung cancer incidence rate (WV: 481.5 per 100,000, US:
378.5 per 100,000), and mortality rate (WV: 390.6 per 100,000, US: 310.8 per 100,000)
among the elderly were higher in the state in comparison to rest of the country.44;45
Interestingly, the proportional difference in age-adjusted lung cancer mortality rates
among the elderly from WV and the US was lower than the difference in age-adjusted
lung cancer incidence rates. This might suggest better survival outcomes among
elderly lung cancer patients in WV as compared to the US; however, such a hypothesis
remains unexplored. The observed lung cancer disparities in the rural population can
be attributed to limited access to quality medical care facilities, less access to or
utilization of early cancer detection programs, increased prevalence of behavioral risk
factors like tobacco use and sedentary life style, and socioeconomic factors, such as
low income and education.46-52 In addition to being medically underserved, the rural
population may also experiences variations in the quality, availability, and accessibility
of services when compared to their urban counterparts.53
While numerous studies have examined timeliness of lung cancer care, a
majority of them have been conduced in European Union healthcare settings.7-21 Few
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studies performed in the US were either limited to small sample sizes, restricted to
NSCLC patients, included both elderly and non-elderly patients, focused on specific
demographic subgroups, performed within specific health care settings, or failed to
examine health outcomes associated with timely care.22-28;54 As elderly carry a
disproportionate burden of lung cancer in the US, studies that examine timeliness of
lung cancer care, based on clinical opinion-based guidelines, and the associated health
outcomes in the elderly are much needed.1 Furthermore, comparison of variations in
timeliness of lung cancer care based on clinical opinion-based guidelines, and the
associated health outcomes among the elderly from a diverse region like WV with those
in the US may help to explain the observed geographical disparities in lung cancer
mortality. To this end, the main focus of this study is to investigate and compare the
timeliness of lung cancer care based on clinical opinion-based guidelines, among the
elderly in WV, and in a representative US population. Specifically the objectives of this
study include: (1) to compare delays in diagnosis and treatment among elderly with lung
cancer in the WV-US populations; (2) to compare the proportion of elderly receiving
timely lung cancer care based on clinical opinion-based guidelines in the WV-US
populations; (3) to compare the factors associated with receipt of timely lung cancer
care based on clinical opinion-based guidelines in the WV-US elderly populations; (4) to
compare survival outcomes by receipt of timely lung cancer care based on clinical
opinion-based guidelines in the WV-US elderly populations; and (5) to compare lung
cancer mortality risk associated with non-receipt of timely lung cancer care based on
clinical opinion-based guidelines in the WV-US elderly populations.
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Methods

Data sources
This retrospective study was conducted using cancer registry linked Medicare data files
for the years 2002 through 2007. While the cancer registry data files provide clinical,
demographic, cause of death, and initial treatment information for elderly individuals
with lung cancer in selected geographic regions, the Medicare administrative data files
provided the health service claims information for care provided by physicians, inpatient
hospital stays, hospital outpatient clinics, home health care agencies, skilled nursing
facilities, and hospice programs.
Specifically, the Surveillance, Epidemiology, and End Results (SEER) - Medicare
linked data files were purchased from the National Cancer Institute, and were used to
estimate the timeliness of lung cancer care based on clinical opinion-based guidelines
in the elderly US population. The data from SEER program are representative of the
US cancer incidence and mortality as they contain information from 20 populationbased cancer registries covering approximately 28 percent of the US population.55
To estimate the timeliness of lung cancer care based on clinical opinion-based
guidelines in the elderly WV population, we used West Virginia Cancer Registry
(WVCR) - Medicare linked data files. The WVCR-Medicare linked data files are similar
in structure to the SEER-Medicare linked data files and represent data from the West
Virginia Cancer Registry, which does not participate in the SEER program. Details on
the creation of WVCR-Medicare linked data files can be found elsewhere.56
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Study populations
We initially identified all Medicare Fee-for-service (FFS) beneficiaries, aged 66 years
and older with incident lung cancer (Stages I-IV) diagnosis during the years 2003
through 2006 from the SEER-Medicare linked data files (hereafter referred to as ‘US
population’) and the WVCR-Medicare linked data files (hereafter referred to as ‘WV
population’), separately. Lung cancer diagnosis was identified among individuals in the
cancer registry files using International Classification of Diseases for Oncology (ICD-O)
codes (C34.0, C34.1, C34.2, C34.3, C34.8, C34.9, and C33.9). Lung cancer stage was
identified using American Joint Committee on Cancer (AJCC), Tumor Node Metastasis
(TNM), 3rd edition stage (for 2003 diagnosis) and 6th edition stage (for 2004-2006
diagnosis).57;58 While Medicare eligibility starts at age 65, we only included
beneficiaries aged 66 years and older at the time of diagnosis so that we would have a
full year of Medicare claims before lung cancer diagnosis for assessing comorbidity.
We then excluded individuals with multiple primary cancer diagnosis or whose diagnosis
was made only at the time of death (death certificate review/autopsy diagnosis). We
also excluded beneficiaries who were enrolled in Medicare managed care plan or who
had non-continuous Medicare Part A and Part B enrollment in the year prior to
diagnosis and during the year following diagnosis. This is because their Medicare files
would not have complete treatment information. The remaining cohorts of continuously
enrolled elderly Medicare FFS beneficiaries in the WV and US populations (study
cohorts) were then used to compare delays in diagnosis and treatment. To compare
the proportion of beneficiaries receiving timely lung cancer care, based on clinical
opinion-based guidelines, and to compare the factors associated with receipt of timely
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lung cancer care, we subset the study cohorts to include only those beneficiaries that
received any treatment during the year following diagnosis.
Given the limited years of data available for follow-up in our data sources, we
further subset the above study cohorts for survival analysis. Specifically, we selected
beneficiaries with lung cancer diagnosis during the years 2003 and 2004 in the study
cohorts, and who received any treatment during the year following the diagnosis. We
then followed these beneficiaries for three years after the incident lung cancer diagnosis
to determine lung cancer specific mortality. These subsets of study cohorts were then
used to compare survival outcomes by receipt of timely lung cancer care and to
compare lung cancer mortality risk associated with non-receipt of timely lung cancer
care.

Assessing delays in diagnosis and treatment
Continuously enrolled elderly Medicare FFS beneficiaries in the WV and US populations
were followed during the year prior to the incident lung cancer diagnosis to determine
delays in diagnosis. The delays in diagnosis were categorized as ’symptom to chest xray’ delay, ‘chest x-ray to specialist visit’ delay, specialist delay, and referral delay.
Given the retrospective nature of our data sources, we estimated the occurrence of
earliest lung cancer symptoms by identifying the date of the earliest Medicare claim,
which had an International Classification of Diseases (ICD-9) code associated with
symptoms of primary tumor (cough, weight loss, dyspnea, chest pain, hemoptysis, bone
pain, clubbing, fever, weakness, superior vena cava obstruction, dysphagia, wheezing
and stridor), symptoms of intrathoracic spread (recurrent laryngeal nerve palsy, pancost
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tumor/superior sulcus tumor, horner syndrome), symptoms of extrathoracic metastases
(headache, nausea\vomiting, seizures, confusion, personality change, musculoskeletal
pain, syncope, lympadenopathy\enlargement of lymph nodes, hoarseness,
hepatomegaly, papilledema), or paraneoplastic syndromes (Appendix 3.1). The
‘symptom to chest x-ray’ delay was then defined as the time from the earliest Medicare
claim date, which had an ICD-9 code associated with lung cancer symptom, until the
date of first Medicare claim for a chest x-ray. The ‘chest x-ray to specialist visit’ delay
was defined as the time from the first Medicare claim for a chest x-ray until the date of
first Medicare claim on which the service provider was a specialist, such as
respiratory/chest physician, pulmonologist, oncologist, cardiologist, or
thoracic/cardiac/regular surgeon. The specialist delay was defined as the time from the
Medicare claim for the first specialist appointment until the date of cancer diagnosis.
Among beneficiaries that were referred to the specialist, referral delay was defined as
the time from the last Medicare claim associated with services provided by the referring
physician, until the date of first Medicare claim on which the service provider was the
referred specialist. The overall delay in diagnosis was defined as the time from the
earliest Medicare claim date, which had an ICD-9 code associated with lung cancer
symptom, until the date of cancer diagnosis. Delays in diagnosis were identified only
among those beneficiaries who had Medicare claims associated with events of interest
necessary to calculate the type of delay.
Continuously enrolled elderly Medicare FFS beneficiaries in the WV and US
populations were followed for one year following incident lung cancer diagnosis to
determine delays in treatment. Specifically, treatment delay was defined as the time
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from cancer diagnosis until the date of first Medicare claim for surgery, radiation, or
chemotherapy. Lung cancer specific treatments and procedures were identified from
the Medicare claim data files using appropriate ICD-9 diagnosis and procedure codes,
Healthcare Common Procedure Coding System (HCPCS) codes, Current Procedural
Terminology (CPT) codes and revenue center codes (Appendix 3.1).

Assessing receipt of timely lung cancer care based on clinical opinion-based guidelines
Timeliness of lung cancer care based on clinical opinion-based guidelines (hereafter
referred to as ‘timely care’) was determined among continuously enrolled elderly
Medicare FFS beneficiaries who received treatment during the year following an
incident lung cancer diagnosis in the WV and US populations. Timely care was defined
using clinical opinion-based guidelines published by the BTS, and the RAND
Corporation.4;5 The British Thoracic Society recommends duration between first
consultation with respiratory physician and surgery to be no more than eight weeks,
between physician referral to see a clinical oncologist and start of radiotherapy to be no
more than seven weeks, and between physician referral to see an oncologist and start
of chemotherapy to be no more than four weeks, approximately.4 On the other hand,
the RAND Corporation recommends that any planned treatment should be offered
within six weeks of the diagnosis date.5 To incorporate recommendations from both
guidelines, we defined timely care by selecting the maximum duration allowed under
either guideline for a given type of treatment. Specifically, initial treatment was
considered timely if the duration between diagnosis date and treatment date was no
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more than eight weeks for surgery, seven weeks for radiotherapy, and six weeks for
chemotherapy.

Dependent variables
The primary outcome of interest was receipt of timely lung cancer care based on clinical
opinion-based guidelines, which was categorized as (a) timely care, or (b) non-timely
care. Survival time in days was calculated for each beneficiary from the time of incident
lung cancer diagnosis to date of death or the three year follow-up cutoff date, which
ever came first. To estimate lung cancer specific survival, beneficiaries who were not
found to be deceased by the cutoff date, or who died due to causes other than lung
cancer were censored at that time and considered to be alive. We measured lung
cancer specific survival, instead of overall survival, as we wanted to determine the
association between receipt of timely lung cancer care based on clinical opinion-based
guidelines and survival.
While exact date of lung cancer diagnosis was available in the WVCR-Medicare
linked data files to calculate survival time, the SEER-Medicare linked data files only
contained the month and year of diagnosis. Hence, to approximate the date of lung
cancer diagnosis in the US population, we used the earliest Medicare claim date, which
had a lung cancer diagnosis code, and which was in the month of lung cancer
diagnosis. This approximation is appropriate given the high level of agreement (nearly
90%) within one month of diagnosis between the SEER diagnosis date and the first
Medicare claim date with a cancer diagnosis.59 In cases were beneficiaries had no
Medicare claims with a lung cancer diagnosis code, earliest date from any claim in the
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month of cancer diagnosis was used as the date of diagnosis. Finally, in beneficiaries
with no Medicare claim in the month of diagnosis, the date of diagnosis was
approximated as the 15th day of the diagnosis month. Date of death was identified from
Medicare enrollment records.

Independent variables
The main independent variables were lung cancer type and stage, age at diagnosis,
gender, race, urban-rural residence, Charlson comorbidity index score, and census tract
level measures of education and income. These variables were considered in our
analysis because of their prognostic significance. Lung cancer type was categorized
based on cell histology. Beneficiaries with ICD-O histology codes 8000-8040 or 80469989 were categorized as NSCLC, and those with codes 8041-8045 were categorized
as SCLC. Lung cancer stage was categorized based on AJCC TNM staging
system.57;58 Age at diagnosis was categorized as 66-69 years, 70-74 years, 75-79
years, and 80 years and older. Given that WV population is predominantly White, race
was classified as White and others. Based on Rural-Urban Continuum codes
developed by the US Department of Agriculture (USDA), urban-rural residence was
categorized as Metro, Urban, and Rural. Charlson comorbidity index score was
calculated using diagnosis and procedure codes reported in Medicare inpatient claims
from the year prior to incident lung cancer diagnosis.60-62 Comorbidities related to
cancer were excluded from the index score. The Charlson comorbidity index score was
used to categorize comorbidity into three groups: 0, 1 and 2 or more, with a higher
score indicating a greater burden of comorbid illness.
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Given the lack of individual socioeconomic status measures in our data sources,
we used as proxy the year 2000 US Census tract level measures of college education
and income.63 Specifically, we used the percentage of individuals in the census tract
with some college education as a proxy measure for education, and categorized it
based on tertile distribution (using WV population) as 0%-0.10%, 0.11%-0.20%, and
0.21% or greater. Similarly, we used median household income at the census tract
level as a proxy measure of income and categorized it based on tertile distribution
(using the WV population) as $0-25,000, $25,000-50,000, and $50,001 or more.

Data Analysis
The Pearson chi-square test was used to determine unadjusted associations between
categorical variables of interest. Median delays (with 25% and 75% interquartiles) in
diagnosis and treatment were calculated for each population. Non-parametric tests
were used to compare delays, as the distribution was not normal. The Mann-Whitney
test was used for pair wise comparison of delays, and the Kruskal-Wallis test was used
for analyses involving multiple groups.
Three hierarchical generalized logistic models were constructed with PROC
GLIMMIX procedure in SAS 9.2 64 to assess the association between independent
variables and the receipt of timely care. In each model, the estimated probability of a
beneficiary receiving timely care conditioned on a set of predictor variables was
modeled. First and second model included beneficiaries from the WV and US
populations, respectively. The third model was constructed to determine population
variation in likelihood of beneficiaries receiving timely care, and therefore included
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beneficiaries from both populations combined. The hierarchical model was chosen as
individual measures of socioeconomic status were not available in our data sources,
and since we relied on census tract level measures of education and income. This was
done by treating census tract as a random effect to account for potential correlation
among beneficiaries within the same county. Odds ratios, 95% confidence intervals,
and two-sided p-values were calculated for each predictor.
Non-parametric estimates of the survivor function by receipt of timely care were
calculated for each population using the Kaplan-Meier method. The log-rank test was
used to assess the statistical significance of the differences in survival outcomes.
Three-year survival estimates were also computed by receipt of timely care within each
population. Stratified analysis was performed by lung cancer type and stage within
each population.
Three multivariate Cox proportional hazards models were constructed to
estimate lung cancer mortality risk associated with non-receipt of timely care. First and
second model included beneficiaries from the WV and US populations, respectively.
The third model was constructed to determine population variation in lung cancer
mortality risk, and therefore included beneficiaries from both populations combined. To
evaluate the proportional hazards assumption, we plotted smoothed Schoenfeld
residuals against time and found no evidence of a systematic deviation from
proportional hazards in any model. Variance in all Cox models were adjusted to
account for patient clustering at the census tract level by use of the robust inference of
Lin and Wei.65 Stratified analysis was performed by lung cancer type and stage within
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each population. Adjusted hazard ratios, 95% confidence intervals, and their two-sided
p-values were calculated for each predictor.
All data were analyzed using the SAS Version 9.2 (SAS Institute, Cary, NC)
statistical software package.64 Results were considered to be statistically significant
when p ≤ 0.05. This study was approved by the West Virginia Institutional Review
Board, and is in full compliance with federal, state, and institutional regulations and
guidelines.

Results

Study population characteristics
Based on study inclusion and exclusion criteria, we identified 1,924 beneficiaries in WV
population, and 48,850 beneficiaries in the US population. Table 3.1 shows the
distribution of clinical and sociodemographic characteristics of these beneficiaries by
type of lung cancer. Compared to beneficiaries with NSCLC in the US population,
beneficiaries with NSCLC in WV population were younger, male, white, resided in nonmetro areas, had higher comorbidity score, and were diagnosed at earlier stages (p ≤
0.05). Similarly, compared to beneficiaries with SCLC in the US population,
beneficiaries with SCLC in WV population were of white race, resided in non-metro
areas, and were diagnosed at earlier stages (p ≤ 0.05). In both populations,
beneficiaries with SCLC were diagnosed at late stages, compared to beneficiaries with
NSCLC (p ≤ 0.05). In the US population, compared to beneficiaries with SCLC,
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beneficiaries with NSCLC were older, male, of non-white race, resided in metro areas,
and had lower comorbidity scores (p ≤ 0.05).

Delays in diagnosis and treatment
Table 3.2 shows the earliest lung cancer symptoms reported among beneficiaries in the
WV and US populations. In both population, common symptoms of primary tumor
included chest pain, cough, weakness, and dyspnea. Table 3.3 shows the delays in
diagnosis and treatment among beneficiaries in the WV and US populations. Median
delay from symptom to diagnosis was approximately six months in each population.
Diagnosis to treatment interval was less than a month on average, and was shorter
among beneficiaries in the WV population as compared to the US population (p ≤ 0.05).
Compared to beneficiaries in the US population, beneficiaries in the WV population had
shorter referral delay, specialist delay, ‘diagnosis to surgery’ delay, and ‘diagnosis to
chemotherapy’ delay (p ≤ 0.05). However, ‘chest x-ray to specialist visit’ delay was
longer among beneficiaries in WV population as compared to the US population (p ≤
0.05).
Table 3.4 shows the delays in diagnosis and treatment in relation to clinical
characteristics among beneficiaries in the WV and US populations. Longer delay in
symptom to diagnosis was observed among female beneficiaries and among
beneficiaries residing in urban areas in the WV population as compared to the US
population (p ≤ 0.05). However, beneficiaries with no comorbid illness had shorter
‘symptom to diagnosis’ delay in the WV population, as compared to the US population
(p ≤ 0.05). Significant population variation in diagnosis to treatment interval was
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observed by lung cancer type, stage, age, gender, race, urban-rural residence, and by
comorbidity score. In all comparisons, the diagnosis to treatment interval was shorter
among beneficiaries in WV population than in the US population (p ≤ 0.05). Within the
two populations, beneficiaries with longer symptom to diagnosis delay were old aged,
male sex, had higher comorbidity score, and were diagnosed at early stages (p ≤ 0.05).
Significant variation in symptom to diagnosis delay by lung cancer type, race and urbanrural residence were only observed among beneficiaries in the US population (p ≤ 0.05).
Longer diagnosis to treatment interval was observed among beneficiaries with NSCLC,
and who were diagnosed at earlier stages, in both populations (p ≤ 0.05). Significant
variation in diagnosis to treatment interval by age, race and comorbidity score were only
observed among beneficiaries in the US population (p ≤ 0.05).

Receipt of timely care
In both populations, the proportion of beneficiaries receiving timely care was highest
among those receiving radiation as initial therapy (WV: 80.1%; US: 80.3%). Among
beneficiaries receiving chemotherapy as initial treatment, the proportion was higher in
the WV population than in the US population (79.6% vs. 74.6%). However, the
proportion was lower among beneficiaries receiving surgery as initial treatment in WV
population than in the US population (75.9% vs. 76.8%).
Table 3.5 shows the descriptive characteristics of beneficiaries by receipt of
timely care in the WV and US populations. Overall, the proportion of beneficiaries
receiving timely care was 78.7% in the WV population and 77.5% in the US population.
However, this population variation in overall receipt of timely care was not significant.
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Significant population variation in receipt of timely care was observed only among
beneficiaries diagnosed in the year 2004. Specifically, the proportion of beneficiaries
diagnosed in the year 2004 receiving timely care was higher in the WV population as
compared to the US population (83.2% vs. 78.7%) (p ≤ 0.05). In both populations,
compared to beneficiaries receiving non-timely care, beneficiaries receiving timely care
had SCLC and were diagnosed at late stage (p ≤ 0.05). Variations in receipt of timely
care by age, race, urban-rural residence, comorbidity score, and year of diagnosis were
only observed among beneficiaries in the US population (p ≤ 0.05).

Factors associated with receipt of timely care
Controlling for all sociodemographic variables, lung cancer type and stage remained
strong predictors of receipt of timely care in all three models (Table 3.6). Specifically,
compared to beneficiaries with late stage diagnosis, beneficiaries diagnosed at early
stage were less likely to receive timely care and these odds gradually increased with
increase in stage at diagnosis (p ≤ 0.05). Beneficiaries with NSCLC were also less
likely to receive timely care as compared to beneficiaries with SCLC (p ≤ 0.05). While
no other factor significantly predicted receipt of timely care in model 1 (WV population),
age, race, comorbidity score, and census tract level measure of income significantly
predicted receipt of timely care in model 2 (US population) and model 3 (Combined
population). Compared to beneficiaries aged 80 years and older, beneficiaries aged 66
to 69 years were 10% more likely to receive timely care (p ≤ 0.05). Beneficiaries of nonwhite race were 21% less likely to receive timely care as compared to whites (p ≤ 0.05).
The likelihood of receipt of timely care was also higher among beneficiaries with low
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comorbidity score compared to those with high comorbidity score (p ≤ 0.05). Finally, the
likelihood of receipt of timely care decreased with decrease in median household
income (p ≤ 0.05). Gender, urban-rural residence, and census tract level measure of
education were not statistically significant in any model. After controlling for all
sociodemographic variables, population variation in likelihood of beneficiaries receiving
timely care was not significant.

Survival outcomes by receipt of timely care
Table 3.7 shows the three year survival rates and median survival times by receipt of
timely care and by lung cancer type, among beneficiaries in the WV and US
populations. Overall, timely care was associated with poorer survival outcomes only
among beneficiaries in the US population (p ≤ 0.05). In stratified analysis by lung
cancer type, similar results were observed among beneficiaries in the US population (p
≤ 0.05). However, in the WV population timely care was associated with poorer survival
outcomes only among beneficiaries with SCLC (p ≤ 0.05). Among those beneficiaries
receiving non-timely care, survival outcomes were also poorer in the WV population as
compared to the US population (p ≤ 0.05). Among beneficiaries receiving timely care,
survival outcomes were better in the WV population as compared to the US population
(p ≤ 0.05). Significant population variations in survival by receipt of timely care were
also observed among beneficiaries in the stratified analysis by cancer type.
Figure 3.1 compares the three year Kaplan-Meier survival curves by cancer
stage and by receipt of timely care in the WV and US populations. In both populations,
among beneficiaries with early stage disease (stage I or stage II) better survival
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outcomes with receipt of timely care were observed, but were not significant. However,
timely care was associated with significantly poorer survival outcomes among
beneficiaries with stage IV disease in the WV population, and among those with stage
III/IV disease in the US population. Significant population variation in survival outcomes
by receipt of timely care were also observed among beneficiaries with late stage
disease (stage III or stage IV), and were generally poorer in the WV population as
compared to the US population.

Lung cancer mortality risk associated with non-receipt of timely care
In all Cox proportional hazards models, the adjusted lung cancer mortality risk was
significantly lower among beneficiaries not receiving timely care, relative to those who
did receive timely care (Table 3.8). Specifically, lung cancer mortality risk among
beneficiaries not receiving timely care decreased by 25% in the WV population, by 32%
in the US population, and by 31% in the combined population (p ≤ 0.05). In all models,
NSCLC diagnosis, early stage disease, and young age were the only other factors
independently associated with lower lung cancer specific mortality (p ≤ 0.05). While no
other factor was independently associated with lung cancer specific mortality in model 1
(WV population), male sex, higher comorbidity score, less education and low income,
were significantly associated with higher lung cancer specific mortality in model 2 (US
population) and model 3 (Combined population). After controlling for all clinical and
sociodemographic variables, and for timeliness of care, population variation in lung
cancer mortality risk was significantly higher among beneficiaries in the WV population
as compared to the US population.
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In stratified analysis by lung cancer type, receipt of non-timely care was
associated with lower lung cancer specific mortality within each population (p ≤ 0.05)
(Table 3.9). However, in stratified analysis by cancer stage, similar results were
observed only among beneficiaries with stage IV disease in the WV population and
among those with stage III/IV disease in the US population (p ≤ 0.05).

Discussion
Compared to other types of cancer, lung cancer diagnosis in the elderly is usually
associated with poor prognosis. This burden is especially higher among elderly residing
in rural and medically underserved regions of the US.38-40 Reducing delays in diagnosis
and treatment of lung cancer have the potential to prolong survival in this population. In
this study, using cancer registry-linked Medicare administrative data files, we compared
geographic variations in timeliness of lung cancer care and associated health outcomes
among elderly in a representative rural and medically underserved state population, and
in a representative US population.
Overall, delays in diagnosis and treatment ranged widely and also varied
significantly among beneficiaries with lung cancer in the WV and US populations. The
median delay from symptom to diagnosis was more than six months in either
population. Such delays may occur, as several invasive procedures may be needed to
establish the diagnosis. These delays could be minimized if all investigations are
planned during the initial visit to a physician. Compared to the US population, ‘chest xray to specialist visit’ delay was longer among beneficiaries in the WV population. This
may have resulted from shortage of qualified health professionals in the medically
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underserved state. Longer ‘symptom to diagnosis’ delay was also observed among
female beneficiaries and among beneficiaries residing in urban areas in the WV
population, as compared to the US population. Diagnosis to treatment intervals were
similar to that reported in a prior study by Riedel and colleagues, and were shorter
among beneficiaries in the WV population as compared to the US population.22 In
either population, surgically treated patients had longer delays than those treated nonsurgically, a difference that is likely to reflect the extra time needed to refer patents to
thoracic surgeon for additional treatment consideration. A multidisciplinary team
approach involving both surgeons and oncologist in the care process, may help to
minimize such delay.6 Population variations in diagnosis and treatment delay were also
observed by clinical characteristics, and may be related to differences in disease
severity, comorbid illness burden, physician and/or individual treatment preferences.
Timely care was received by most beneficiaries in each population and was
highest among those receiving radiotherapy. Contrary to what we expected, the
proportion of beneficiaries receiving timely care did not vary between the two
populations. Controlling for other factors, beneficiaries with NSCLC disease, as
compared to SCLC disease, and those with early stage diagnosis as compared to late
stage diagnosis, were less likely to receive timely care in both populations. This finding
is likely as patients with limited disease may have to wait significantly longer for
treatment than those with advanced disease.6 The finding also indicates that severity of
disease at presentation may influence the speed of the medical decision-making
process. Differences in receipt of timely care by age, race, comorbidity, and census
tract level measure of income were only observed in the US population. Contrary to
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results from a prior study, increasing age was inversely associated with receipt of timely
care in the US population.29 This may occur as compared to younger individuals some
physicians may be conservative in their choice of aggressive treatment for the elderly,
given its impact on patient morbidity and quality of life. Similar to results found in prior
studies, comorbidity was inversely associated with receipt of timely care in the US
population.30;36 This may be due to less aggressive treatment approach by physicians
in elderly with higher comorbidities, or due to individual preference to avoid aggressive
treatments in favor of better quality of life. Increasing poverty was associated with a
decrease in likelihood of receipt of timely care in the US population. Compared to the
US population, the WV population is poorer and that may explain the non-significance of
income on receipt of timely care among beneficiaries in the WV population. Similar to
results found in a prior study, gender, urban-rural residence, and education were not
associated with receipt of timely care in either population.30 After controlling for all
sociodemographic variables, likelihood of receipt of timely care among beneficiaries in
the WV and US populations were not significantly different.
This study is one of the few that have assessed the influence of timely lung
cancer care on survival outcomes. Contrary to what would be expected, the results of
this study indicate that non-timely care is not associated with poorer prognosis in lung
cancer. This results corroborate findings from earlier studies.8;10;24;36;37 Survival
outcomes associated with receipt of timely care varied by lung cancer type and stage
among beneficiaries in both the populations. Similar to findings from prior studies, the
association between shorter delay and poorer outcomes was most pronounced in
patients with advanced stage disease in both populations.37 Compared to the US
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population, survival outcomes were poorer among beneficiaries receiving non-timely
care and among those with late stage disease in the WV population. In both
populations, we found the adjusted lung cancer mortality risk significantly lower among
beneficiaries not receiving timely care than those who did receive such care. However,
the magnitude of risk associated with non-receipt of timely care was higher in the WV
population than in the US population. Young age, early stage disease, and NSCLC
diagnosis were the only other factors independently associated with lower lung cancer
mortality risk in both populations. This is true given that the treatment management for
beneficiaries is easier among those with early stage disease compared to late stage
disease, and is also easier also among those with NSCLC diagnosis compared to SCLC
diagnoses. Variations in lung cancer mortality risk by sex, comorbidity score, education
and income were only observed in the US population. In stratified analysis, by cancer
type and stage, we again found the adjusted lung cancer mortality risk significantly
lower among beneficiaries not receiving timely care than those who did receive such
care, and the results were most pronounced in patients with advanced stage disease.
After controlling for the variability associated with receipt of timely care and all
sociodemographic variables, lung cancer mortality risk was significantly higher among
beneficiaries in WV population as compared to the US population. This finding
highlights the need to address underlying geographic disparities in lung cancer risk.
Based on mathematical models of lung cancer growth, it takes 10-15 years from
appearance of the first cancer cell to the possibility of detecting lung cancer by
conventional chest x-ray.66 Given this slow growth, it seems unlikely that the prognosis
is changed by delay in diagnosis or treatment, and the results from this study agree to
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that theory. However, the tumor volume expands exponentially, and it can turn from
being potentially curable to incurable over a period of 1 month.67 Timely care may
therefore be beneficial in patients with tumors with aggressive phenotypes.
Nonetheless, delays in diagnosis and treatment should be avoided, as it may increase
psychological stress in patients.68
Although delays in diagnosis and treatment varied between the two populations,
significant population variation in receipt of timely care was not observed in this study.
These findings are contrary to what would be expected given that the WV population is
more rural and medically underserved, and has a higher lung cancer mortality rate, as
compared to the US population. The finding suggests that observed geographic
differences in lung cancer mortality may not be associated with variation in receipt of
timely care among elderly beneficiaries with an incident diagnosis of lung cancer.
However, population variation in lung cancer mortality risk was observed in this study.
This may have resulted from higher lung cancer incidence in WV population, as
compared to the US population. Higher incidence may also partly explain the disparities
seen in lung cancer mortality among these populations. Future cancer prevention
efforts directed towards promoting smoking cessation are much needed in rural WV
population, where the smoking prevalence rates are the highest in the nation.69 In the
long run, these cancer prevention efforts can help reduce the incidence of lung cancer
in this rural population which in turn can help reduce the geographic disparities in lung
cancer mortality.
The findings from this study are subject to several limitations. Although we used
cancer registry linked claims data, an inherent limitation of using administrative claims
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data for epidemiologic studies is the possibility of misclassification as a result of coding
errors.70;71 However, claims data have been evaluated for their utility as a source of
epidemiologic or health services information in cancer patients.70-74 Increasing the use
of these types of data to assess the quality of cancer care has also been identified as a
priority by the Institute of Medicine.75 Studies using claims data are usually population
based and have the potential to address a number of priority questions regarding the
quality of cancer care and health care disparities. These population-based studies
provide valuable information for future planning and prioritization of health programs
that improve cancer outcomes. Therefore, there is an increasing interest in analyzing
large health claims databases to assess treatment and outcomes for cancer.70;71;75
The results of this study are generalizable only to the elderly Medicare FFS
population aged 66 years and older, as encounter data for Medicare recipients enrolled
in the managed care plan were not available for this study. There was a small increase
in the percentage of Medicare recipients enrolled in managed care during the study
years in both populations; in 2007 it was ~16% in WV population and ~19% in the US
population.76 Information on care received by the Medicare recipients outside of the
Medicare system or through non-Medicare providers was also not available in the
claims data for our study. However, Medicare is the largest and most comprehensive
insurance provider to the elderly in the US. Racial disparities in cancer outcomes could
not be ascertained in this study as the populations were predominantly White.
One of the inclusion criteria for cohort selection in this study was continuous
enrollment in Medicare Part A and B during the study period. This resulted in the noninclusion of individuals with non-continuous enrollment and the loss of individuals who
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were enrolled intermittently. Given the limitations in our data sources, the delays in
diagnosis and treatment were defined appropriately using claim dates, and may not be
exact. Retrospective review of health services usage to estimate date of earliest lung
cancer symptoms was limited to the year prior to diagnosis since findings from prior
research have shown delays in symptom to diagnosis to be less than a year.77 Our
estimates of ‘symptom to diagnosis’ delay may be biased, as beneficiaries in whom
earliest symptom date could not be identified were excluded from our analysis. These
beneficiaries may have either had no health services usage or may have had no
Medicare claim with an ICD-9 code associated with lung cancer symptom in the year
prior to diagnosis. It is less likely that we missed any reported lung cancer symptom as
the list of symptoms searched for in this study was comprehensive, and was derived
from ACCP guidelines for management and treatment of lung cancer (Appendix 3.1).78
Overall, date of earliest lung cancer symptom was identified in 88% of beneficiaries in
WV population, and in 90% of beneficiaries in the US population. Our estimates of
‘symptom to diagnosis’ delay may also be biased, as the earliest symptom identified
may have been unrelated to lung cancer. We acknowledge that our definition of timely
care may be too narrow, and that given the heterogeneity of patients seen by
physicians, receipt of non-timely care or no care may still be considered appropriate.
Furthermore, given the limitations in our data sources we could not determine whether
delays in lung cancer diagnosis and treatment were attributable to patient’s delay in
seeking medical services. None the less, our definition of timely care provides a
conceptual framework to assess and compare patterns of care that were prevalent
during the years 2002 through 2007. Because of limited data availability at the time of
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study, we were unable to conduct a long-term (5-10 years) follow-up to assess the
health outcomes associated with receipt of timely care. Individual level socioeconomic
measures of educational attainment, marital status, and family income were also
unavailable for this study. However aggregate measures of socioeconomic status at the
census tract level from 2000 decennial census data were used as a proxy. Finally, our
definition of timely versus non-timely care is limited to the data recorded in the claims
such as the presence or absence of ICD-9 diagnosis and procedure codes, HCPCS
procedure codes, CPT procedure codes and revenue center codes. Future studies can
overcome the barriers seen in this study by collecting data on physician behaviors and
patient preferences on treatment choices.
This study is the first of its kind to compare geographic variations in timely lung
cancer care based on clinical opinion-based guidelines and associated health outcomes
among elderly Medicare FFS beneficiaries. Although lung cancer diagnostic and
management services are covered under Medicare program, delays in diagnosis and
treatment among recipients in the Medicare FFS population are a concern. Increasing
patient awareness of lung cancer symptoms and better coordination of care among
providers may help to reduce the delays in diagnosis and treatment. Results of this
study also emphasize the need to address disparities in receipt of timely care among
recipients in the Medicare FFS population. Although longer delay in treatment is not
associated with poorer prognosis, delayed care may increase the risk of disease
progression and psychological stress in patients. Finally, increased lung cancer risk
and incidence among the elderly from economically underdeveloped and medically
underserved regions, such as WV, may be the reason behind observed geographical
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disparities in lung cancer mortality. Promoting smoking cessation among individuals
residing in such rural areas has the potential to reduce observed geographic disparities
in lung cancer mortality.
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Figure 3.1. Kaplan-Meier survival curves by cancer stage, and by receipt of timely lung
cancer care, based on clinical opinion-based guidelines, among continuously enrolled
Medicare Fee-for-service beneficiaries with incident diagnosis of lung cancer in West
Virginia and in the United States from 2003 through 2004. Curves (unadjusted) show
cause-specific mortality.

WV = West Virginia population, US = United States population represented by the Surveillance, Epidemiology and End Results
(SEER) population, CI = confidence interval, - = median survival time not yet reached.
Stage based on American Joint Committee on Cancer (AJCC), Tumor Node Metastasis (TNM) system.
* Survival times and rates were obtained from Kaplan-Meier survival estimates.
^ Upper limit of confidence interval is not available because of censoring.
Timeliness of lung cancer care determined using British Thoracic Society and RAND Corporation clinical opinion-based guidelines
for diagnosis and management of lung cancer.
#
Log-rank test (p ≤ 0.05) comparing differences in survival by receipt of timely care, among beneficiaries within US population.
+
Log-rank test (p ≤ 0.05) comparing differences in survival by receipt of timely care, among beneficiaries within WV population.
$
Log-rank test (p ≤ 0.05) comparing population differences in survival among beneficiaries receiving timely care.
@
Log-rank test (p ≤ 0.05) comparing population differences in survival among beneficiaries receiving non-timely care.
Source: West Virginia Cancer Registry - Medicare linked data files, 2002-2007, Surveillance, Epidemiology and End Results Medicare linked data files, 2002-2007.
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Table 3.1. Descriptive characteristics of continuously enrolled Medicare Fee-for-service
beneficiaries with incident diagnosis of lung cancer in West Virginia and in the United
States from 2003 through 2006.
Proportion (%)
Characteristics

NSCLC

SCLC

WV

US

WV

US

1,641
(85.3)

42,089
(86.2)

283
(14.7)

6,761
(13.8)

AJCC TNM stage * # + ^
I
II
III
IV

27.1
9.4
23.6
39.9

20.8
4.5
29.3
45.5

7.1
4.6
25.8
62.5

5.5
2.1
30.3
62.1

Age (years) * ^
66-69
70-74
75-79
80 or more

22.6
29.9
26.3
21.2

19.1
25.9
26.0
28.9

25.8
30.0
23.7
20.5

23.8
28.9
26.1
21.1

Gender * ^
Male
Female

58.0
42.0

52.1
47.9

53.0
47.0

47.4
52.6

Race * # ^
Other
White

2.1
97.9

13.3
86.7

0.7
99.3

9.4
90.6

Urban-rural residence * # + ^
Metro
Urban
Rural

54.2
40.1
5.7

83.1
14.9
2.0

60.4
32.5
7.1

80.1
17.3
2.6

Comorbidity, Charlson score * ^
0
1
2 or more

26.9
30.0
43.1

31.9
28.6
39.5

30.0
30.0
39.9

29.7
28.5
41.8

Year of diagnosis * ^
2003
2004
2005
2006

22.1
25.5
25.9
26.6

26.7
24.5
24.6
24.2

25.1
25.4
25.4
24.0

26.0
26.2
24.5
23.3

Overall, n (%)

WV = West Virginia population, US = United States population represented by the Surveillance, Epidemiology and End Results
(SEER) population, NSCLC = Non-Small Cell Lung Cancer, SCLC = Small Cell Lung Cancer, AJCC = American Joint Committee
on Cancer, TNM = Tumor Node Metastasis.
*
Chi-square test (p ≤ 0.05) measuring association between beneficiary characteristics and population type, among beneficiaries
with non-small cell lung cancer.
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#

Chi-square test (p ≤ 0.05) measuring association between beneficiary characteristics and population type, among beneficiaries
with small cell lung cancer.
+
Chi-square test (p ≤ 0.05) measuring association between beneficiary characteristics and cancer type, among beneficiaries in
West Virginia population.
^
Chi-square test (p ≤ 0.05) measuring association between beneficiary characteristics and cancer type, among beneficiaries in
United States population.
Source: West Virginia Cancer Registry - Medicare linked data files, 2002-2007, Surveillance, Epidemiology and End Results Medicare linked data files, 2002-2007.
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Table 3.2. Earliest symptoms reported among continuously enrolled Medicare Fee-forservice beneficiaries with incident diagnosis of lung cancer in West Virginia and in the
United States from 2003 through 2006.
Symptom

^

Symptom of primary tumor
Cough
Weight loss
Dyspnea
Chest pain
Hemoptysis
Bone pain
Clubbing
Fever
Weakness
Superior vena cava obstruction
Dysphagia
Wheezing and stridor

~

Symptoms of intrathoracic spread
Symptoms of extrathoracic
metastases
Paraneoplastic syndromes

West Virginia
(N = 1,702)

United States ~
(N = 43,833)

No.

%

No.

%

262
88
252
372
0
44
0
35
254
1
30
31

15.4
5.2
14.8
21.9
0.0
2.6
0.0
2.1
14.9
0.1
1.8
1.8

6,143
2,087
6,820
8,947
0
1,107
3
925
6,519
71
680
462

14.0
4.8
15.6
20.4
0.0
2.5
0.0
2.1
14.9
0.2
1.6
1.1

37

2.2

1,228

2.8

240
337

14.1
19.8

6,501
9,553

14.8
21.8

United States population represented by the Surveillance, Epidemiology and End Results (SEER) population.
Earliest symptoms reported among beneficiaries were identified from the earliest Medicare claim in the year prior to cancer
diagnosis, which had an International Classification of Disease (ICD-9) code associated with lung cancer symptom.
Source: West Virginia Cancer Registry - Medicare linked data files, 2002-2007, Surveillance, Epidemiology and End Results Medicare linked data files, 2002-2007.

^
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Table 3.3. Delays in diagnosis and treatment among continuously enrolled Medicare Fee-for-service beneficiaries with
incident diagnosis of lung cancer in West Virginia and in the United States from 2003 through 2006.
Type of delay

^

N
Symptom to diagnosis +
Symptom to chest x-ray
Chest x-ray to specialist visit
*

*

Referral delay
Specialist delay *
Diagnosis to treatment *
Diagnosis to surgery *
Diagnosis to radiation
Diagnosis to chemotherapy *

West Virginia
Median
25-75% IQR (days)
(days)

N

United States ~
Median
25-75% IQR
(days)
(days)

1,702
1,591

189
9

39 to 313
0 to 136

43,833
37,302

187
15

36 to 308
0 to 154

662
513
662

21
0
11

2 to 109
0 to 6
2 to 73

19,066
14,349
19,066

14
1
14

2 to 69
0 to 7
5 to 63

1,420
407
597
416

22
29
20
21

7 to 44
0 to 56
8 to 41
11 to 38

32,441
7,073
13,644
11,724

25
33
22
25

12 to 45
13 to 55
10 to 42
13 to 43

IQR = Interquartile range.
~
United States population represented by the Surveillance, Epidemiology and End Results (SEER) population.
*
Mann-Whitney test (p ≤ 0.05) comparing population differences in delay between beneficiaries from West Virginia population and the United States population.
+
The number of beneficiaries included in the calculation of median delay varied by type of delay, as not all beneficiaries experienced the event of interest necessary to calculate the
delay.
^
'Symptom to diagnosis' delay is time from the earliest Medicare claim date, which had an International Classification of Disease (ICD-9) code associated with lung cancer symptom,
until the date of cancer diagnosis. 'Symptom to chest x-ray' delay is the time from the earliest Medicare claim date, which had an ICD-9 code associated with lung cancer symptom,
until the date of first Medicare claim for a chest x-ray. 'Chest x-ray to specialist' delay is the time from the first Medicare claim for chest x-ray, until the date of first Medicare claim on
which the service provider was a specialist. Specialist delay is the time from the Medicare claim for the first specialist appointment until the date of cancer diagnosis. Referral delay
is the time from the last Medicare claim associated with services provided by the referring physician, until the date of first Medicare claim on which the service provider was the
referred specialist. 'Diagnosis to treatment' interval is the time from cancer diagnosis, until the date of first Medicare claim for surgery, radiation, or chemotherapy.
Source: West Virginia Cancer Registry - Medicare linked data files, 2002-2007, Surveillance, Epidemiology and End Results - Medicare linked data files, 2002-2007.
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Table 3.4. Delays (in days) in diagnosis and treatment in relation to clinical characteristics among continuously enrolled
Medicare Fee-for-service beneficiaries with incident diagnosis of lung cancer in West Virginia and in the United States
from 2003 through 2006.
Symptom to diagnosis delay ^
Characteristics

WV

Diagnosis to treatment interval ^

US

WV

US

N

Median (IQR)

N

Median (IQR)

N

Median (IQR)

N

Median (IQR)

Lung cancer type ~ @ †
NSCLC #
SCLC #

1,456
246

193 (43 to 311)
155 (21 to 314)

37,792
6,041

188 (38 to 308)
178 (27 to 306)

1,217
203

24 (8 to 48)
14 (7 to 28)

27,643
4,798

27 (13 to 48)
18 (8 to 31)

AJCC TNM stage + ~ @ †
I#
II #
III #
IV #

418
154
407
723

222 (66 to 319)
215 (69 to 314)
175 (35 to 308)
167 (28 to 307)

8,428
1,847
12,916
20,642

219 (63 to 319)
188 (40 to 311)
189 (37 to 307)
169 (28 to 302)

388
133
342
557

29 (6 to 55)
29 (11 to 56)
22 (8 to 41)
19 (7 to 35)

6,878
1,682
9,679
14,202

34 (15 to 58)
33 (17 to 56)
26 (13 to 47)
20 (9 to 37)

Age (years) + ~ †
66-69
70-74 #
75-79 #
80 or more #

384
509
442
367

152 (23 to 307)
187 (43 to 307)
195 (44 to 308)
223 (54 to 322)

8,441
11,487
11,477
12,428

146 (24 to 293)
174 (31 to 304)
197 (42 to 311)
213 (54 to 315)

355
454
365
246

22 (8 to 45)
22 (7 to 42)
22 (10 to 43)
20 (7 to 49)

7,404
9,483
8,559
6,995

24 (11 to 43)
25 (12 to 46)
25 (12 to 46)
26 (12 to 48)

Gender + ~
Male #
Female * #

921
781

151 (31 to 295)
225 (60 to 322)

21,904
21,929

162 (27 to 299)
209 (49 to 315)

783
637

21 (7 to 42)
22 (8 to 48)

16,645
15,796

25 (12 to 45)
25 (12 to 46)

30
1,672

221 (77 to 325)
189 (39 to 312)

5,500
38,333

191 (41 to 313)
187 (36 to 307)

21
1,399

26 (15 to 56)
21 (7 to 44)

3,846
28,595

27 (12 to 51)
25 (12 to 45)

Race ~ †
Other
White #
Urban-rural
residence ~
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Metro #
Urban *
Rural #
Comorbidity,
Charlson score + ~ †
0*
1#
2 or more #

943
656
103

181 (34 to 309)
194 (42 to 317)
209 (78 to 298)

36,248
6,648
937

190 (38 to 308)
167 (30 to 304)
169 (27 to 299)

778
551
91

21 (7 to 48)
22 (8 to 43)
19 (7 to 41)

27,020
4,759
662

25 (12 to 46)
25 (12 to 43)
25 (12 to 44)

388
518
796

29 (8 to 218)
171 (47 to 304)
253 (112 to 329)

12,127
12,932
18,774

43 (11 to 222)
171 (40 to 296)
259 (122 to 331)

368
450
602

22 (9 to 45)
21 (7 to 43)
22 (7 to 44)

10,271
9,832
12,338

24 (12 to 43)
25 (12 to 45)
26 (12 to 47)

WV = West Virginia population, US = United States population represented by the Surveillance, Epidemiology and End Results (SEER) population, NSCLC = Non-Small Cell Lung
Cancer, SCLC = Small Cell Lung Cancer, AJCC = American Joint Committee on Cancer, TNM = Tumor Node Metastasis, IQR = 25-75% Interquartile range.
*
Mann-Whitney test (p ≤ 0.05) comparing population differences in 'symptom to diagnosis' delay between beneficiaries from West Virginia population and the United States
population.
#
Mann-Whitney test (p ≤ 0.05) comparing population differences in ‘diagnosis to treatment’ interval between beneficiaries from West Virginia population and the United States
population.
+
Kruskal-Wallis/Mann-Whitney test (p ≤ 0.05) comparing differences in 'symptom to diagnosis' delay among beneficiaries within West Virginia population.
@
Kruskal-Wallis/Mann-Whitney test (p ≤ 0.05) comparing differences in ‘diagnosis to treatment’ interval among beneficiaries within West Virginia population.
~
Kruskal-Wallis/Mann-Whitney test (p ≤ 0.05) comparing differences in 'symptom to diagnosis' delay among beneficiaries within the United States population.
†
Kruskal-Wallis/Mann-Whitney test (p ≤ 0.05) comparing differences in ‘diagnosis to treatment’ interval among beneficiaries within the United States population.
^
'Symptom to diagnosis' delay is time from the earliest Medicare claim date, which had an International Classification of Disease (ICD-9) code associated with lung cancer symptom,
until the date of cancer diagnosis. ‘Diagnosis to treatment’ interval is the time from cancer diagnosis, until the date of first Medicare claim for surgery, radiation, or chemotherapy.
Source: West Virginia Cancer Registry - Medicare linked data files, 2002-2007, Surveillance, Epidemiology and End Results - Medicare linked data files, 2002-2007.
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Table 3.5. Descriptive characteristics by receipt of timely lung cancer care, based on
clinical opinion-based guidelines, among continuously enrolled Medicare Fee-forservice beneficiaries with incident diagnosis of lung cancer in West Virginia and in the
United States from 2003 through 2006.
Timely Care ~
Characteristics

WV

US

WV

Non-timely Care
US

No.

%#

No.

%#

No.

%#

No.

%#

1,118

78.7

25,139

77.5

302

21.3

7,302

22.5

Lung cancer type + ^
NSCLC
SCLC

935
183

76.8
90.2

20,960
4,179

75.8
87.1

282
20

23.2
9.9

6,683
619

24.2
12.9

AJCC TNM stage + ^
I
II
III
IV

287
99
271
461

74.0
74.4
79.2
82.8

4,924
1,220
7,315
11,680

71.6
72.5
75.6
82.2

101
34
71
96

26.0
25.6
20.8
17.2

1,954
462
2,364
2,522

28.4
27.5
24.4
17.8

Age (years) ^
66-69
70-74
75-79
80 or more

279
365
284
190

78.6
80.4
77.8
77.2

5,857
7,330
6,642
5,310

79.1
77.3
77.6
75.9

76
89
81
56

21.4
19.6
22.2
22.8

1,547
2,153
1,917
1,685

20.9
22.7
22.4
24.1

Gender
Male
Female

626
492

79.9
77.2

12,953
12,186

77.8
77.1

157
145

20.1
22.8

3,692
3,610

22.2
22.9

14
1,104

66.7
78.9

2,818
22,321

73.3
78.1

7
295

33.3
21.1

1,028
6,274

26.7
21.9

596
446
76

76.6
80.9
83.5

20,833
3,777
529

77.1
79.4
79.9

182
105
15

23.4
19.1
16.5

6,187
982
133

22.9
20.6
20.1

284
361
473

77.2
80.2
78.6

8,123
7,638
9,378

79.1
77.7
76.0

84
89
129

22.8
19.8
21.4

2,148
2,194
2,960

20.9
22.3
24.0

264

79.8

6,762

79.1

67

20.2

1,786

20.9

Overall

Race ^
Other
White
Urban-rural
residence ^
Metro
Urban
Rural
Comorbidity,
Charlson score ^
0
1
2 or more
Year of diagnosis ^
2003

111

2004 *
2005
2006

306
278
270

83.2
77.0
75.0

6,450
6,214
5,713

78.7
77.5
74.4

62
83
90

16.8
23.0
25.0

1,749
1,804
1,963

WV = West Virginia population, US = United States population represented by the Surveillance, Epidemiology and End Results
(SEER) population, NSCLC = Non-Small Cell Lung Cancer, SCLC = Small Cell Lung Cancer, AJCC = American Joint Committee
on Cancer, TNM = Tumor Node Metastasis.
~
Timeliness of lung cancer care determined using British Thoracic Society and RAND Corporation clinical opinion-based guidelines
for diagnosis and management of lung cancer.
#
Proportions reported are row percentages of beneficiaries receiving timely care, or non-timely care, within WV or the US
population.
*
Chi-square test (p ≤ 0.05), measuring association between receipt of timely care and population type, among beneficiaries within
each row category.
+
Chi-square test (p ≤ 0.05) measuring association between beneficiary characteristics and receipt of timely care, among
beneficiaries in West Virginia population.
^
Chi-square test (p ≤ 0.05) measuring association between beneficiary characteristics and receipt of timely care, among
beneficiaries in United States population.
Source: West Virginia Cancer Registry - Medicare linked data files, 2002-2007, Surveillance, Epidemiology and End Results Medicare linked data files, 2002-2007.
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21.3
22.5
25.6

Table 3.6. Factors associated with receipt of timely lung cancer care, based on clinical
opinion-based guidelines, among continuously enrolled Medicare Fee-for-service
beneficiaries with incident diagnosis of lung cancer in West Virginia and in the United
States from 2003 through 2006.
Model 1: WV

Odds Ratio (95% Confidence Interval)
Model 2: US
Model 3: WV + US

Intercept (p-value)

0.11

0.07

0.09

Population
WV
US

NA
NA

NA
NA

1.03 (0.85 to 1.24)
1 (Ref)

Lung cancer type
NSCLC
SCLC

0.40*** (0.24 to 0.66)
1 (Ref)

0.51*** (0.47 to 0.56)
1 (Ref)

0.51*** (0.47 to 0.56)
1 (Ref)

AJCC TNM stage
I
II
III
IV

0.67* (0.48 to 0.93)
0.69 (0.43 to 1.09)
0.83 (0.58 to 1.19)
1 (Ref)

0.59*** (0.55 to 0.64)
0.60*** (0.53 to 0.68)
0.68*** (0.64 to 0.73)
1 (Ref)

0.59*** (0.56 to 0.64)
0.60*** (0.54 to 0.68)
0.69*** (0.64 to 0.73)
1 (Ref)

Age (years)
66-69
70-74
75-79
80 or more

1.06 (0.70 to 1.59)
1.24 (0.84 to 1.85)
1.06 (0.71 to 1.58)
1 (Ref)

1.10* (1.02 to 1.20)
1.02 (0.94 to 1.10)
1.07 (1.00 to 1.16)
1 (Ref)

1.10* (1.01 to 1.19)
1.02 (0.95 to 1.10)
1.07 (0.99 to 1.15)
1 (Ref)

Gender
Male
Female

1.16 (0.89 to 1.52)
1 (Ref)

1.05 (0.99 to 1.10)
1 (Ref)

1.05 (1.00 to 1.11)
1 (Ref)

Race
Other
White

0.60 (0.21 to 1.69)
1 (Ref)

0.79*** (0.73 to 0.86)
1 (Ref)

0.79*** (0.73 to 0.86)
1 (Ref)

0.63 (0.33 to 1.19)
0.91 (0.48 to 1.73)
1 (Ref)

0.89 (0.72 to 1.11)
1.01 (0.80 to 1.26)
1 (Ref)

0.86 (0.70 to 1.06)
1.00 (0.80 to 1.23)
1 (Ref)

0.85 (0.61 to 1.17)
1.07 (0.78 to 1.47)
1 (Ref)

1.13*** (1.06 to 1.20)
1.08* (1.01 to 1.15)
1 (Ref)

1.12*** (1.05 to 1.19)
1.07* (1.01 to 1.14)
1 (Ref)

Urban-rural
residence
Metro
Urban
Rural
Comorbidity,
Charlson
score
0
1
2 or more
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Percentage
with some
college
education ^
0.0-0.10
0.11-0.20
≥ 0.21

0.70 (0.24 to 2.08)
1.01 (0.74 to 1.37)
1 (Ref)

0.62 (0.01 to 0.69)
0.69 (0.11 to 0.75)
1 (Ref)

0.60 (0.51 to 0.72)
1.02 (1.00 to 1.90)
1 (Ref)

0.74 (0.33 to 1.63)
1.03 (0.49 to 2.17)
1 (Ref)

0.89* (0.80 to 0.98)
0.93 (0.84 to 1.01)
1 (Ref)

0.89* (0.80 to 0.98)
0.93 (0.85 to 1.02)
1 (Ref)

Median
household
income ^
0-25000
25001-50000
≥ 50001

WV = West Virginia population, US = United States population represented by the Surveillance, Epidemiology and End Results
(SEER) population, Ref = reference category, NA = Not Applicable, NSCLC = Non-Small Cell Lung Cancer, SCLC = Small Cell
Lung Cancer, AJCC = American Joint Committee on Cancer, TNM = Tumor Node Metastasis.
* Estimates are statistically significant (p ≤ 0.05).
**
Estimates are statistically significant (p ≤ 0.01).
***
Estimates are statistically significant (p ≤ 0.001).
^
Census tract level measures of beneficiaries socioeconomic status.
Model 1: WV population (N = 1,420), Fit Statistics: -2 restricted log pseudo-likelihood = 6639.58, Covariance parameter estimates:
Intercept = county, estimate = 0.14, standard error = 0.10.
Model 2: US population (N = 32,441), Fit Statistics: -2 restricted log pseudo-likelihood = 150424.20, Covariance parameter
estimates: Intercept = county, estimate = 0.09, standard error = 0.02.
Model 3: Combined WV + US population (N = 33,861), Fit Statistics: -2 restricted log pseudo-likelihood = 157037.00, Covariance
parameter estimates: Intercept = county, estimate = 0.09, standard error = 0.02.
Timeliness of lung cancer care determined using British Thoracic Society and RAND Corporation clinical opinion-based guidelines
for diagnosis and management of lung cancer.
Source: West Virginia Cancer Registry - Medicare linked data files, 2002-2007, Surveillance, Epidemiology and End Results Medicare linked data files, 2002-2007.
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Table 3.7. Three-year median survival time and survival rate by cancer type, and by receipt of timely lung cancer care,
based on clinical opinion-based guidelines, among continuously enrolled Medicare Fee-for-service beneficiaries with
incident diagnosis of lung cancer in West Virginia and in the United States from 2003 through 2004.
Timely Care ~

Non-timely Care

WV

US

WV

US

Overall $ @ #
N
Percent censored
Median survival time, days (95% CI) *
3-year survival rate (95% CI) *

570
30.9%
299 (262 to 364)
0.26 (0.22 to 0.30)

13,212
25.2%
273 (266 to 282)
0.21 (0.20 to 0.22)

129
31.8%
467 (344 to 692)
0.27 (0.19 to 0.35)

3,535
32.8%
491 (466 to 508)
0.28 (0.27 to 0.30)

NSCLC $ @ #
N
Percent censored
Median survival time, days (95% CI) *
3-year survival rate (95% CI) *

473
34.7%
364 (276 to 460)
0.30 (0.26 to 0.35)

10,949
27.9%
281 (271 to 291)
0.24 (0.23 to 0.25)

122
32.8%
472 (344 to 705)
0.28 (0.20 to 0.37)

3,269
33.9%
500 (479 to 520)
0.29 (0.28 to 0.31)

SCLC $ + #
N
Percent censored
Median survival time, days (95% CI) *
3-year survival rate (95% CI) *

97
12.4%
236 (164 to 270)
0.06 (0.02 to 0.12)

2,263
12.4%
252 (239 to 266)
0.07 (0.06 to 0.09)

7
14.3%
427 (113 to 958)
0

266
20.3%
372 (324 to 428)
0.16 (0.11 to 0.21)

WV = West Virginia population, US = United States population represented by the Surveillance, Epidemiology and End Results (SEER) population, NSCLC = Non-small cell lung
cancer, SCLC = Small cell lung cancer, CI = confidence interval.
* Survival times and rates were obtained from Kaplan-Meier survival estimates.
~ Timeliness of lung cancer care determined using British Thoracic Society and RAND Corporation clinical opinion-based guidelines for diagnosis and management of lung cancer.
$
Log-rank test (p ≤ 0.05) comparing population differences in survival among beneficiaries receiving timely care.
@
Log-rank test (p ≤ 0.05) comparing population differences in survival among beneficiaries receiving non-timely care.
#
Log-rank test (p ≤ 0.05) comparing differences in survival by receipt of timely care, among beneficiaries within US population.
+
Log-rank test (p ≤ 0.05) comparing differences in survival by receipt of timely care, among beneficiaries within WV population.
Source: West Virginia Cancer Registry - Medicare linked data files, 2002-2007, Surveillance, Epidemiology and End Results - Medicare linked data files, 2002-2007.
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Table 3.8. Lung cancer mortality risk associated with receipt of non-timely lung cancer
care, based on clinical opinion-based guidelines, among continuously enrolled Medicare
Fee-for-service beneficiaries with incident diagnosis of lung cancer in West Virginia and
in the United States from 2003 through 2004.
Model 1: WV
Population
WV
US

Hazard Ratio (95% Confidence Interval)
Model 2: US
Model 3: WV + US

NA
NA

NA
NA

1.14* (1.00 to 1.29)
1 (Ref)

Timeliness of care ~
Non-timely care
Timely care

0.75* (0.60 to 0.95)
1 (Ref)

0.68*** (0.66 to 0.71)
1 (Ref)

0.69*** (0.66 to 0.72)
1 (Ref)

Lung cancer type
NSCLC
SCLC

0.78* (0.61 to 0.99)
1 (Ref)

0.94** (0.90 to 0.98)
1 (Ref)

0.93** (0.89 to 0.98)
1 (Ref)

AJCC TNM stage
I
II
III
IV

0.16*** (0.12 to 0.22)
0.28*** (0.20 to 0.40)
0.49*** (0.39 to 0.62)
1 (Ref)

0.15*** (0.14 to 0.16)
0.28*** (0.25 to 0.31)
0.52*** (0.50 to 0.54)
1 (Ref)

0.15*** (0.14 to 0.16)
0.28*** (0.25 to 0.31)
0.52*** (0.50 to 0.54)
1 (Ref)

Age (years)
66-69
70-74
75-79
80 or more

0.76* (0.57 to 1.00)
0.74* (0.56 to 0.98)
0.93 (0.70 to 1.25)
1 (Ref)

0.70*** (0.66 to 0.75)
0.75*** (0.71 to 0.79)
0.80*** (0.77 to 0.84)
1 (Ref)

0.71*** (0.67 to 0.75)
0.75*** (0.71 to 0.79)
0.81*** (0.77 to 0.85)
1 (Ref)

Gender
Male
Female

1.10 (0.91 to 1.32)
1 (Ref)

1.24*** (1.20 to 1.28)
1 (Ref)

1.23*** (1.19 to 1.27)
1 (Ref)

Race
Other
White

1.27 (0.61 to 2.61)
1 (Ref)

0.97 (0.90 to 1.04)
1 (Ref)

0.97 (0.91 to 1.04)
1 (Ref)

Urban-rural residence
Metro
Urban
Rural

0.99 (0.62 to 1.58)
1.18 (0.73 to 1.91)
1 (Ref)

1.00 (0.88 to 1.14)
0.99 (0.87 to 1.13)
1 (Ref)

1.01 (0.89 to 1.14)
1.01 (0.88 to 1.15)
1 (Ref)

0.92 (0.74 to 1.14)
0.93 (0.76 to 1.14)
1 (Ref)

0.87*** (0.83 to 0.91)
0.90*** (0.86 to 0.94)
1 (Ref)

0.87*** (0.83 to 0.91)
0.90*** (0.86 to 0.94)
1 (Ref)

Comorbidity, Charlson
score
0
1
2 or more
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Percentage with some
college education ^
0.0-0.10
0.11-0.20
≥ 0.21
Median household income ^
0-25000
25001-50000
≥ 50001

0.99 (0.43 to 2.29)
0.86 (0.69 to 1.07)
1 (Ref)

1.91** (1.18 to 3.11)
1.89** (1.15 to 3.05)
1 (Ref)

1.15* (0.56 to 2.36)
0.89 (0.72 to 1.09)
1 (Ref)

1.18 (0.66 to 2.11)
0.96 (0.56 to 1.63)
1 (Ref)

1.22*** (1.13 to 1.33)
1.10* (1.02 to 1.19)
1 (Ref)

1.22*** (1.13 to 1.33)
1.10* (1.02 to 1.18)
1 (Ref)

WV = West Virginia population, US = United States population represented by the Surveillance, Epidemiology and End Results
(SEER) population, NSCLC = Non-Small Cell Lung Cancer, SCLC = Small Cell Lung Cancer, AJCC = American Joint Committee
on Cancer, TNM = Tumor Node Metastasis, Ref = reference category, NA = Not Applicable.
* Estimates are statistically significant (p ≤ 0.05).
**
Estimates are statistically significant (p ≤ 0.01).
***
Estimates are statistically significant (p ≤ 0.001).
^
Census tract level measures of beneficiaries socioeconomic status.
Model 1: WV population (N = 699), Fit Statistics: -2 log likelihood = 5767.84 (without covariates) and 5511.39 (with covariates),
Global null hypothesis: Likelihood ratio chi-square test = 256.4 (p ≤ 0.05).
Model 2: US population (N = 16,747), Fit Statistics: -2 log likelihood = 223470.70 (without covariates) and 217646.99 (with
covariates), Global null hypothesis: Likelihood ratio chi-square test = 5823.7 (p ≤ 0.05).
Model 3: Combined WV + US population (N = 17,446), Fit Statistics: -2 log likelihood = 233349.14 (without covariates) and
227268.20 (with covariates), Global null hypothesis: Likelihood ratio chi-square test = 6075.9 (p ≤ 0.05).
~
Timeliness of lung cancer care determined using British Thoracic Society and RAND Corporation clinical opinion-based guidelines
for diagnosis and management of lung cancer.
Source: West Virginia Cancer Registry - Medicare linked data files, 2002-2007, Surveillance, Epidemiology and End Results Medicare linked data files, 2002-2007.
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Table 3.9. Adjusted lung cancer mortality risk associated with receipt of non-timely lung
cancer care, based on clinical opinion-based guidelines, by cancer type and stage,
among continuously enrolled Medicare Fee-for-service beneficiaries with incident
diagnosis of lung cancer in West Virginia and in the United States from 2003 through
2004.
Hazard Ratio ^ (95% Confidence Interval)
WV
US
Lung cancer type
NSCLC
SCLC

0.77* (0.60 to 0.98)
0.33*** (0.19 to 0.57)

0.68*** (0.65 to 0.71)
0.68*** (0.60 to 0.78)

AJCC TNM stage
I
II
III
IV

1.22 (0.73 to 2.06)
0.69 (0.30 to 1.56)
0.78 (0.49 to 1.23)
0.53*** (0.39 to 0.74)

1.01 (0.90 to 1.13)
1.04 (0.82 to 1.31)
0.71*** (0.66 to 0.76)
0.58*** (0.55 to 0.62)

WV = West Virginia population, US = United States population represented by the Surveillance, Epidemiology and End Results
(SEER) population, NSCLC = Non-Small Cell Lung Cancer, SCLC = Small Cell Lung Cancer, AJCC = American Joint Committee
on Cancer, TNM = Tumor Node Metastasis.
* Estimates are statistically significant (p ≤ 0.05).
***
Estimates are statistically significant (p ≤ 0.001).
^
Hazard ratios associated with receipt of non-timely care (Reference: Receipt of timely care), adjusted for age, gender, race, urbanrural residence, comorbidity, and census tract level measure of education and income.
Timeliness of lung cancer care determined using British Thoracic Society and RAND Corporation clinical opinion-based guidelines
for diagnosis and management of lung cancer.
Stage I: WV: N = 205, US: N = 3,478; Stage II: WV: N = 60, US: N = 766; Stage III: WV: N = 163, US: N = 5,291; Stage IV: WV: N =
271, US: N = 7,212. NSCLC: WV: N = 595, US: N = 14,218; SCLC: WV: N = 104, US: N = 2,529.
Source: West Virginia Cancer Registry - Medicare linked data files, 2002-2007, Surveillance, Epidemiology and End Results Medicare linked data files, 2002-2007.
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CHAPTER 4:
PATTERNS OF RECEIPT OF TOBACCO-USE CESSATION COUNSELING
SERVICES AND ASSOCIATED HEALTH OUTCOMES AMONG ELDERLY MEDICARE
FEE-FOR-SERVICE BENEFICIARIES WITH LUNG CANCER, AND WITH A HISTORY
OF TOBACCO USE, IN WEST VIRGINIA

Introduction
Tobacco use is the leading preventable cause of lung cancer in the United States (US).
It accounts for 90% of all lung cancer cases, and for 87% of all lung cancer deaths in
the US.1 The causal association of tobacco use with lung cancer is one of the most
thoroughly documented causal relationships in biomedical research.2;3 More individuals
die of lung cancer each year than the next three most common cancers combined
(colon, breast, and prostate), and the efforts to decrease lung cancer mortality have
been focused on early detection and treatment of lung cancer and smoking avoidance
and cessation.4-7
Clinical practice guidelines for preventive care in lung cancer have been
published by American Society of Clinical Oncology (ASCO), authors Biesalski et al,
Cancer Guidance Group (CGG), College des Medecins du Quebec, National Cancer
Institute (NCI), US Department of Health and Human Services (DHHS), and US
Preventive Services Task Force.8-13 While these guidelines recommend smoking
cessation among asymptomatic individuals, it is strongly encouraged among individuals
diagnosed with lung cancer. This is because, growing evidence suggests that smoking
may compromise the effectiveness of lung cancer treatment, reduce the tolerance of
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patients for lung cancer treatment, and increase the risk of complications.14 Specifically,
continued smoking following lung cancer diagnosis can interfere with cancer therapies,
such as radiation therapy and chemotherapy, increase risk of infection due to surgery
and decrease post-operative wound healing.14
Prior research has shown smoking to be common among patients at the time of
lung cancer diagnosis, and that patients continue to smoke following diagnosis. In one
study of smoking behavior among 840 adults with stage I non-small cell lung cancer
(NSCLC), 60% of patients were smokers at the time of diagnosis, and only 40% of them
had quit smoking after two years.15 However, almost 90% of patients had made one or
more attempts to quit smoking, suggesting an increased motivation to quit.15 Continued
smoking after lung cancer diagnosis was associated with lower quality of life among
patients in one study.16 Among lung cancer patients receiving surgery, a history of
smoking doubled the likelihood of complications in another study.17
Continued smoking, following lung cancer diagnosis, also increases the risk of
metachronous tumors/new primary cancer for up to 20 years after original diagnosis.14
In two studies of survivors of small cell lung cancer (SCLC), the risk of a second cancer
was higher among those who continued to smoke, and the risk was particularly higher
following curative-intent therapy.18;19 However, in individuals who stopped smoking at
the time of diagnosis, the risk was no higher than in those who had stopped smoking at
least six months before diagnosis.
Studies examining survival outcomes associated with continued smoking have
reported mixed results. In one study of patients with SCLC, continued smokers had the
poorest survival, followed by patients who had quit at diagnosis, and then by patients
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who had quit on average 2.5 years before diagnosis.20 However, survival curves of
recent ex-smokers did not differ statistically from continued smokers. In another study,
no significant differences in prognosis in resected stage I NSCLC patients, were
observed on the basis of smoking status.21 Regardless of its impact on survival,
promoting smoking cessation among lung cancer patients at the time of diagnosis is
much needed. Time of cancer diagnosis has also been described as a teachable
moment for intervening with smokers and providing cessation treatment.22
Given the fact that smoking is common among patients with lung cancer,
preventive care services, such as tobacco-use cessation counseling can have a
profound impact on health outcomes. To that end, many insurance agencies including
Medicare cover tobacco-use cessation counseling services. Beginning in March 2005,
the Centers for Medicare and Medicaid Services (CMS) began providing coverage for
tobacco-use cessation counseling for outpatient and hospitalized beneficiaries, who
were smokers and had a disease or adverse health effect that is tobacco related or who
were taking a medication whose metabolism or effect is affected by tobacco use.23
However, the use of such services and its impact on health outcomes among elderly
lung cancer patients remains unknown. To this end, the main focus of this study is to
determine the patterns of receipt of tobacco-use cessation counseling services among
elderly Medicare Fee-for-service (FFS) beneficiaries with lung cancer and with a history
of tobacco use in a state population. Specifically, the objectives of this study include:
(1) to determine the proportion of elderly lung cancer patients receiving tobacco-use
cessation counseling services; (2) to determine the factors associated with receipt of
tobacco-use cessation counseling services among elderly lung cancer patients; (3) to
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determine survival benefits associated with receipt of tobacco-use cessation counseling
services among elderly lung cancer patients; and (4) to determine lung cancer mortality
risk associated with non-receipt of tobacco-use cessation counseling services among
elderly lung cancer patients.

Methods

Data sources
This retrospective study was conducted using cancer registry linked Medicare data files
for the years 2004 through 2007. While cancer registry data files provide clinical,
demographic, cause of death, initial treatment, and tobacco-use history information for
elderly individuals with lung cancer in selected geographic regions, the Medicare
administrative data files provided the health service claims information for care provided
by physicians, inpatient hospital stays, hospital outpatient clinics, home health care
agencies, skilled nursing facilities, and hospice programs.
Specifically, the West Virginia Cancer Registry (WVCR) - Medicare linked data
files were used to estimate the receipt to tobacco-use cessation counseling services
and associated health outcomes among elderly lung cancer patients with a history of
tobacco use. The WVCR-Medicare linked data files are similar in structure to the well
known Surveillance, Epidemiology, and End Results (SEER) - Medicare linked data
files, and represent data from the West Virginia (WV) Cancer Registry, which does not
participate in the SEER program. Unlike the SEER-Medicare data files, the WVCRMedicare data files contain information on history of tobacco use among individuals
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diagnosed with lung cancer, and were therefore used for this study. Details on the
creation of WVCR-Medicare linked data files can be found elsewhere.24 West Virginia is
also the third most rural state in the nation, and is the only state situated entirely within
the Appalachian region, a region well known for cancer disparities.25 The state has the
second highest lung cancer death rate and the highest smoking prevalence rate
(26.8%) in the nation.26 During 2002-2006, the age-adjusted lung cancer incidence rate
(WV: 481.5 per 100,000, US: 378.5 per 100,000), and mortality rate (WV: 390.6 per
100,000, US: 310.8 per 100,000) among the elderly were higher in the state in
comparison to rest of the country.27;28 Fifty of the 55 counties in the state are
designated as medically underserved areas, and all or part of 40 counties in the state
are classified as health professional shortage areas.29 The state is similar to many
other rural and medically underserved states, and therefore serves as an excellent
laboratory for studying and addressing lung cancer disparities in the rural and medically
underserved population.

Study population
We initially identified all Medicare FFS beneficiaries, aged 66 years and older with an
incident lung cancer diagnosis between July 1, 2005 and October 31, 2007, and with a
history of tobacco use from the WVCR-Medicare linked data files. Lung cancer
diagnosis was identified among individuals in the cancer registry files using International
Classification of Diseases for Oncology (ICD-O) codes (C34.0, C34.1, C34.2, C34.3,
C34.8, C34.9, and C33.9). Lung cancer stage was identified using American Joint
Committee on Cancer (AJCC), Tumor Node Metastasis (TNM), 6th edition stage.30;31
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While Medicare eligibility starts at age 65, we only included beneficiaries aged 66 years
and older at the time of diagnosis, so that we would have a full year of Medicare claims
before lung cancer diagnosis for assessing comorbidity. We then excluded individuals
with multiple primary cancer diagnosis or whose diagnosis was made only at the time of
death (death certificate review/autopsy diagnosis). We also excluded beneficiaries who
were enrolled in Medicare managed care plan or who had non-continuous Medicare
Part A and Part B enrollment in the year prior to diagnosis, and during the two months
following diagnosis. This is because their Medicare files would not have complete
health services usage information. The remaining cohort (Cohort A) of continuously
enrolled elderly Medicare FFS beneficiaries was then used to determine the proportion
of beneficiaries receiving tobacco-use cessation counseling services, and to determine
the factors associated with receipt of tobacco-use cessation counseling services.
Given the limited years of data available for follow up in our data sources, we
identified a separate cohort to determine association between receipt of tobacco-use
cessation counseling services and survival outcomes. Specifically, we selected
beneficiaries aged 66 years and older, with an incident lung cancer diagnosis (Stages IIV) between July 1, 2005 and December 31, 2005, and with a history of tobacco use
from the WVCR-Medicare linked data files. We then excluded individuals with multiple
primary cancer diagnosis or whose diagnosis was made only at the time of death (death
certificate review\autopsy diagnosis). We also excluded beneficiaries who were
enrolled in Medicare managed care plan or who had non-continuous Medicare Part A
and Part B enrollment, in the year prior to diagnosis and during the year following
diagnosis. The remaining cohort (Cohort B) was then followed for two years following
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the incident lung cancer diagnosis to determine lung cancer specific mortality. This
cohort was then used to determine survival benefits associated with receipt of tobaccouse cessation counseling services, and to determine lung cancer mortality risk
associated with non-receipt of tobacco-use cessation counseling services.

Assessing receipt of tobacco-use cessation counseling services
In both cohort A and B, continuously enrolled elderly Medicare FFS beneficiaries were
followed for two months following incident lung cancer diagnosis to determine receipt of
tobacco-use cessation counseling services. A cessation counseling session refers to
face-to-face patient contact by the practitioner following an incident lung cancer
diagnosis and can be minimal (3 minutes or less), intermediate (3-10 minutes), or
intensive (greater than 10 minutes). Tobacco-use cessation counseling services were
identified from the Medicare claim data files using appropriate Current Procedural
Terminology (CPT) codes (Appendix 4.1).

Dependent variables
The primary outcome of interest was receipt of tobacco-use cessation counseling
services, which was categorized as: (a) receipt, or (b) non-receipt. Survival time in days
was calculated for each beneficiary from the time of incident lung cancer diagnosis to
date of death or the two year follow-up cutoff date, which ever came first. To estimate
lung cancer specific survival, beneficiaries who were not found to be deceased by the
cutoff date, or who died due to causes other than lung cancer were censored at that
time and considered to be alive. We measured lung cancer specific survival instead of
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overall survival, since we wanted to determine the association between receipt of
tobacco-use cessation counseling services and survival.

Independent variables
The main independent variables were lung cancer type and stage, age at diagnosis,
gender, race, urban-rural residence, Charlson comorbidity index score, census tract
level measures of education and income, and receipt of minimally appropriate clinical
guideline based lung cancer care. These variables were considered in our analysis
because of their prognostic significance. Lung cancer type was categorized based on
cell histology. Beneficiaries with ICD-O histology codes 8000-8040 or 8046-9989 were
categorized as NSCLC, and those with codes 8041-8045 were categorized as SCLC.
Lung cancer stage was categorized based on AJCC TNM staging system.30;31 Age at
diagnosis was categorized as 66-69 years, 70-74 years, 75-79 years, and 80 years and
older. Given that the WV population is predominantly White, race was classified as
White and others. Based on Rural-Urban Continuum codes developed by the US
Department of Agriculture (USDA), urban-rural residence was categorized as Metro,
Urban, and Rural. Charlson comorbidity index score was calculated using diagnosis
and procedure codes reported in Medicare inpatient claims from the year prior to the
incident lung cancer diagnosis.32-34 Comorbidities related to cancer were excluded from
the index score. The Charlson comorbidity index score was used to categorize
comorbidity into three groups: 0, 1 and 2 or more, with a higher score indicating a
greater burden of comorbid illness.
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Given the lack of individual socioeconomic status measures in our data sources,
we used as proxy, the year 2000 US Census tract level measures of college education
and income.35 Specifically, we used the percentage of individuals in the census tract
with some college education as a proxy measure for education, and categorized it
based on tertile distribution as 0%-0.10%, 0.11%-0.20%, and 0.21% or greater.
Similarly, we used median household income at the census tract level as a proxy
measure of income, and categorized it based on tertile distribution as $0-25,000,
$25,000-50,000, and $50,001 or more.
To account for the variability in receipt of lung cancer treatment while estimating
lung cancer mortality risk associated with non-receipt of tobacco-use cessation
counseling services, we estimated the receipt of minimally appropriate clinical guideline
based lung cancer care among beneficiaries in cohort B. Specifically, continuously
enrolled elderly Medicare FFS beneficiaries in cohort B were followed for one year
following incident lung cancer diagnosis to determine receipt of minimally appropriate
clinical guideline based lung cancer care (hereafter referred to as ‘minimally appropriate
care’). Minimally appropriate care was defined using the American College of Chest
Physicians (ACCP) evidence-based guidelines for diagnosis and management of lung
cancer, published in January, 2003.36 We choose ACCP evidence-based guidelines, as
they are the most comprehensive of all published clinical guidelines.36-40 Figure 4.1
shows the algorithm adapted from the ACCP guidelines, and used to determine receipt
of minimally appropriate care. Lung cancer specific treatments and procedures were
identified from the Medicare claim data files using appropriate International
Classification of Diseases (ICD-9) diagnosis and procedure codes, Healthcare Common
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Procedure Coding System (HCPCS) codes, Current Procedural Terminology (CPT)
codes and revenue center codes (Appendix 4.1).

Data Analysis
The Pearson chi-square test was used to determine unadjusted associations between
categorical variables of interest. Hierarchical generalized logistic model was
constructed with PROC GLIMMIX procedure in SAS 9.2 41 to assess the association
between independent variables and the receipt of tobacco-use cessation counseling
services. In the model, the estimated probability of a beneficiary receiving tobacco-use
cessation counseling services conditioned on a set of predictor variables was modeled.
The hierarchical model was chosen as individual measures of socioeconomic status
were not available in our data sources, and that we relied on census tract level
measures of education and income. This was done by treating census tract as a
random effect to account for potential correlation among beneficiaries within the same
county. Odds ratios, 95% confidence intervals, and two-sided p-values were calculated
for each predictor.
Nonparametric estimates of the survivor function by receipt of tobacco-use
cessation counseling services were calculated using the Kaplan-Meier method. The
log-rank test was used to assess the statistical significance of the differences between
the survival curves. Two-year survival estimates were also computed by receipt of
tobacco-use cessation counseling services.
Two multivariate Cox proportional hazards models were constructed to estimate
lung cancer mortality risk associated with non-receipt of tobacco-use cessation
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counseling services. While the first model controlled for variability in beneficiary’s
clinical and sociodemographic characteristics, the second model additionally controlled
for the variability in receipt of lung cancer treatment. To evaluate the proportional
hazards assumption, we plotted smoothed Schoenfeld residuals against time and found
no evidence of a systematic deviation from proportional hazards in any model.
Variance in Cox models were adjusted to account for patient clustering at the census
tract level by use of the robust inference of Lin and Wei.42 Adjusted hazard ratios, 95%
confidence intervals and their two-sided p-values were calculated for each predictor.
All data were analyzed using the SAS Version 9.2 (SAS Institute, Cary, NC)
statistical software package.41 Results were considered to be statistically significant
when p ≤ 0.05. This study was approved by the West Virginia Institutional Review
Board, and is in full compliance with federal, state, and institutional regulations and
guidelines.

Results
Based on study inclusion and exclusion criteria, we identified 922 continuously enrolled
elderly Medicare FFS beneficiaries in cohort A. Table 4.1 shows the distribution of
clinical and sociodemographic characteristics of these beneficiaries by type of lung
cancer. Overall, majority of beneficiaries had late stage disease, were in the age group
70-74 years, were of white race, resided in metro areas, and had comorbidity scores of
two or more. While a majority of these beneficiaries had NSCLC (82.8%), the
distribution of beneficiary characteristics by lung cancer type did not vary significantly,

136

except by cancer stage. Specifically, compared to beneficiaries with SCLC,
beneficiaries with NSCLC were diagnosed at earlier stages (p ≤ 0.05).

Receipt of tobacco-use cessation counseling services
Table 4.2 shows the descriptive characteristics of beneficiaries by receipt of tobaccouse cessation counseling services. Overall, the proportion of beneficiaries receiving
tobacco-use cessation counseling services was high (76.7%) in the study population.
Receipt of tobacco-use cessation counseling services was higher among beneficiaries
with early stage disease compared to those with late stage disease (p ≤ 0.05).
Compared to older beneficiaries, the proportion of beneficiaries receiving tobacco-use
cessation counseling services was also higher among younger beneficiaries, and the
proportions significantly decreased with increase in age. Receipt of tobacco-use
cessation counseling services was also higher among beneficiaries residing in rural
areas as compared to those residing in non-rural areas (p ≤ 0.05). Variations in receipt
of tobacco-use cessation counseling services by lung cancer type, gender, race,
comorbidity score, and year of diagnosis were not observed among beneficiaries in the
study population.

Factors associated with receipt of tobacco-use cessation counseling services
Controlling for all sociodemographic variables, age remained a strong predictor of
receipt of tobacco-use cessation counseling services (Table 4.3). Compared to
beneficiaries aged 80 years and older, beneficiaries aged 66 to 69 years were more
than twice likely to receive tobacco-use cessation counseling services, and these odds
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gradually decreased with increase in age. Other significant predictors of receipt of
tobacco-use cessation counseling services were lung cancer stage and rural-urban
residence. Specifically, beneficiaries with early stage disease were 55-65% more likely
to receive tobacco-use cessation counseling services as compared to those with late
stage disease. However, the likelihood of receipt of tobacco-use cessation counseling
services was lower among beneficiaries residing in non-rural areas as compared to
those residing in rural areas. Lung cancer type, gender, race, comorbidity, and census
tract level measure of education and urban-rural residence were not statistically
significant in the model.

Survival benefits associated with receipt of tobacco-use cessation counseling services
Figure 4.2 compares the two year Kaplan-Meier survival curves by receipt of tobaccouse cessation counseling services in cohort B. The unadjusted two year survival rates
and median survival times were significantly greater among beneficiaries receiving
tobacco-use cessation counseling services as compared to those not receiving such
services (p ≤ 0.05). Specifically, for beneficiaries who received tobacco-use cessation
counseling services, the two year median survival time exceeded by 159 days in the
study population (p ≤ 0.05).

Lung cancer mortality risk associated with non-receipt of tobacco-use cessation
counseling services
Controlling for variability in beneficiary’s clinical and sociodemographic characteristics,
the adjusted lung cancer mortality risk among beneficiaries not receiving tobacco-use
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cessation counseling services was higher, but not significant (Table 4.4). The
magnitude of this risk decreased slightly after controlling for variability in receipt of
minimally appropriate care among beneficiaries. Receipt of minimally appropriate care,
early stage disease, young age, rural residence, higher comorbid illness, and higher
education, were the only factors independently associated with lower lung cancer
specific mortality in the study population.

Discussion
Smoking is common among patients diagnosed with lung cancer. Promoting smoking
cessation in these patients is important, as continued smoking has substantial adverse
effects on treatment effectiveness, risk of second primary malignancies, and quality of
life. Lung cancer diagnosis can be used by healthcare providers as a teachable
moment for smoking cessation, as a patient’s motivation and interest in smoking
cessation may increase after such an event. In this study, using cancer registry-linked
Medicare administrative data files, we determined the patterns of receipt of tobacco-use
cessation counseling services among elderly Medicare FFS beneficiaries with lung
cancer and with a history of tobacco use.
Tobacco-use cessation counseling services were received by more than half of
all elderly Medicare FFS beneficiaries in the study population. The use of these
services was higher among younger beneficiaries, and after controlling for other factors,
increasing age at diagnosis was associated with decline in receipt of tobacco-use
cessation counseling services. This finding may have resulted from variation in
physician practice patterns, and/or individual treatment preferences. Compared to
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younger individuals, poor prognosis is common among older individuals, and that may
influence physician’s decision to not provide tobacco-use cessation counseling services.
This observed variation in receipt of tobacco-use cessation counseling services may
also be related to differences in disease severity, and burden of comorbid illness among
beneficiaries. Furthermore, older individuals with poor prognosis may choose to not
receive such services, regardless of its impact on health outcomes. Receipt of tobaccouse cessation counseling was also higher among elderly with early stage disease, as
compared to those with late stage disease. This finding is expected, as beneficiaries
with early stage disease are good candidates for curative therapy, and are expected to
survive longer than those with late stage disease. Therefore, beneficiaries with early
stage disease can expect to have substantial benefits in health outcomes following
smoking cessation, as compared to those with late stage disease. This finding is similar
to that reported in one study, where patients with late stage disease were less likely to
enroll in smoking cessation programs as compared to those with early stage disease.43
Surprisingly, receipt of tobacco-use cessation counseling was found to be higher among
beneficiaries residing in rural areas as compared to those residing in non-rural areas.
This finding may have resulted from the fact that prevalence of smoking is higher
among beneficiaries in rural areas, and that awareness of risks associated with
continued smoking may be higher among these individuals and their providers, resulting
in increased receipt of tobacco-use cessation counseling services.
Prior studies of impact of smoking cessation following lung cancer diagnosis on
survival outcomes have shown mixed results. Although in this study we could not
determine the success or failure of tobacco-use cessation counseling attempt, receipt of
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such services by beneficiaries was associated with longer survival times. However, it is
very likely that this finding may have resulted from the increased disease severity
among beneficiaries who did not receive tobacco-use cessation counseling services.
When controlled for, such variability in patient clinical and sociodemographic
characteristics, the adjusted lung cancer mortality risk was higher, but not significant,
among beneficiaries not receiving tobacco-use cessation counseling services. Even
after controlling for the variability in lung cancer care received among beneficiaries, the
adjusted lung cancer mortality risk remained unchanged. Receipt of minimally
appropriate care, early stage disease, young age, rural residence, higher comorbid
illness, and higher education, were the only factors independently associated with lower
lung cancer mortality risk. This finding is expected, as prognosis is better among
beneficiaries receiving minimally appropriate care and among those with early stage
disease. Although findings from this study show no increase in adjusted lung cancer
mortality risk among beneficiaries not receiving tobacco-use cessation counseling
services, promoting smoking cessation at any stage of the disease is important.
The findings from this study are subject to several limitations. A major limitation
of this study is the lack of information on success or failure of tobacco-use cessation
counseling attempts among beneficiaries receiving such services. Specifically, the data
sources used for this study do not capture information on whether or not a beneficiary
quit smoking following the receipt of tobacco-use cessation counseling services. Such
information is necessary to accurately quantify the health benefits associated with
receipt of tobacco-use cessation counseling services. Given the limited years of followup data, the frequency and intensity of tobacco-use cessation counseling attempts
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among beneficiaries was also not examined in this study. Also, any variation in type of
counseling services offered by different providers was not captured in our data sources,
and was not controlled for in our analysis. Although we used cancer registry-linked
claims data, an inherent limitation of using administrative claims data for epidemiologic
studies is the possibility of misclassification as a result of coding errors.44;45 However,
claims data have been evaluated for their utility as a source of epidemiologic or health
services information in cancer patients.44-48 Increasing the use of these types of data to
assess the quality of cancer care also has been identified as a priority by the Institute of
Medicine.49 Studies using claims data are typically population-based and have the
potential to address a number of priority questions regarding the quality of cancer care
and health care disparities. These population-based studies provide valuable
information for future planning and prioritization of health programs that improve cancer
outcomes. Therefore, there is an increasing interest in analyzing large health claims
databases to assess treatment and outcomes for cancer.44;45;49
The results of this study are generalizable only to the elderly Medicare FFS
population, aged 66 years and older, as encounter data for Medicare recipients enrolled
in the managed care plan were not available for this study. There was a small increase
in the percentage of Medicare recipients enrolled in managed care during the study
years; in 2007 it was ~16% in WV population.50 Information on care received by the
Medicare recipients outside of the Medicare system or through non-Medicare providers
was also not available in the claims data for our study. However, Medicare is the
largest and the most comprehensive insurance provider to the elderly in the US. Racial
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disparities in cancer outcomes could not be ascertained in this study, as the population
was predominantly White.
One of the inclusion criteria for cohort selection in this study was continuous
enrollment in Medicare Part A and B during the study period. This resulted in the noninclusion of individuals with non-continuous enrollment and the loss of individuals who
were enrolled intermittently. Although the WV legislative rule requires cancer reporting
sources to provide patient’s tobacco-use history to the WVCR, few records with missing
information on patient’s tobacco-use history were identified and therefore excluded from
these study. It is very likely that these individuals may have been diagnosed at the time
of death (death certificate review/autopsy diagnosis) or the cancer reporting source may
have failed to collect information on their tobacco-use history. We acknowledge that our
definition of receipt of minimally appropriate care may be too narrow, and that given the
heterogeneity of patients seen by physicians, receipt of no therapy may still be
considered as appropriate care. None the less, our definition of receipt of minimally
appropriate care provides a conceptual framework to assess and control for treatment
variability among beneficiaries. Because of limited data availability at the time of study,
we were unable to conduct a long-term (5-10 year) follow-up to assess the health
outcomes associated with receipt of tobacco-use cessation counseling services.
Individual-level socioeconomic measures of educational attainment, marital status, and
family income were also unavailable for this study. However, aggregate measures of
socioeconomic status at the census tract level from 2000 decennial census data were
used as a proxy. Finally our assessment of tobacco-use cessation counseling services
is limited to the data recorded in the claims. Future studies can overcome the barriers
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seen in this study by collecting data on success/failure of counseling attempts, and
physician behaviors/patient preferences in using tobacco-use cessation counseling
services.
Significant reduction in lung cancer mortality can be achieved if elderly receive
timely and medically effective treatments. Promoting smoking cessation through
tobacco-use cessation counseling services is of vital importance to ensure success of
such treatments. The diagnosis of lung cancer can be used as a teachable moment for
smoking cessation. Although smoking cessation is beneficial, barriers to successful
smoking cessation attempt include patient’s unwillingness to quit, comorbid conditions,
or lack of access to care.43 Given that motivation to quit smoking may vary among
smokers, physicians may benefit by understanding the underlying motivational issues
through application of theories of behavior change. Specifically, the Stages of Change
Model suggests that most individuals attempting to quit smoking may go through
several predictable stages, from pre-contemplation to contemplation to preparation and,
finally, to action. Successful counseling would help to move patients along these
stages, until they are more motivated to quit.
This study is the first of its kind to determine the patterns of receipt of tobaccouse cessation counseling services among elderly Medicare FFS beneficiaries with lung
cancer, and with a history of tobacco use. Although preventive care services, such as
tobacco-use cessation counseling services are covered under Medicare program,
underutilization of these services among elderly lung cancer patients with a history of
tobacco use, is a concern. Most patients with smoking-related cancer would be
motivated to quit smoking at the time of diagnosis, and promoting smoking cessation in
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these individuals may improve health outcomes. Although some encouraging results
have been demonstrated with use of tobacco-use cessation counseling services in this
study, more empirical studies of such interventions are needed. Also, future cancer
prevention efforts should be directed towards promoting smoking cessation in rural
populations, such as West Virginia, where the smoking prevalence rates are the highest
in the nation. In the long run, these cancer prevention efforts can help reduce the
incidence of lung cancer, which in turn can help reduce the burden of lung cancer
mortality.
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Figure 4.1. Algorithm adapted from American College of Chest Physicians (ACCP)
evidence-based guidelines for diagnosis and management of lung cancer published in
January, 2003, and used to determine receipt of minimally appropriate clinical guideline
based lung cancer care.
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Figure 4.2. Kaplan-Meier survival curves (with 95% confidence limits) by receipt of
tobacco-use cessation counseling services among continuously enrolled Medicare Feefor-service beneficiaries with an incident diagnosis of lung cancer (Stages I-IV) and with
a history of tobacco use in West Virginia, July 2005 through December 2005. Curves
(unadjusted) show cause-specific mortality.

CI = confidence interval.
*
Survival times and rates were obtained from Kaplan-Meier survival estimates.
~
Receipt of tobacco-use cessation counseling services.
Log-rank test (p ≤ 0.05) comparing differences in survival by receipt of tobacco-use cessation counseling services.
Source: West Virginia Cancer Registry - Medicare linked data files, 2004-2007.
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Table 4.1. Descriptive characteristics of continuously enrolled Medicare Fee-for-service
beneficiaries with an incident diagnosis of lung cancer and with a history of tobacco use
in West Virginia, July 2005 through October 2007.
Characteristics

Proportion (%)
NSCLC
SCLC
764
(82.8)

158
(17.1)

AJCC TNM stage *
I
II
III
IV
Unstaged

17.9
8.5
22.0
27.6
24.0

4.4
1.3
21.5
38.0
34.8

Age (years)
66-69
70-74
75-79
80 or more

23.4
29.8
24.9
21.9

28.5
27.2
25.3
19.0

Gender
Male
Female

57.3
42.7

50.0
50.0

Race
Other
White

2.2
97.8

0.0
100.0

Urban-rural residence
Metro
Urban
Rural

55.8
38.9
5.4

58.2
34.8
7.0

Comorbidity, Charlson score
0
1
2 or more

20.7
30.1
49.2

24.7
26.6
48.7

Year of diagnosis
2005 (July-Dec)
2006
2005 (Jan-Oct)

21.1
47.0
31.9

19.6
47.5
32.9

Overall, n (%)

NSCLC = Non-Small Cell Lung Cancer, SCLC = Small Cell Lung Cancer, AJCC = American Joint Committee on Cancer, TNM =
Tumor Node Metastasis.
*
Chi-square test (p ≤ 0.05) measuring association between beneficiary characteristics and cancer type, among beneficiaires in
West Virginia.
Source: West Virginia Cancer Registry - Medicare linked data files, 2004-2007.
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Table 4.2. Descriptive characteristics by receipt of tobacco-use cessation counseling
services, among continuously enrolled Medicare Fee-for-service beneficiaries with an
incident diagnosis of lung cancer and with a history of tobacco use in West Virginia, July
2005 through October 2007.
Characteristics

Receipt ~

Non-receipt
No.
%

No.

%

Overall

707

76.7

215

23.3

Lung cancer type
NSCLC
SCLC

595
112

77.9
70.9

169
46

22.1
29.1

AJCC TNM stage *
I
II
III
IV
Unstaged

126
58
156
196
171

87.5
86.6
77.2
72.3
71.8

18
9
46
75
67

12.5
13.4
22.8
27.7
28.2

Age (years) *
66-69
70-74
75-79
80 or more

182
224
172
129

81.3
82.7
74.8
65.5

42
47
58
68

18.8
17.3
25.2
34.5

Gender
Male
Female

388
319

75.0
78.8

129
86

25.0
21.2

Race
Other
White

12
695

70.6
76.8

5
210

29.4
23.2

387
271
49

74.7
77.0
94.2

131
81
3

25.3
23.0
5.8

147
216
344

74.6
79.4
75.9

50
56
109

25.4
20.6
24.1

146

76.0

46

24.0

Urban-rural
residence *
Metro
Urban
Rural
Comorbidity,
Charlson score
0
1
2 or more
Year of diagnosis
2005 (July-Dec)
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2006
2007 (Jan-Oct)

331
230

76.3
77.7

103
66

23.7
22.3

NSCLC = Non-Small Cell Lung Cancer, SCLC = Small Cell Lung Cancer, AJCC = American Joint Committee on Cancer, TNM =
Tumor Node Metastasis.
~
Receipt of tobacco-use cessation counseling services.
*
Chi-square test (p ≤ 0.05) measuring association between beneficiary characteristics and receipt of tobacco-use cessation
counseling services, among beneficiaries in West Virginia.
Source: West Virginia Cancer Registry - Medicare linked data files, 2004-2007.
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Table 4.3. Factors associated with receipt of tobacco-use cessation counseling services
among continuously enrolled Medicare Fee-for-service beneficiaries with an incident
diagnosis of lung cancer and with a history of tobacco use in West Virginia, July 2005
through October 2007.
Odds Ratio

95% Confidence
Interval

p-value

Intercept (p-value)

NA

NA

0.24

Lung cancer type
NSCLC
SCLC

1.31

0.86 to 1.99
1 (Ref)

0.20

AJCC TNM stage
Unstaged
I
II
III
IV

1.05
2.65**
2.55*
1.16

0.70 to 1.59
1.47 to 4.80
1.16 to 5.59
0.74 to 1.81
1 (Ref)

0.81
< 0.01
0.02
0.52

Age (years)
66-69
70-74
75-79
80 or more

2.58***
2.69***
1.68*

1.60 to 4.15
1.71 to 4.25
1.08 to 2.61
1 (Ref)

< 0.001
< 0.001
0.02

Gender
Male
Female

0.83

0.59 to 1.16
1 (Ref)

0.27

Race
Other
White

0.68

0.20 to 2.34
1 (Ref)

0.52

Urban-rural
residence
Metro
Urban
Rural

0.16**
0.19**

0.04 to 0.55
0.05 to 0.67
1 (Ref)

< 0.01
< 0.01

0.93
1.27

0.61 to 1.41
0.86 to 1.88
1 (Ref)

0.74
0.23

Comorbidity,
Charlson score
0
1
2 or more
Percentage with
some college
education ^
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0.0-0.10
0.11-0.20
≥ 0.21

0.34
1.00

0.10 to 1.20
0.68 to 1.46
1 (Ref)

0.09
0.99

0.79
0.89

0.27 to 2.35
0.32 to 2.51
1 (Ref)

0.67
0.83

Median household
income ^
0-25000
25001-50000
≥ 50001

NSCLC = Non-Small Cell Lung Cancer, SCLC = Small Cell Lung Cancer, AJCC = American Joint Committee on Cancer, TNM =
Tumor Node Metastasis, Ref = reference category, NA = Not Applicable.
*
Estimates are statistically significant (p ≤ 0.05).
**
Estimates are statistically significant (p ≤ 0.01).
***
Estimates are statistically significant (p ≤ 0.001).
^
Census tract level measures of beneficiaries socioeconomic status.
WV population (N = 956), Fit Statistics: -2 restricted log pseudo-likelihood = 4308.15, Covariance parameter estimates: Intercept =
county, estimate = 0.17, standard error = 0.16.
Source: West Virginia Cancer Registry - Medicare linked data files, 2004-2007.
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Table 4.4. Lung cancer mortality risk associated with non-receipt of tobacco cessation
counseling services among continuously enrolled Medicare Fee-for-service
beneficiaries with an incident diagnosis of lung cancer (Stages I-IV) and with a history of
tobacco use in West Virginia, July 2005 through December 2005.
Hazard Ratio (95% Confidence Interval)
Model 1
Model 2
Tobacco-use cessation
counseling services
Non-receipt
Receipt

1.78 (0.87 to 3.64)
1 (Ref)

1.22 (0.59 to 2.51)
1 (Ref)

NA
NA

2.34** (1.38 to 3.95)
1 (Ref)

Lung cancer type
NSCLC
SCLC

1.04 (0.64 to 0.1.71)
1 (Ref)

0.68 (0.39 to 1.17)
1 (Ref)

AJCC TNM stage
I
II
III
IV

0.06*** (0.02 to 0.18)
0.30** (0.12 to 0.74)
0.51** (0.31 to 0.82)
1 (Ref)

0.08*** (0.03 to 0.23)
0.33* (0.14 to 0.82)
0.67 (0.42 to 1.06)
1 (Ref)

Age (years)
66-69
70-74
75-79
80 or more

0.46* (0.22 to 0.94)
0.69 (0.31 to 1.55)
0.48* (0.24 to 0.96)
1 (Ref)

0.48* (0.24 to 0.96)
0.78 (0.36 to 1.68)
0.45* (0.22 to 0.91)
1 (Ref)

Gender
Male
Female

0.62 (0.37 to 1.03)
1 (Ref)

0.70 (0.43 to 1.13)
1 (Ref)

Race
Other
White

0.70 (0.11 to 4.28)
1 (Ref)

0.85 (0.16 to 4.42)
1 (Ref)

Urban-rural residence
Metro
Urban
Rural

3.12* (1.22 to 7.96)
2.63 (0.96 to 7.21)
1 (Ref)

3.06* (1.11 to 8.46)
2.45 (0.86 to 6.97)
1 (Ref)

2.44*** (1.46 to 4.08)
0.77 (0.43 to 1.39)

2.66*** (1.56 to 4.55)
0.79 (0.44 to 1.43)

Appropriateness of care ~
In-appropriate care
Minimally appropriate care

Comorbidity, Charlson
score
0
1
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2 or more

1 (Ref)

1 (Ref)

7.77*** (2.50 to 9.08)
0.67 (0.45 to 1.01)
1 (Ref)

7.24*** (2.23 to 9.98)
0.79 (0.51 to 1.25)
1 (Ref)

0.76 (0.26 to 2.19)
1.27 (0.57 to 2.80)
1 (Ref)

0.69 (0.26 to 1.83)
1.18 (0.61 to 2.28)
1 (Ref)

Percentage with some
college education ^
0.0-0.10
0.11-0.20
≥ 0.21
Median household income ^
0-25000
25001-50000
≥ 50001

NSCLC = Non-Small Cell Lung Cancer, SCLC = Small Cell Lung Cancer, AJCC = American Joint Committee on Cancer, TNM =
Tumor Node Metastasis, Ref = reference category, NA = Not Applicable.
*
Estimates are statistically significant (p ≤ 0.05).
**
Estimates are statistically significant (p ≤ 0.01).
***
Estimates are statistically significant (p ≤ 0.001).
^
Census tract level measures of beneficiaries socioeconomic status.
~
Minimally appropriate care determined using American College of Chest Physicians (ACCP) evidence-based guidelines for
diagnosis and management of lung cancer published in January, 2003.
Model 1: N = 140, Fit Statistics: -2 log likelihood = 835.92 (without covariates) and 758.44 (with covariates), Global null hypothesis:
Likelihood ratio chi-square test = 77.48 (p ≤ 0.05).
Model 2: N = 140, Fit Statistics: -2 log likelihood = 835.92 (without covariates) and 750.10 (with covariates), Global null hypothesis:
Likelihood ratio chi-square test = 85.82 (p ≤ 0.05).
Source: West Virginia Cancer Registry - Medicare linked data files, 2004-2007.
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CHAPTER 5:
SUMMARY AND CONCLUSIONS

Study Summary
In the United States (US), lung cancer is the second most diagnosed cancer and the
leading cause of cancer deaths in both men and women.1;2 It causes more deaths than
the next three most common cancers combined (colon, breast, and prostate).1-3 The
number of deaths due to lung cancer has increased approximately 4.3% between 1999
and 2008 from 152,156 to 158,656.4 The elderly carry a disproportionate burden of lung
cancer and this pattern is expected to persist as the estimated number of elderly in the
US doubles to nearly 70 million by 2030.
Significant improvements have been made during the past decade in treatment
and survival after the diagnosis of cancer.5 Still, substantial disparities exist in both
cancer outcomes and the receipt of guideline-based cancer-related health care.6 Lack
of timely and high quality cancer care is still a concern and it might be attributable to
variations in the use of appropriate standards of care and the resulting treatment
variations.7;8
A significant reduction in lung cancer mortality can be achieved if elderly patients
receive timely and medically effective therapies. Unfortunately, many rural areas of the
US are economically underdeveloped and medically underserved.9;10 The elderly in
these regions carry a higher burden of lung cancer compared to their urban
counterparts.11 These rural areas are also known to report a higher prevalence of lung
cancer and a higher crude all-cause mortality rates among elderly.12 One such area is

160

the Appalachian region, a population representing 8.1% of the total US population.13
West Virginia (WV) is the only state situated entirely within the Appalachian region and
is the third most rural state in the nation.13 Fifty of the 55 counties in the state are
designated as medically underserved areas, and all or part of 40 counties in the state
are classified as health professional shortage areas.14 During 2002-2006, the ageadjusted lung cancer incidence rate (WV: 481.5 per 100,000, US: 378.5 per 100,000),
and mortality rate (WV: 390.6 per 100,000, US: 310.8 per 100,000) among the elderly
was higher in the state in comparison to rest of the country.15;16 Interestingly, the
proportional difference in age-adjusted lung cancer mortality rates, among the elderly
from WV and the US, was lower than the difference in age-adjusted lung cancer
incidence rates. This might suggest better survival outcomes among elderly lung
cancer patients in WV as compared to the US; however, such a hypothesis remains
unexplored. The observed lung cancer disparities in rural populations can be attributed
to limited access to quality medical care facilities; less access to or utilization of early
cancer detection programs; increased prevalence of behavioral risk factors, such as
tobacco use and sedentary life style, and socioeconomic factors, such as low income
and education.17-23 In addition to being medically underserved, the rural population may
also experience variations in the quality, availability, and accessibility of services when
compared to their urban counterparts.24
Using cancer registry linked Medicare data files, this study compared the
appropriateness and timeliness of lung cancer care among elderly, in a representative
rural and medically underserved WV state population, with a representative US
population. The study also determines the patterns of receipt of tobacco-use cessation
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counseling services among elderly lung cancer patients with a history of tobacco use.
The purpose of this study was to fill critical gaps in clinical guideline based lung cancer
care and outcomes literature. First, the study examined the appropriateness of lung
cancer care and associated health outcomes among WV-US elderly populations. While
numerous studies have examined lung cancer treatment variations in the US,
comprehensive evaluation of variations in clinical guideline based lung cancer care and
its impact on health outcomes in the elderly remains unexplored. Furthermore, no
information is currently available about geographic variations in clinical guideline based
lung cancer care and associated health outcomes among WV-US elderly populations.
Therefore, we investigate and compare the appropriateness of lung cancer care based
on clinical guidelines and associated health outcomes among elderly Medicare fee-forservice (FFS) beneficiaries in a representative rural and medically underserved WV
state population, and in a representative US population.
The second study examined the timeliness of lung cancer care among the
elderly. Timeliness of care is important dimension of cancer care quality. While
numerous studies have examined timeliness of lung cancer care, a majority of them
have been conduced in European Union healthcare settings.25-39 Few studies
performed in the US were either limited to small sample sizes, restricted to non-small
cell lung cancer (NSCLC) patients, included both elderly and non-elderly patients,
focused on specific demographic subgroups, performed within specific health care
settings, or failed to examine health outcomes associated with timely care.40-47 As the
elderly carry a disproportionate burden of lung cancer in the US, studies that examine
timeliness of lung cancer care based on clinical opinion-based guidelines, and the
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associated health outcomes in the elderly are much needed.2 Furthermore, there is no
study that compares geographic variations in timeliness of lung cancer care based on
clinical opinion-based guidelines, and the associated health outcomes among WV-US
elderly populations. Therefore, in the second study we investigate and compare the
timeliness of lung cancer care based on clinical opinion-based guidelines among elderly
Medicare FFS beneficiaries in a representative rural and medically underserved WV
state population and in a representative US population.
The third study in this project was conducted with the purpose of determining the
receipt of tobacco-use cessation counseling services among elderly lung cancer
patients with a history of tobacco use. Smoking is common among patients diagnosed
with lung cancer and promoting smoking cessation in these patients is important, as
continued smoking has substantial adverse effects on treatment effectiveness, risk of
second primary malignancies, and quality of life. In the third study, we examined the
patterns of receipt of tobacco-use cessation counseling services among elderly
Medicare FFS beneficiaries, with lung cancer and with a history of tobacco use, in a
state (West Virginia) population. Together, the three studies provide an in-depth view of
patterns of lung cancer care in the WV and US elderly populations, and contribute
uniquely to the clinical guideline based lung cancer care and outcomes literature. The
results from each of the three studies have been discussed in detail in the previous
chapters. Key results from each of the three studies and their implications on lung
cancer care are discussed below.
In the first study, treatment patterns varied significantly among beneficiaries with
lung cancer in the WV and US populations. Despite availability of various treatment
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options to treat the disease, many beneficiaries did not receive any treatment in either
population. Minimally appropriate clinical guideline based lung cancer care (hereafter
referred to as ‘minimally appropriate care’) was only received by less than half of all
beneficiaries in each population. However, the likelihood of receipt of minimally
appropriate care among beneficiaries in the WV and US populations was not
significantly different.
Receipt of minimally appropriate care by beneficiaries was associated with longer
survival times in both populations. Although beneficiaries receiving minimally
appropriate care in the WV population had greater median survival times, compared to
the US population, their three year survival rates were significantly lower. In both
populations, we found the adjusted lung cancer mortality risk significantly higher among
beneficiaries not receiving minimally appropriate care than those who did receive such
care. However, the magnitude of risk associated with non-receipt of minimally
appropriate care was lower in WV population than in the US population. When
controlled for the variability associated with receipt of minimally appropriate care and all
sociodemographic variables, lung cancer mortality risk was no different among
beneficiaries in the WV and US populations.
The second study assessed the timeliness of lung cancer care among elderly in
WV-US populations. The study revealed that delays in diagnosis and treatment ranged
widely, and also varied significantly among beneficiaries with lung cancer in the WV and
US populations. Timely lung cancer care based on clinical opinion-based guidelines
(hereafter referred to as ‘timely care’) was received by most beneficiaries in each
population and was highest among those receiving radiotherapy. Contrary to what is
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expected, the proportion of beneficiaries receiving timely care did not vary between the
two populations. This study is one of the few that have assessed the influence of timely
lung cancer care on survival outcomes. Contrary to what would be expected, the
results of this study indicate that non-timely care is not associated with poorer prognosis
in lung cancer. This results corroborate finding from earlier studies.26;28;42;48;49 As
reported in other studies, the association between shorter delay and poorer outcomes
was most pronounced in patients with advanced stage disease in both populations.49
Compared to the US population, survival outcomes were poorer among beneficiaries
receiving non-timely care and among those with late stage disease in the WV
population. In both populations, we found the adjusted lung cancer mortality risk
significantly lower among beneficiaries not receiving timely care than those who did
receive such care. However, the magnitude of risk associated with non-receipt of timely
care was higher in the WV population than in the US population. In stratified analysis
by cancer type and stage, we again found the adjusted lung cancer mortality risk
significantly lower among beneficiaries not receiving timely care than those who did
receive such care, and the results were most pronounced in patients with advanced
stage disease. After controlling for the variability associated with receipt of timely care
and all sociodemographic variables, lung cancer mortality risk was significantly higher
among beneficiaries in WV population as compared to the US population. Regardless
of its impact on health outcomes, delays in diagnosis and treatment should be avoided,
as it may increase psychological stress in patients.50
The third study revealed that tobacco-use cessation counseling services were
received by more than half of all elderly Medicare FFS beneficiaries in the WV
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population. The use of these services was higher among younger beneficiaries, and
after controlling for other factors, increasing age at diagnosis was associated with
decline in receipt of tobacco-use cessation counseling services. This finding may have
resulted from variation in physician practice patterns, and/or individual treatment
preferences. Receipt of tobacco-use cessation counseling was also higher among the
elderly with early stage disease as compared to those with late stage disease. This
finding is expected, and is similar to that reported in one study, where patients with late
stage disease were less likely to enroll in smoking cessation programs, as compared to
those with early stage disease.51 Surprisingly, receipt of tobacco-use cessation
counseling was found to be higher among beneficiaries residing in rural areas, as
compared to those residing in non-rural areas. This finding may have resulted from the
fact that prevalence of smoking is higher among beneficiaries in rural areas, and that
awareness of risks associated with continued smoking may be higher among these
individuals and their providers, resulting in increased receipt of tobacco-use cessation
counseling services.
Although in this study, we could not determine the success or failure of tobaccouse cessation counseling attempts, receipt of such services by beneficiaries was
associated with longer survival times. However, it is very likely that this finding may
have resulted from the increased disease severity among beneficiaries who did not
receive tobacco-use cessation counseling services. When controlled for such variability
in patient clinical and sociodemographic characteristic, the adjusted lung cancer
mortality risk was higher, but not significant, among beneficiaries not receiving tobaccouse cessation counseling services. Even after controlling for the variability in lung
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cancer care received among beneficiaries, the adjusted lung cancer mortality risk
remained unchanged. Although findings from this study show no increase in adjusted
lung cancer mortality risk among beneficiaries not receiving tobacco-use cessation
counseling services, promoting smoking cessation at any stage of the disease is
important.
To summarize, this project provides an in-depth view of patterns of lung cancer
care and outcomes among elderly lung cancer patients from the WV and US
populations. Furthermore, the results from this project help to explain the observed
geographic disparities in lung cancer mortality among the elderly.

Significance of the study
Significance of study I: Appropriateness of lung cancer care and associated health
outcomes among elderly Medicare FFS beneficiaries in West Virginia and in the United
States
The study reveals that although lung cancer diagnostic and management services are
covered under Medicare program, underutilization of these services among recipients in
the Medicare FFS population is a concern. These results highlight the critical need to
address disparities in receipt of minimally appropriate care among recipients in the
Medicare FFS population. Reducing observed treatment variations according to
individual characteristics can help to improve the use of clinical guideline-based
treatments in the elderly, and that in turn would improve health outcomes. The findings
from this study can aid policy makers and health care providers to reduce treatment
variations in the future. The study also reveals that although lung cancer treatment
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patterns vary between WV-US elderly populations, significant population variation in
receipt of minimally appropriate care, and associated lung cancer mortality risk, does
not exist. These findings are contrary to what would be expected, given that the WV
population is more rural and medically underserved and has higher lung cancer
mortality rates, compared to the US population. The finding suggests that observed
geographic differences in lung cancer mortality may not be associated with variation in
receipt of minimally appropriate care among elderly beneficiaries with an incident
diagnosis of lung cancer. Furthermore, higher lung cancer incidence in the WV
population, as compared to the US population, may partly explain the disparities seen in
lung cancer mortality among these populations. Therefore, this study reveals the urgent
need for future cancer prevention efforts directed towards promoting smoking cessation
in a rural WV population where the smoking prevalence rates are the highest in the
nation. In the long run, these cancer prevention efforts can help to reduce the incidence
of lung cancer in this rural population which in turn can help to reduce the geographic
disparities in lung cancer mortality.

Significance of study II: Timeliness of lung cancer care and associated health
outcomes among elderly Medicare FFS beneficiaries in West Virginia and in the United
States
Lung cancer care may require complex coordination of services by medical and surgical
specialists, and the traditional approach of referring patients for consultation with
multiple specialists in a sequential fashion often results in care that is perceived as
slow. Timely lung cancer care based on clinical opinion-based guidelines is important
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to reduce the burden of lung cancer among elderly. The results from this study reveal
that although lung cancer diagnostic and management services are covered under the
Medicare program, delays in diagnosis and treatment among recipients in the Medicare
FFS population exists, and are a concern. Increasing patient awareness of lung cancer
symptoms, and better coordination of care among providers, may help to reduce the
delays in diagnosis and treatment. Results of this study also emphasize the need to
address disparities in receipt of timely care among recipients in the Medicare FFS
population. The study also revealed that longer delays in treatment are not associated
with poorer prognosis. Nonetheless, delayed care should be avoided as it may increase
the risk of disease progression and psychological stress in patients.
Finally, this study reveals that although delays in diagnosis and treatment varied
between the WV-US populations, significant population variation in receipt of timely care
does not exist. These findings are similar to that observed in the first study and are
contrary to what would be expected given that WV population is more rural and
medically underserved, and has higher lung cancer mortality rates as compared to the
US population. This finding suggests that observed geographic differences in lung
cancer mortality may not be associated with variation in receipt of timely care, and may
have resulted from differences in lung cancer incidence. Future cancer prevention
efforts directed towards promoting smoking cessation can help to reduce the incidence
of lung cancer in the rural WV population, which in turn can help reduce the geographic
disparities in lung cancer mortality.
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Significance of study III: Patterns of receipt of tobacco-use cessation counseling
services usage and associated health outcomes among elderly Medicare FFS
beneficiaries with lung cancer and a history of tobacco use in West Virginia
Smoking is common among patients diagnosed with lung cancer and promoting
smoking cessation among these individuals through tobacco-use cessation counseling
services is of vital importance to ensure treatment success. The diagnosis of lung
cancer can be used as a teachable moment for smoking cessation. However, the
results from this study show that although preventive care services, such as tobaccouse cessation counseling services, are covered under the Medicare program,
underutilization of these services among elderly lung cancer patients with a history of
tobacco use exists and is a concern. The study also reveals that there are survival
benefits associated with receipt of tobacco-use cessation counseling services.
However, more empirical studies of such interventions are needed to accurately
quantify the benefits of such services. The results suggests that promoting smoking
cessation among lung cancer patients in rural populations, such as West Virginia where
the smoking prevalence rates are the highest in the nation, is much needed.

Study Limitations
For each of the three studies, their limitations have been discussed in detail previously.
However, a general summary of the overall study limitations has been provided in this
section. Although we used cancer registry-linked claims data, an inherent limitation of
using administrative claims data for epidemiologic studies is the possibility of
misclassification as a result of coding errors.52;53 However, claims data have been
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evaluated for their utility as a source of epidemiologic or health services information in
cancer patients.52-56 Increasing the use of these types of data to assess the quality of
cancer care also has also been identified as a priority by the Institute of Medicine.57
Studies using claims data are usually population-based and have the potential to
address a number of priority questions regarding the quality of cancer care and health
care disparities. These population-based studies provide valuable information for future
planning and prioritization of health programs that improve cancer outcomes.
Therefore, there is increasing interest in analyzing large health claims databases to
assess treatment and outcomes for cancer.52;53;57
The results of this study are generalizable only to the elderly Medicare FFS
population, aged 66 years and older, as encounter data for Medicare recipients enrolled
in the managed care plan were not available for this study. There was a small increase
in the percentage of Medicare recipients enrolled in managed care during the study
years in both populations; in 2007 it was ~16% in WV population and ~19% in the US
population.58 Information on care received by the Medicare recipients outside of the
Medicare system, or through non-Medicare providers, was also not available in the
claims data for our study. However, Medicare is the largest and most comprehensive
insurance provider for the elderly in the US. Racial disparities in cancer outcomes could
not be ascertained in this study as the populations were predominantly White.
One of the inclusion criteria for cohort selection in this study was continuous
enrollment in Medicare Part A and B during the study period. This resulted in the noninclusion of individuals with non-continuous enrollment and the loss of individuals who
were enrolled intermittently. Because of limited data availability at the time of study, we
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were unable to conduct a long-term (5-10 year) follow-up to assess the health outcomes
associated with receipt of minimally appropriate care. Individual-level socioeconomic
measures of educational attainment, marital status, and family income were also
unavailable for this study. However, aggregate measures of socioeconomic status at
the census tract level from 2000 decennial census data were used as a proxy.
In the first study, we acknowledge that various clinical guidelines have been
published for lung cancer diagnosis and management, each with recommendations that
are more or less are the same.59-63 For the purpose of that study, we choose ACCP
guidelines for lung cancer management and outcomes, as it is the most comprehensive
of all available guidelines.60 The algorithm we adapted from these guidelines to identify
minimally appropriate care takes into account the limitations in our data sources.
Specifically, information on various lung function test results and lung performance
scores were not available in our data source, and were not considered in our analysis.
However, these indicators of lung performance are most crucial only in planning for
chemotherapy in NSCLC stage IV individuals who we excluded from our analysis. Our
estimates of proportion of beneficiaries receiving minimally appropriate care may be
biased slightly upward, as we included patients who received minimally appropriate
care, followed by additional unproven therapies. We also acknowledge that our
definition of receipt of minimally appropriate care may be too narrow and that given the
heterogeneity of patients seen by physicians, receipt of no therapy may still be
considered as appropriate care. None the less, our definition of receipt of minimally
appropriate care provides a conceptual framework to assess and compare patterns of
care that were prevalent during the years 2002 through 2007.

172

In the second study, given the limitations in our data sources, the delays in
diagnosis and treatment were defined appropriately, and may not be accurate.
Retrospective review of health services usage to estimate date of earliest lung cancer
symptoms was limited to the year prior to diagnosis since findings from prior research
have shown delays in symptom to diagnosis to be less than a year.64 Our estimates of
‘symptom to diagnosis’ delay may be biased, as beneficiaries in whom earliest symptom
date could not be identified were excluded from our analysis. These beneficiaries may
either had no health services usage or may had no Medicare claim with an ICD-9 code
associated with lung cancer symptom in the year prior to diagnosis. It is less likely that
we missed any reported lung cancer symptom as the list of symptoms searched for in
this study was comprehensive, and was derived from ACCP guidelines for management
and treatment of lung cancer (Appendix 3.1).65 Overall, date of earliest lung cancer
symptom was identified in 88% of beneficiaries in WV population, and in 90% of
beneficiaries in the US population. Our estimates of ‘symptom to diagnosis’ delay may
also be biased, as the earliest symptom identified may have been unrelated to lung
cancer. We acknowledge that our definition of timely care may be too narrow, and that
given the heterogeneity of patients seen by physicians, receipt of non-timely care or no
care may still be considered appropriate. None the less, our definition of timely care
provides a conceptual framework to assess and compare patterns of care that were
prevalent during the years 2002 through 2007.
A major limitation of third study was the lack of information on success or failure
of tobacco-use cessation counseling attempts in beneficiaries receiving such services.
Specifically, the data sources used for the third study do not capture information on
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whether or not a beneficiary quit smoking following the receipt of tobacco-use cessation
counseling services. Such information is necessary to accurately quantify the health
benefits associated with receipt of tobacco-use cessation counseling services. Also,
any variation in type of counseling services offered by different providers was not
captured in our data sources, and was not controlled for in our analysis.
Finally our definition of minimally appropriate versus inappropriate care, timely
versus non-timely care, and receipt of tobacco-use cessation counseling service is
limited to the data recorded in the claims such as the presence or absence of ICD-9
diagnosis and procedure codes, HCPCS procedure codes, CPT procedure codes and
revenue center codes. Future studies can overcome the barriers seen in this study by
collecting data on physician behaviors, patient preferences on treatment choices, and
success/failure of counseling attempts.

Directions for Future Research
This study revealed that geographic disparities in lung cancer mortality among elderly
from the WV and US populations do not result from variations in appropriateness or
timeliness of lung cancer care. Future studies can use both qualitative and quantitative
tools to determine if increased lung cancer risk, fragmented health care services
structure, and poor accessibility to services help to explain the observed geographic
disparities in lung cancer mortality.
Given that the study population in this project was predominately White, racial
disparities in lung cancer care and outcomes were not observed. Racial disparities in
lung cancer mortality exist as the mortality rates are higher for Blacks (53.4 per
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100,000) as compared to Whites (50.2 per 100,000). While Black men have a far
higher age-adjusted lung cancer death rate that White men, and Black and White
women have similar rates.1;2 Future studies can explore the role of treatment variation
in observed lung cancer mortality differences by race. While the number of lung cancer
deaths among men has reached a plateau, the number is still rising among women.4
However, the age-adjusted death rate for lung cancer is higher for men (63.6 per
100,000) than for women (39.0 per 100,000). Given the fact that women were relatively
late adopters of cigarette smoking, future studies can be carried out to determine other
factors associated with observed gender disparities.
Given that we could not capture the success or failure of tobacco-use cessation
counseling attempts among beneficiaries receiving such services, future studies can be
carried out by collecting data on success/failure of counseling attempts and physician
behaviors/patient preferences in using tobacco-use cessation counseling services.
Such studies can provide the evidence needed to promote tobacco-use cessation
counseling services among lung cancer patients with a history of tobacco use.
Finally, our study was limited to retrospective data sources. Future studies can
overcome the barriers seen in this project by prospectively collecting data on
provider/patient treatment preferences. Prospective data on elderly lung cancer patient
experiences, needs, and concerns, as they receive care should be collected in future
studies. Future studies could also validate the results seen in our study among younger
individuals. While in this project follow up was limited to few years, future studies could
be carried out to assess the long-term impact of treatment variation on lung cancer
outcomes.
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Appendix 2.1. List of International Classification of Diseases (ICD-9) diagnosis and
procedure codes, Healthcare Common Procedure Coding System (HCPCS) codes,
Current Procedural Terminology (CPT) codes and revenue center codes, used to
identify lung cancer specific treatments and procedures in Medicare claim data files
Surgery:
ICD-9: 324,3240,3249,3241,325,3250,3259,3250,323,3230,3239,3230,3229,
3220,329,3290,3399,344,3440,3409,3228,4029,326,3260,3401,344,3440
CPT: 32480,32482,32486,32663,32440,32442,32445,32488,32484,32663,
32500,32657,38746,32520,32522,32525,32310,32320,32656
Chemotherapy:
ICD-9: V5811,V581,V662,V672,9925,9928,0015,3492
CPT: 96400,96405,96406,96408,96410,96412,96414,96420,96422,96423,
96425,96440,96445,96450,96520,96530,96542,96545,96549
HCPCS:Q0083,Q0084,Q0085,G0355,G0356,G0357,G0358,G0359,G0360,G036
1,G0362,G0363, G9021-G9032,J9060,J9062,J9265,J9390,J9201,J9170,J9045
Radiation:
ICD-9: V580,V661,V671,9229,9221,9222,9223,9224,9225,9226,9227,9228
CPT: 77401,77402,77403,77404,77406,77407,77408,77409,77411,77412,
77413,77414,77416,77417,77418,77427,77431,77432,77470,77499,77520,
77523,77750-77799
HCPCS: G0256,G0261
Revenue center: 0330,0333
Mediastinal lymph node evaluation:
ICD-9: 3425,3422,3426,325,3250
CPT: 39400,32405,39000,39010,39200,39220,32662,38746
Mediastinoscopy:
ICD-9: 3422
CPT: 39000,39010,39400
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Appendix 3.1. List of International Classification of Diseases (ICD-9) diagnosis and
procedure codes, Healthcare Common Procedure Coding System (HCPCS) codes,
Current Procedural Terminology (CPT) codes, and revenue center codes used to
identify symptoms associated with lung cancer, and lung cancer specific treatments and
procedures in Medicare claim data files.
Symptoms associated with lung cancer (ICD-9):
Symptoms of primary tumor:
Cough
Weight loss
Dyspnea
Chest pain\Pleuritic pain
Hemoptysis
Bone pain
Clubbing
Fever
Weakness
Superior vena cava obstruction
Dysphagia
Wheezing and Stridor

7862,4910
78321
7860,7861,7862,7863,
7864,7865,7866,7867,
7869
78650,78651,78652,78659
7863
73390
7815
7806,78060
78079
4592
7872
78607,7861

Symptoms of intrathoracic spread :
Recurrent laryngeal nerve palsy
Pancost tumor/superior sulcus tumor
Horner syndrome

47830,47831,47832,47833,
47834
1623
3379

Symptoms of extrathoracic metastases:
Headache
Nausea\vomiting
Seizures
Confusion
Personality change
Musculoskeletal pain
Syncope
Lympadenopathy\enlargement of
lymph nodes
Hoarseness
Hepatomegaly
Papilledema
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7840
78701,78702,78703
78039
2930,2931
3101
7291
7802
7856
78449,78442
7891
37700,37701,37702,37703,

37704
Paraneoplastic syndromes:
Endrocrine
Nonmetastatic hypercalcaemia
Cushing syndrome
Gynecomastia
Hypoglycaemia
Hyperthyroidsm
Carcinoid syndrome

27542
2550
6111
2512
24290,24291
2592

Skeletal
Hypertrophic osteoarthropathy

7312

Neurologic
Mononeuritis multiplex
Intestinal pseudo obstruction
Lambert Eaton syndrome
Encephalomyetitis
Neurotising myelopathy
Cancer associated retinopathy

3545
5609
1991,3581
3239
3369
36210

Collagen\Vascular
Dermatomyositis
Polymyositis
Vasculitis
Systemic lupus erythematosus

7103
7104
4476
7100

Glomerulonephritis
Nephrotic syndrome

5839
5819

Renal

Metabolic
Lactic acidosis
Hypouricemia

2762
7906

Systemic
Anorexia
Cachexia

7830
7994
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Cutaneous
Acquires hypertrichosis languinosa
7041
Erythema gyratum repens
6951
Erythema multiforme
6951
Tylossi
700
Erythrodermia
6959
Exfoliative dermatitis
69589
Acanthosis nigricans
7012
Pruritus
6989
Urticaria
7089
Hematologic
Anemia
Leukemoid reactions
Thrombocytosis
Thrombocytopenic purpura

2859
2888
2899
2873

Coagulopathies
Thrombophlebitis
Disseminated intravasular
coagulation

4519
2866

Chest x-ray:
ICD-9 (V725,8744,8739,8749)
CPT (71010,71015,71020,71021,71022,71023,71030,71034,71035)
Surgery:
ICD-9:
324,3240,3249,3241,329,3290,3399,344,3440,3409,3228,325,3250,3259,3250
323,3230,3239,3230,3229,3220,3220,326,3260,344,3440,3401
CPT
32480,32482,32486,32663,32440,32442,32445,32488,32484,32663,32500,
32657,32310,32320,32656,32520,32522,32525

Chemotherapy:
ICD-9: V5811,V581,V662,V672,9925,9928,0015,3492
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CPT:
96400,96405,96406,96408,96410,96412,96414,96420,96422,96423,96425,
96440,96445,96450,96520,96530,96542,96545,96549
HCPCS: Q0083,Q0084,Q0085,G0355,G0356,G0357,G0358,G0359,
G0360,G0361,G0362,G0363, G9021-G9032,J9060,J9062,J9265,J9390,
J9201,J9170,J9045
Radiation:
ICD-9
V580,V661,V671,9229,9221,9222,9223,9224,9225,9226,9227,9228
CPT
77401,77402,77403,77404,77406,77407,77408,77409,77411,
77412,77413,77414,77416,77417,77418,77427,77431,77432,77470,
77499,77520,77523,77750-77799
HCPCS: G0256,G0261
Revenue center: 0330,0333
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Appendix 4.1. List of International Classification of Diseases (ICD-9) diagnosis and
procedure codes, Healthcare Common Procedure Coding System (HCPCS) codes,
Current Procedural Terminology (CPT) codes and revenue center codes, used to
identify lung cancer specific treatments, procedures, and other health care services in
Medicare claim data files.
Surgery:
ICD-9: 324,3240,3249,3241,325,3250,3259,3250,323,3230,3239,3230,3229,
3220,329,3290,3399,344,3440,3409,3228,4029,326,3260,3401,344,3440
CPT: 32480,32482,32486,32663,32440,32442,32445,32488,32484,32663,
32500,32657,38746,32520,32522,32525,32310,32320,32656
Chemotherapy:
ICD-9: V5811,V581,V662,V672,9925,9928,0015,3492
CPT: 96400,96405,96406,96408,96410,96412,96414,96420,96422,96423,
96425,96440,96445,96450,96520,96530,96542,96545,96549
HCPCS:Q0083,Q0084,Q0085,G0355,G0356,G0357,G0358,G0359,G0360,G036
1,G0362,G0363, G9021-G9032,J9060,J9062,J9265,J9390,J9201,J9170,J9045
Radiation:
ICD-9: V580,V661,V671,9229,9221,9222,9223,9224,9225,9226,9227,9228
CPT: 77401,77402,77403,77404,77406,77407,77408,77409,77411,77412,
77413,77414,77416,77417,77418,77427,77431,77432,77470,77499,77520,
77523,77750-77799
HCPCS: G0256,G0261
Revenue center: 0330,0333
Mediastinal lymph node evaluation:
ICD-9: 3425,3422,3426,325,3250
CPT: 39400,32405,39000,39010,39200,39220,32662,38746
Mediastinoscopy:
ICD-9: 3422
CPT: 39000,39010,39400
Tobacco-use cessation CPT (99201,99202,99203,99204,99205,99211,99212,
counseling services:
99213,99214,99215,99406,99407,G0375,G0376)
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Management: Responsibilities included grading student exercises, facilitating
student projects, and management of course materials
July 2005 – December 2006
Graduate Teaching Assistant, School of Pharmacy and Health Sciences, St. John’s
University
- Teach 5th year Pharm.D students pharmaceutical compounding labs
- Coordinate with laboratory supervisor for smooth running of labs
PUBLICATIONS
Nadpara P, Madhavan SS. Linking Medicare, Medicaid, and Cancer Registry Data to
Study Burden of Cancers in West Virginia. Medicare & Medicaid Research Review.
2012; 2(4), E1-E25.
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Nadpara P, Madhavan SS, Khanna R, Smith M, Miller LA. Patterns of Cervical Cancer
Screening, Diagnosis and Follow-up Treatment in a State Medicaid Fee-for Service
Population. Population Health Management. 2012 December; 15(6):362-71.
Tworek C, Nadpara P, Adkins B, Horn K, Dino G, Christy D, Madhavan SS. Smoking
and breast cancer screening in West Virginia: Opportunities for intervention. West
Virginia Medical Journal. 2009 October; 105 Spec No:48-53.
PRESENTATIONS
Nadpara P, Madhavan SS, Khanna R, Atkins E, Smith M. Miller LA. “Using Health
Claims Data to Study Patterns of Cervical cancer Screening and Diagnosis in a State
Medicaid Fee-for-service Population.” Poster presented at the International Society for
Pharmacoeconomics and Outcomes Research 16th Annual Meeting, Baltimore, MD,
May 2011. Value in Health. 2011;14(3):A155. Abstract PCN 5.
Nadpara P, Madhavan SS, Tworek C. “Breast, Prostate, and Colorectal Cancer
Screening Behavior and Incidence of Late Stage Cancer Diagnosis in Elderly West
Virginians.” Poster presented at the International Society for Pharmacoeconomics and
Outcomes Research 16th Annual Meeting, Baltimore, MD, May 2011. Value in Health.
2011;14(3):A155. Abstract PCN 6.
Nadpara P, Madhavan SS. “Linking Medicare, Medicaid, Cancer registry Data to Study
Burden of Cancers in West Virginia.” Poster presented at the International Society for
Pharmacoeconomics and Outcomes Research 16th Annual Meeting, Baltimore, MD,
May 2011. Value in Health. 2011;14(3):A178. Abstract PCN 128.
Nadpara P, Madhavan SS, Tworek C. “Social Disparities Across the Continuum of Lung
Cancer: A Systematic Review of the Literature.” Poster presented at the International
Society for Pharmacoeconomics and Outcomes Research 15th Annual Meeting,
Atlanta, GA, May 2010. Value in Health. 2010; 13(3): A48. Abstract PCN 128.
Nadpara P, Tworek C, Madhavan SS. “Characteristics of Patients and predictors of inhospital Mortality After Hospitalization for Lung cancer in West Virginia.” Poster
presented at the International Society for Pharmacoeconomics and Outcomes Research
15th Annual Meeting, Atlanta, GA, May 2010. Value in Health. 2010; 13(3): A50.
Abstract PCN 137.
Nadpara P, Tworek C, Madhavan SS. “The Cost of Treating Lung Cancer in the United
States: An Analysis of the Medical Expenditure Panel Survey.” Poster presented at the
International Society for Pharmacoeconomics and Outcomes Research 15th Annual
Meeting, Atlanta, GA, May 2010. Value in Health. 2010; 13(3): A48. Abstract PCN 131.
Nadpara P. “Health Status and Attitudes Towards Health Insurance in MEPS Sample
Population.” Poster presented at the International Society for Pharmacoeconomics and
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Outcomes Research 14th Annual Meeting, Orlando, FL, May 2009. Value in Health.
2009; 12(3): A90. Abstract PHP67.
Nadpara P, Wu W, Pantaleo N. “Evaluation of Pharmacist Intervention in Response to
Patient Provided Allergy Information.” Poster presented at the St. John’s University
Annual Student Research Day, April 2006, Queens, New York.
CERTIFICATION
Faculty Development Teaching Scholars Summer Institute 2008 Certificate, West
Virginia University
RELEVANT COURSEWORK
Multivariate Analysis, Secondary Data Analysis, Pharmacoeconomics, Decision
Analysis in Healthcare, Social and Behavioral Theory, Survey Research Methods,
Research Design and Data Analysis, Statistical Analysis System, Applied Biostatistics,
Pharmacoepidemiology, Health Systems
MANUSCRIPT REVIEWER
Journal of the American Pharmacists Association (JAPhA)
COMPUTER SKILLS
Statistical Software (SAS, SPSS), Database Development System (Microsoft Visual
FoxPro), Decision Analysis Software (DATA TreeAge), Microsoft Office
PROFESSIONAL AFFILIATIONS
2006–Current
2005–Current
2008–2009

Member – Rho Chi Pharmaceutical Honor Society
Member – International Society for Pharmacoeconomics and
Outcomes Research (ISPOR)
Secretary – WVU ISPOR Student Chapter
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